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ABSTRACT 
 
 South Africa has a national HIV-1 prevalence of 12.2% and due to the large 
population size of 52.9 million, this equates to a 6.5 million people living with HIV-1. The 
high HIV-1 prevalence has warranted the scaling up of the national antiretroviral treatment 
program with over 2 million people accessing treatment since 2012. The population of South 
Africa is genetically diverse and consists of South African Black (SAB), South African 
Mixed ancestry (SAM), South African Caucasian (SAC) and South African Indian (SAI) 
populations that constitute 79.8%, 9.0%, 8.7% and 2.5% of the total population. The reasons 
for the disproportionate HIV-1 prevalence rates estimated for the different populations 
(15.0%, 3.1%, 0.3% and 0.8% for the SAB, SAM, SAC and SAI populations, respectively) 
are unknown; however, host genetic differences may be a contributory factor. Human 
leukocyte antigen (HLA) class I genes play a crucial role in the antiviral innate and adaptive 
immune response, since HLA class I proteins present antigenic peptides to CD8+ Cytotoxic T 
cells (CTLs) of the adaptive immune system and are also involved in the innate immune 
response via interaction with killer-cell immunoglobulin-like receptors (KIRs) expressed by 
Natural Killer cells (NK cells). 
 
 Different HLA class I alleles associate with HIV-1 acquisition and disease progression 
and some alleles can precipitate adverse antiretroviral drug reactions. HLA class I allele 
frequencies in the SAC and SAB populations are known, however, limited information is 
available for the SAI and SAB populations. An immunogenetic characterisation study in 
healthy SAI (n=50) and SAM (n=50) individuals was performed to establish the prevalence 
of HLA class I alleles and other host genetic factors including CCR5Δ32, KIR genes, HLA-
Bw480I/Bw480T/C1/C2 ligands, HLA-B p2 signal peptide variants and HLA-C 3’untranslated 
region +263 insertion/deletion variants. The results were compared to the available gene 
frequencies in healthy SAC and SAB populations and as expected the populations showed 
distinct differences in the prevalence of several of the genes studied. The comparative 
analyses are presented in Chapter 3.  
 
 In Chapter 4, a real-time AS-PCR assay was developed to detect specific HLA class I 
alleles associated with immune hypersensitivity reaction (IHR) to Abacavir (ABC) and 
Nevirapine (NVP). IHR can be fatal and develops in HLA-B*57:01 carriers exposed to ABC 
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and in HLA-B*35:05, -C*04 or -C*08 carriers exposed to NVP. SAI and SAM populations 
were screened for these alleles and the frequencies compared to SAC and SAB populations. 
HLA-B*57:01 was prevalent in 8.0%, 12.0% and 8.2% of SAM, SAI and SAC individuals, 
respectively and absent in the SAB population, while HLA-B*35:05 was present in 6.0% and 
1.0% in SAM and SAC populations, respectively and absent in SAC and SAB populations. 
HLA-C*04 was present at frequencies of 22.0%, 24.0%, 18.6% and 23.7% in SAM, SAI, 
SAC and SAB populations, respectively, while HLA-C*08 was present at frequencies of 
10.0%, 8.0%, 6.9% and 10.2% in SAM, SAI, SAC and SAB populations, respectively. The 
number of HIV-1 infected South Africans potentially at risk of developing ABC IHR and 
NVP IHR, was estimated at 14,235 and 2,212,700 people, respectively. Since treatment of 
HIV-1 infected individuals is underway on a large scale in South Africa and both ABC and 
NVP are in current use, it was concluded that a substantial number of individuals could 
benefit from a pre-screening test before treatment is started. 
 
 The possibility that differences in the prevalence of HLA class I genes and other host 
genetic factors that have been shown associate with HIV-1 acquisition/transmission might 
influence HIV-1 prevalence rates in the four populations was explored in Chapter 5. Using 
new data generated for the SAI and SAM populations and available data for the SAC and 
SAB populations, a cumulative analysis of genes associated with HIV-1 acquisition and viral 
load setpoint (VLS) was performed and compared between the populations. Significant 
results regarding HIV-1 acquisition suggested that more SAB individuals may be susceptible 
compared to SAI individuals (42.8% vs. 14.0%, respectively; p=0.0002), while more SAI 
individuals may be resistant compared to SAB individuals (68.0% vs. 31.4%, respectively; 
p<0.0001). Similarly, significant results regarding genotypes associated with VLS suggested 
that more SAB individuals may have genotypes associated with high VLS compared to SAI 
individuals (59.7% vs. 30.0%, respectively; p=0.0003), while more SAI individuals may have 
a genotypes associated with low VLS compared to SAB individuals (48.0% vs. 13.2%, 
respectively; p<0.0001). Although not statistically significant, SAM and SAC individuals 
may also be less susceptible and more resistant to HIV-1 infection compared to SAB 
individuals. More SAM and SAC individuals have overall genotypes associated with a low 
VLS compared to SAB individuals, but the frequency of SAM and SAC individuals with 
overall genotypes associated with a high VLS was similar compared to SAB individuals. 
Based on extrapolation from these data analysed in healthy individuals, it was concluded that 
host genetic differences may plausibly influence HIV-1 prevalence in the four populations. 
vii 
 
 Next we examined the impact of viral mutagenesis on the role of HLA class I 
molecules in antiviral immunity studied in HIV-1 infected SAB individuals (Chapter 6). Viral 
evolution in the gag gene was studied in the context of two common HLA class I alleles 
present in the SAB population, HLA-B*58:01 and -B*58:02, that associate with opposite 
clinical outcomes. HLA-B*58:01 is a protective allele associated with low viral load and 
higher CD4+ T cell count. HLA-B*58:01 (n=5) and HLA-B*58:02 (n=13) carriers, classified 
as progressors due to CD4+ T cell counts declining to <350 cells/µl, were selected for the 
study. No significant differences were found between the two groups regarding viral load, 
CD4+ T cell count or rates of CD4+ T cell decline. Sequences of the gag gene were generated 
from viral RNA extracted from plasma samples at baseline, 6 months and 12 months that 
were available prior to initiation of treatment. Deduced Gag protein sequences were 
examined and CTL escape mutations were identified in HLA-B*58:01-restricted epitopes, 
while no probable HLA-B*58:02-restricted epitopes were identified. Escape mutations in 
other HLA class I restricted epitopes, compensatory mutations, NK cell escape mutations and 
mutations associated with reduced TRIM5α sensitivity were detected in both HLA-B*58:01 
and HLA-B*58:02 carriers. PTAP duplications in p6Gag known to enhance Tsg101-mediated 
viral budding were detected in some sequences and a rare PYRE insertion in p6Gag known to 
mediate viral budding via an alternative ALIX-mediated pathway. As other investigators have 
shown, disease progression in HLA-B*58:01 carriers associates with CTL escape mutations 
in HLA-B*58:01-restricted Gag epitopes and compensatory mutations, while in contrast, 
HLA-B*58:02 carriers did not target Gag. However, additional escape from other antiviral 
mechanisms such as the additive effect of other HLA class I molecules, NK cell activation 
and TRIM5α sensitivity were observed. Furthermore, increased virus production mediated by 
compensatory mutations and insertions that enhance viral budding, infectivity and replication 
kinetics were identified. The study concluded that disease progression can occur in both 
HLA-B*58:01 and -B*58:02 carriers as a consequence of both immune escape mutations and 
enhancement of virus production. 
 
 Overall, the findings presented in this thesis regarding the crucial roles played by 
HLA class I molecules and other immunogenetic factors in mediating adaptive and innate 
immune responses to HIV-1, provides insight into the complex and variable nature of host 
genetics in different populations that govern viral susceptibility, resistance and infectivity as 
well as in treatment-related  immune hypersensitivity reactions. Viral mutagenesis was shown 
to mediate the failure of HLA class I molecules to maintain antiviral immune responses. 
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1.1. An Overview of HIV-1 
 
1.1.1. Discovery of HIV-1 
 
On June 5, 1981, an article appeared in the Morbidity and Mortality Weekly Report 
(MMWR), published by the USA Centers for Disease Control and Prevention (CDC), 
highlighting five unusual cases of Pneumocystis carinii pneumonia (PCP) as well as 
Cytomegalovirus (CMV) co-infection in young homosexual men (29-36 years) living in the 
Los Angeles area, California (Centers for Disease, 1981). The previously healthy men, who 
were not acquainted with each other or others with the same symptoms, had been treated for 
PCP during the period October 1980 to May 1981. Two deaths had occurred subsequently 
and three of the patients demonstrated poor in vitro lymphocyte proliferation responses to 
mitogens and antigens, suggestive of an underlying immunodeficiency. The report concluded 
that “All the above observations suggest the possibility of a cellular-immune dysfunction 
related to a common exposure that predisposes individuals to opportunistic infections such as 
pneumocystosis and candidiasis.” In retrospect, this article was to become the first clinical 
report to describe what was later to be termed “Acquired Immunodeficiency Syndrome” 
(AIDS). 
 
An initiative to identify the causative agent of AIDS began in December 1982, when 
French clinicians contacted the laboratory of Dr. Luc Montagnier at the Pasteur Institute, 
Paris, and provided a lymph node biopsy, donated by a patient with lymphadenopathy and 
early symptoms of AIDS, for analysis (Barre-Sinoussi, 2009). The laboratory isolation and 
characterisation of a previously unknown human retrovirus was successfully achieved by a 
post-doctoral virologist, Dr. Francoise Barre-Sinoussi, who was able to demonstrate reverse 
transcriptase activity in T lymphocytes cultured from the sample (Barre-Sinoussi, 2009). 
These investigations determined that the cultured virus was closely related to the human T-
lymphotrophic leukaemia virus (HTLV), the only known human retrovirus at the time. The 
novel retrovirus was named lymphadenopathy-associated virus (LAV) and details of its 
discovery were published in 1983, although the authors were cautious in extrapolating a 
direct link to AIDS (Barre-Sinoussi et al., 1983). LAV was later confirmed by other 
investigators to be the causative agent of AIDS (Gallo et al., 1984, Levy et al., 1984); 
although in these reports the virus was termed HTLV-III or AIDS-associated retrovirus 
(ARV). 
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In 1985, a second putative human retrovirus, closely related but not identical to LAV, 
was identified by serological evidence in an infected man in Senegal, West Africa (Barin et 
al., 1985). The virus was later isolated and characterised and due to the similarity to LAV, 
given the name LAV-II (Clavel et al., 1986). In 1986, due to confusion in the scientific 
community regarding virus nomenclature, the International Committee on Taxonomy of 
Viruses (ICTV) recommended the re-naming of LAV, also referred to as HTLV-III, ARV or 
immunodeficiency-associated virus (IDAV), to human immunodeficiency virus type 1 (HIV-
1) (Case, 1986). Following on from this LAV-II, was subsequently termed HIV-2. 
 
1.1.2. Taxonomy of HIV-1 
 
The 2012 virus taxonomy release (http://ictvonline.org), compiled by the ICTV, 
classifies HIV-1 and HIV-2 as separate viral species, which together with seven other viral 
species (i.e. Bovine immunodeficiency virus, Caprine arthritis encephalitis virus, Equine 
infectious anaemia virus, Feline immunodeficiency virus, Puma lentivirus, Simian 
immunodeficiency virus and Visna/Maedi virus) are grouped under the genus Lentivirus. The 
Lentivirus genus, along with five other genera (i.e. Alpharetrovirus, Betaretrovirus, 
Deltaretrovirus, Epsilonretrovirus and Gammaretrovirus) is grouped under the virus 
subfamily Orthoretrovirinae. The two subfamilies, Orthoretrovirinae and Spumaretrovirinae, 
are grouped under the virus family Retroviridae, which is one of 72 other families of viruses. 
 
1.1.3. Biology of HIV-1 
 
1.1.3.1. Structure of HIV-1 
 
Using cryogenic electron microscopy (cryo-EM) techniques, characterisation of the 
outer surface of HIV-1 determined that mature viral particles (virions) are lipid enveloped 
with a spherical morphology with a diameter of 110+8 nm (Zhu et al., 2006). Viral spike 
proteins protrude from the viral envelope and are composed of heterodimers of trans-
membrane gp41 molecule and an ectodomain non-covalently associated with a gp120 
molecule. The gp120 proteins are extensively glycosylated and contain 27 or more N-linked 
glycosylation sites. The spike proteins associate into trimeric structures (trimers) that are 
randomly distributed on the viral surface (14+7 per virion), sometimes in clusters, with no 
evidence of even spacing (Figure 1.1). High resolution cryo-EM imaging of trimeric 
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structures (Figure 1.2) measured the height and width at 12 nm and 15.5 nm, respectively 
(Mao et al., 2012). Since, the viral lipid envelope is derived from the infected host cell 
plasma membrane, this leads to the presence of human cellular proteins detectable on the 
viral surface including ICAM-1 (CD54), LFA-1, HLA II-DR, galectin-1, tetraspanin-14, 
CD40L, CD62L, CD9, CD46, CD53, CD55, CD59, CD63, CD80, CD81, CD82 and CD86 
(Ott, 2008). 
 
 
Figure 1.1. Surface-rendered model of SIV and HIV-1 virions (Panel a and b, respectively), 
determined by cryo-EM techniques, showing individual trimers (white) and clusters of 3 or more 
trimers (circled in red).Scale bar represents 50 nm. Taken from (Zhu et al., 2006). 
 
 
Figure 1.2. Surface-rendered models of membrane-bound HIV-1 envelope trimer, determined by 
cryo-EM techniques at 11-Ǻ resolution. Side views (panels a and b) and top views (panels c and d) 
are depicted. Taken from (Mao et al., 2012). 
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The internal constituents of the mature virion (Figure 1.3) are composed of a cone-
shaped viral core (capsid), assembled from multiple p24 capsid (CA) proteins and p17 matrix 
(MA) proteins tethered to the inner surface of the viral envelope (Ganser-Pornillos et al., 
2012). The physical structure of the core was recently imaged at high resolution by cryo-EM 
techniques (Figure 1.4) and revealed that the characteristic bullet-shape is based on a 
“fullerene cone model” consisting of 216 CA hexamers and 12 CA pentamers (5 pentamers at 
the narrow end and 7 at the wider end) totaling 1,356 CA monomers (Zhao et al., 2013). The 
core encloses a non-covalently associated dimeric, positive-sense, 5’-capped, 3’-poly-
adenylated RNA genome of ~9,000-10,000 nucleotides that is bound by nucleocapsid (NC) 
proteins and is also annealed to a host cell derived  tRNALys3 molecule (Watts et al., 2009). 
Viral enzymes reverse transcriptase (RT), protease (PR) and integrase (IN) are also 
incorporated into the capsid as well as the viral accessory protein, Nef, and a range of cellular 
proteins that vary according to the virus-producing cell-type (Santos et al., 2012). 
 
 
Figure 1.3. Structure of mature HIV-1 virion.Taken from (Peters et al., 2013). 
                                                                           
Figure 1.4. HIV-1 capsid structure based on molecular dynamics equilibrated all-atom model 
comprising 216 p24 hexamers (blue) and 12 p24 pentamers (green). Taken from (Zhao et al., 2013). 
6 
 
1.1.3.2. Genomic organisation and viral protein processing 
 
The HIV-1 genome has 9 open reading frames (ORFs) and encodes 15 proteins 
(Watts et al., 2009). In addition, there are two untranslated regions (UTRs) at the 5’ and 3’ 
ends of the genome (Figure 1.5). The first ORF encodes the group associated antigen (gag) 
gene which is located after the 5’UTR. Unspliced full-length mRNA transcripts of ~9kb are 
used to translate the gag ORF into a large precursor polyprotein (Pr5Gag) which is cleaved by 
viral protease into 4 mature proteins: p17 matrix protein (MA), p24 capsid protein (CA), p7 
nucleoprotein (NC) and p6 (Bell and Lever, 2013). The second ORF following gag is the 
polymerase (pol) gene that encodes viral enzymes. The pol gene product is translated as a 
Gag-Pol fusion polyprotein (Pr160Gag-Pol) due to the presence of a -1 ribosomal frameshift 
signal located upstream of the pol start codon and ~5% of transcripts are translated as fusion 
proteins (Bell and Lever, 2013). Pr160Gag-Pol is processed into 4 mature proteins by viral 
protease including p10 protease (PR), p66/p51 reverse transcriptase (RT) heterodimer and 
p31 integrase (IN). The third ORF encodes the envelope (env) glycoproteins. Initially 2kb 
spliced mRNA transcripts are translated to yield the two regulatory proteins, p19 regulator of 
virion expression (Rev) and p14 trans-activator of transcription (Tat) and the accessory 
protein, p27 negative regulatory factor (Nef). A 4kb spliced mRNA transcript is translated to 
yield the viral envelope polyprotein, gp160, and accessory proteins, p16 viral protein U 
(Vpu), p23 viral infectivity factor (Vif) and p15 viral protein R (Vpr) (Bell and Lever, 2013). 
The gp160 protein is translated and concomitantly glycosylated and later cleaved by a 
cellular protease, Furin, in the Golgi body, to generate the gp41 transmembrane (TM) 
envelope glycoproteins and the ectodomain gp120 surface (SU) glycoproteins (Checkley et 
al., 2011). 
 
 
Figure 1.5. Genomic organisation of HIV-1.Taken from (Peters et al., 2013). 
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1.1.3.3. HIV-1 replication cycle 
 
Mature, infectious HIV-1 virions preferentially infect CD4+ T cells and cells of the 
macrophage/monocyte lineage and this tropism is largely determined by the envelope 
glycoproteins (Checkley et al., 2011). Viral entry is initiated by recognition of cell surface 
CD4 molecules by gp120, which induces a conformational change that exposes the binding 
site for a co-receptor molecule, either C-C chemokine receptor type 5 (CCR5) or C-X-C 
chemokine receptor type 4 (CXCR4). The entry inhibitor, Maraviroc, a CCR5 antagonist, 
binds and distorts the external structural domains of the co-receptor thereby preventing  
recognition of the amino-terminus and second extracellular loop by gp120 (Menendez-Arias, 
2013). Reduced infectivity of target cells is mediated by a naturally occurring mutant of the 
CCR5 gene that encodes a truncated protein that is not expressed at the cell surface due to a 
32-bp deletion (CCR5Δ32) (Liu et al., 1996). Binding of gp120 to CCR5 promotes insertion 
of the fusion peptide, located at the gp41 amino-terminus, into the host cell membrane, 
followed by interaction between the heptad repeat domains 1 and 2 of trimeric gp41 to form a 
six-helical bundle that facilitates fusion of the viral envelope with the plasma membrane 
(Engelman and Cherepanov, 2012). Membrane fusion introduces the viral core into the 
cytoplasm, however, contrary to previous conceptions, the core does not uncoat immediately 
post-fusion, but undergoes intracellular trafficking towards the nuclear membrane using 
cytoplasmic actin and microtubule networks (Arhel et al., 2007). The mechanism of action of 
the intrinsic retroviral restriction factor, TRIM5α, is direct binding to the capsid which 
promotes premature uncoating and exposure of viral RNA to intracellular innate antiviral 
sensing mechanisms (Bieniasz, 2012). 
 
Reverse transcription takes place inside the intact core, referred to as the reverse 
transcription complex (RTC), since the core is permeable to dNTPs required for DNA 
polymerisation, and following completion of reverse transcription, uncoating is triggered by 
the partially double stranded DNA flap structure (Arhel et al., 2007). A second antiretroviral 
intrinsic restriction factor, APOBEC3G, a cytidine deaminase enzyme, that is incorporated 
into virions and converts cytidine to uracil in viral cDNA leading to G-A hypermutation in 
the viral genome, although this can be counteracted by Vif that prevents encapsidation of 
APOBEC3G (Bieniasz, 2012). A recently identified third antiretroviral intrinsic restriction 
factor, SAMHD1, a dGTP-regulated deoxynucleotide triphosphohydrolase enzyme that 
reduces cytoplasmic dNTP levels in myeloid cells, has been shown to inhibit reverse 
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transcription and is counteracted by HIV-2 Vpx proteins (Bieniasz, 2012). The NRTI and 
NNRTI antiretroviral drug classes also inhibit reverse transcription by respective chain-
terminating or enzyme active-site blocking mechanisms (Menendez-Arias, 2013). Uncoating 
of the core leads to the formation of the pre-integration complex (PIC), composed of linear 
blunt-ended proviral double-stranded DNA, IN, RT, MA protein and cellular proteins, such 
as LEDGF, that facilitates translocation of proviral DNA into the nucleus via a nucleopore 
(Engelman and Cherepanov, 2012, Coiras et al., 2009). 
 
At this stage two forms of viral latency can occur, the formation of unintegrated 
circularised viral genomes containing one or two LTRs, or the integration of the proviral 
genome into host chromosomal DNA that remains quiescent, i.e. no viral gene transcription 
takes place (Coiras et al., 2009). Immune activation of latently infected cells promotes import 
of transcription factors, such as NF-κB and NFAT, into the nucleus, that binds to the proviral 
5’UTR and recruits RNA polymerase II that is required to initiate viral mRNA transcription 
(Coiras et al., 2009). The first full-length viral mRNA transcripts are spliced to 2 kb 
transcripts encoding the regulatory proteins Rev and Tat as well as Nef accessory proteins 
(Bell and Lever, 2013). These transcripts are translated in the cytoplasm and Rev and Tat is 
imported back into the nucleus where Tat increases the rate of viral mRNA transcription, 
while Rev facilitates export of unspliced 4 kb and 9 kb viral mRNA transcripts. The 4 kb 
transcripts are used to translate envelope gp160 polyproteins, Vpu, Vpr, Vif and Tat, while 
Gag and Gag-Pol polyproteins, pr55Gag and pr160Gag-Pol, are translated from the 9 kb 
transcripts. Envelope gp160 is cleaved by cellular furin, to generate gp41 and gp120 which 
associates into trimers and is exported to the plasma membrane using the cellular secretory 
pathway (Ganser-Pornillos et al., 2012, Checkley et al., 2011). Assembly of a new virus 
particle begins at the plasma membrane with pr160Gag-Pol binding to dimeric viral genomic 
RNA complexes present in the cytoplasm via the NC domain (Ganser-Pornillos et al., 2012). 
This complex is tethered to the inner surface of the plasma membrane via the myristoylated 
amino-terminus of the MA domain (Checkley et al., 2011). The MA domain also interacts 
with the cytoplasmic tail of transmembrane gp41 to facilitate recruitment of trimers (Ganser-
Pornillos et al., 2012). Additional recruitment of ~2,400-2,500 pr55Gag molecules leads to 
formation of a lattice and outward curvature of the plasma membrane until a narrow 
connecting stalk remains (Lee et al., 2012, Ganser-Pornillos et al., 2012). Approximately 120 
molecules of pr160Gag-Pol (Lee et al., 2012) as well as accessory proteins, Nef, and in some 
cases Vif and Vpr are also incorporated into the virion (Sundquist and Krausslich, 2012). 
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Maturation of the newly budded virus is dependent on viral protease activity. The 
interaction of two pr160Gag-Pol molecules leads to an autocatalytic process that generates a 
functional protease enzyme that in turn cleaves pr55Gag into p17 MA, p24 CA, p7 NC and p6 
proteins and pr160Gag-Pol into p51/p66 RT, p10 PR and p31 IN (Lee et al., 2012). The 
abscission of the connecting stalk is facilitated by p6Gag in concert with cellular proteins 
TSG101 and other proteins of the endosomal sorting complexes required for transport 
(ESCRT) (Ganser-Pornillos et al., 2012). The intrinsic antiretroviral restriction factor, 
tetherin, captures budding viruses and prevents their release, but this function is inhibited by 
Vpu (Bieniasz, 2012). The immature virion is non-infectious at this stage and protease 
activity continues until sufficient mature viral proteins have been generated to re-organise the 
internal structure of the virion characterised by a cone-shaped core (Zhao et al., 2013), a 
condensed genomic RNA structure in association with NC and viral enzymes and MA 
proteins that remain associated with the inner envelope. The protease inhibitor class of 
antiretroviral drugs interferes with essential downstream protease functioning and thereby 
inhibits maturation of the virion (Menendez-Arias, 2013). 
 
1.2. Epidemiology of HIV-1 
 
1.2.1. Global 
 
Epidemiological statistics for 2013 (Figure 1.6) released by the Joint United Nations 
HIV and AIDS programme (www.unaids.org) estimated that 35.0 million [33.2-37.2] people 
were living with HIV-1. Of these, 31.8 million [30.1-33.7] were adults, 16.0 million [15.2-
16.9] were women and 3.2 million [2.9-3.5] were children under the age of 15 years. New 
infections were estimated at 2.1 million [1.9-2.4] of which 1.9 million [1.7-2.1] were adults 
and 240,000 [210,000-280,000] were children under the age of 15 years. AIDS deaths were 
1.5 million [1.4-1.7] of which 1.3 million [1.2-1.5] were adults and 190,000 [170,000-
220,000] were children under the age of 15 years. 
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Figure 1.6. Global estimates of people living with HIV-1 in 2013.Taken from www.unaids.org. 
 
1.2.2. Sub-Saharan Africa 
 
Sub-Saharan Africa remains the region of highest HIV-1 burden with an estimated 
24.7 million [23.5-26.1] persons living with HIV-1 of which 2.9 million [2.6-3.2] were 
children. A total of 1.5 million [1.3-1.6] new infections were estimated to have occurred in 
this region and 1.1 million [1.0-1.3] adult and child deaths were due to AIDS. The HIV-1 
prevalence in the 15-49 year adult age group was estimated at 4.7% [4.4-4.9]. 
 
1.2.3. South Africa 
 
Updated survey figures released by Statistics South Africa (www.statssa.gov.za) for 
mid-year 2013 estimated the national HIV-1 prevalence at ~10% and the total population was 
estimated at 52.982 million which equates to 5.298 million people living with HIV-1. This is 
an increase in the number of people living with HIV-1 in 2002, when 4 million people were 
estimated to be HIV-1 positive. In adults aged 15-49 the HIV-1 prevalence is estimated at 
15.9%. The number of individuals in this age group was 29,218,479 which equates to 
4,645,738 HIV-1-positive young adults. The local South African (SA) population is 
ethnically diverse, consisting of SA Black (SAB), SA mixed ancestry (SAM), SA Caucasian 
(SAC) and SA Indian (SAI) individuals (www.statssa.gov.za).The most recent national 
census (2013) provides estimates of the number of individuals per population as follows: 
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SAB (n=42,284,100), SAM (n=4,766,200), SAC (n=4,602,400) and SAI (n=1,329,300). 
Updated HIV prevalence rates stratified by population are not available, however, a national 
survey conducted in 2012 estimated rates of 15.0%, 0.3%, 3.1% and 0.8% in SAB, SAC, 
SAM and SAI populations, respectively (www.hsrc.ac.za/en/research-outputs/view/6871). 
Based on these HIV-1 prevalence rates, this equates to the number of individuals living with 
HIV-1 for SAB (n=6,342,615), SAM (n=147,752), SAC (n=13,807) and SAI (n=10,364) 
populations. 
 
1.3. Origin and genetic diversity of HIV-1 
 
Human adaptation of Simian immunodeficiency viruses (SIV) following zoonotic 
transmission from non-human primate species is thought to have lead to the introduction of 
HIV-1 and HIV-2 into humans, most likely in the Western and Central African regions via 
contact with infected animals through bushmeat hunting practices or keeping animals as pets 
(Hemelaar, 2012). More than 40 non-human primate species that inhabit the African 
continent (Figure 1.7) are known to carry species-specific SIV strains (Chahroudi et al., 
2012). HIV-1 genotypes are sub-divided into 4 groups (group M, N, O and P) with group M 
being the largest group and responsible for the pandemic with millions of infections globally 
(Hemelaar, 2012). Group O HIV-1 infections are in the order of tens of thousands (~1% of all 
HIV-1 infections) and are mostly restricted to Western and Central Africa, while groups N 
and P contain a very small number of viral sequences (n=15 and n=2, respectively) identified 
in individuals from Cameroon (Mourez et al., 2013). 
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Figure 1.7. Natural habitats of some primate species.Taken from (Chahroudi et al., 2012). 
 
The group M and N viruses are closely related to SIV strains circulating in 
chimpanzees (SIVcpz), specifically the species Pan troglodytes troglodytes, populating 
Western and Central Africa, and it is thought that two independent cross-species 
transmissions gave rise to these groups of viruses (Hemelaar, 2012). In contrast, group O and 
P viruses are more closely related to SIV strains circulating in gorillas (SIVgor), specifically 
the species Gorilla gorilla gorilla, populating the Western lowland of Cameroon, however, it 
is not clear from phylogenetic analysis whether these viruses originated from a direct 
zoonotic transmission from gorillas or if an intermediate host species was involved 
(Hemelaar, 2012). HIV-1 group M viruses have diversified considerably in humans and 
genetic variants can be classified into 9 subtypes (A-D, F-H, J and K) based on sequence 
variability. Several circulating recombinant forms (CRFs) of HIV-1 have arisen through 
recombination between viral strains belonging to different clades with a total of 61 HIV-1 
CRFs currently documented by June 2014 
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). Similarly, HIV-1 group O 
viruses are genetically diverse with 5 putative subtypes identified (subtypes 1-5) (Yamaguchi 
et al., 2002). HIV-2 is closely related to SIV strains circulating in the sooty mangabey 
monkey, species Cercocebus atys, populating the Western African region, and is also 
subdivided into groups A-H. Notably, these group variants have resulted from several 
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independent cross-species transmission events while HIV-2 CRFs were subsequently 
generated by genetic recombination in humans (Peeters et al., 2013). 
 
The argument for the origin of HIV-1 in central Africa is supported by evidence such 
as the location of primate species (chimpanzee and gorilla) naturally infected with SIV strains 
closely-related to HIV-1, the presence of all 4 HIV-1 groups (M, N, O and P), the presence of 
all HIV-1 subtypes (A-D, F-H, J and K), higher degrees of intersample sequence diversity, a 
larger representation of CRFs, the location of earliest known HIV-1 positive samples dating 
to 1959 and 1960 (Hemelaar, 2012). HIV-1 prevalence has also declined to stable levels in 
this region, suggestive of an older epidemic. The earliest known HIV-1 strains have been 
detected in a plasma sample from an infected male in 1959 and a lymph node biopsy sample 
from an infected female in 1960, both from the Democratic Republic of Congo. Subsequent 
genotyping determined that these sequences were 12% divergent and belonging to subtype D 
and subtype A, respectively, demonstrating that HIV-1 had already diversified at this early 
time-point during the HIV-1 epidemic (Worobey et al., 2008, Zhu et al., 1998). 
 
The timing of the origin of group M HIV-1 in humans was estimated to have occurred 
between 1915 and 1941, based on extrapolation from mutational rates determined for HIV-1 
sequences available between 1980 and 2000 (Korber et al., 2000). This analysis also correctly 
estimated the age of the 1959 HIV-1 sequence to within a year or two, in support of the 
reliability of the method, however, the authors cannot be certain that the mutational rates was 
constant during the early stages of the epidemic. A recent epidemiological study of HIV-1 
sequence data collected from central Africa has concluded that the epicenter of expansion of 
group M viruses is most likely Kinshasa in the Democratic Republic of Congo around the 
1920s due to the culmination of several factors including extensive urban development and a 
lucrative sex trade industry (Faria et al., 2014). There is also speculation that exposure of 
humans to SIV/HIV may have occurred at much earlier time than current estimates. This is 
based on evidence of positive selection of resistance genes detected in members of the Biaka 
pygmie tribe resident in the Central African Republic (Zhao et al., 2012). 
 
The spread of HIV-1 from central Africa to other regions of the world has lead to 
differential global subtype distributions (Figure 1.8), most likely affected by many factors 
including founder effects, population growth, urbanisation, cultural and sexual behavioural 
practices, transport and migration patterns. Notably, subtype C strains of HIV-1 represent 
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48% of global infections and these viruses predominate in the southern African regions as 
well as Ethiopia and India, possibly reflecting differences in viral or host genetics (Hemelaar, 
2012). It has been postulated that the dominance of subtype C viruses may be related to viral 
and/or host genetic factors that increases susceptibility or promotes higher levels of viraemia 
in infected individuals, thus increasing transmission risk. This may be further exacerbated by 
poor antiretroviral coverage in the areas where subtype C viruses are circulating (Neogi et al., 
2013). However, a recent publication did not find any significant differences in viral load 
setpoint in recent seroconverters from west and southern Africa infected with subtypes A, D 
and C (Campbell et al., 2013). 
 
 
Figure 1.8. Global distribution of HIV-1 subtypes and circulating recombinant forms between 2004 
and 2007. Taken from (Peters et al., 2013). 
 
1.4. HIV-1 transmission, pathogenesis, immunity and treatment 
 
1.4.1. Transmission of HIV-1 
 
Infectious HIV-1 virions are present in semen, genital secretions, blood and 
breastmilk and can be transmitted by homosexual or heterosexual intercourse (which includes 
unprotected vaginal, anal and oral sex), parenteral inoculation (including needlestick injury 
and injecting drug users), exposure to infected blood or blood products (including transfusion 
and organ transplantation) and from mother-to-child (including in utero, intrapartum or post-
natal transmission by breastfeeding) (Moss, 2013). The most common route of infection 
(~80%) is through mucosal surfaces (Cohen et al., 2011) that includes vaginal, penile and 
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rectal tissues, with the risk of acquiring HIV-1 through sexual contact being higher for 
receptive anal intercourse compared to heterosexual intercourse (Tebit et al., 2012). Most 
HIV-1 infections worldwide are through heterosexual contact with a disproportionately 
higher infection rate in women compared to men, partly due to a greater efficiency of HIV-1 
transmission from male-to-female compared to female-to-male (Tebit et al., 2012). 
 
The female genital tract (Figure 1.9a) is subdivided into endocervix and the 
transitional zone, composed of a single layer of simple columnar epithelium, and the vagina 
and ectocervix composed of multiple layers of stratified squamous epithelium  (Carias et al., 
2013, Hladik and McElrath, 2008). It was initially thought that it was more likely that HIV-1 
will penetrate the mucosal barriers of the endocervix or transitional zone due to the relative 
thickness of the ectocervical squamous epithelium, however, in the endocervix most virus is 
efficiently trapped by mucus, while the larger surface area of the ectocervix (~15 times 
greater than the endocervix) provides a better opportunity for HIV-1 to breach mucosal 
barriers. New evidence also suggests that due to a weakening of tight-junctions, HIV-1 viral 
particles can passively diffuse between epithelial cells to an average depth of 2 µm 
(sometimes >10 µm), where contact with immune cells is more likely (Carias et al., 2013). 
 
 
Figure 1.9. Basic cellular structure of female (a) and male (b) genital mucosal surfaces. Taken from  
(Hladik and McElrath, 2008). 
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It has been postulated that the first immune cells to contact HIV-1 are skin resident 
dendritic cells known as Langerhans’ cells, which are abundant in the squamous epithelial 
cell layer and hence are likely to contact HIV-1 that has partially penetrated this epithelial 
layer (Hladik and McElrath, 2008). Langerhans’ cells are also known to sample antigens 
present on the epithelial surface via cytoplasmic projections and may contact HIV-1 in this 
way (Hladik and Hope, 2009). Infection of males is thought to occur in a similar manner via 
the inner foreskin which also has multiple layers of squamous epithelial cells (Figure 1.9b) 
and tissue resident Langerhans’ cells, while simple columnar epithelium is only present in the 
urethra and presents a very small surface area compared to the foreskin (Hladik and 
McElrath, 2008). The surgical removal of the foreskin by circumcision, which has been 
shown to reduce female-to-male HIV-1 transmission (Auvert et al., 2005), is most likely 
protective due to the absence of Langerhans’ cells and increased keratinisation of the skin 
that reduces virus diffusion into the epithelium. 
 
Langerhans’ cells express C-type lectins on the cell surface called langerin (CD207) 
that bind carbohydrate moieties such as those present in gp120 viral envelope proteins. This 
facilitates internalisation of virus for degradation, however, in higher concentrations, HIV-1 
can be trapped on the cell surface and transported to lymphoid tissues where CD4+ T cells 
become infected (Tebit et al., 2012). Myeloid dendritic cells similarly trap HIV-1 on the cell 
surface with an alternative C-type lectin called DC-SIGN (CD209) (Geijtenbeek and van 
Kooyk, 2003). There are reports that Langerhans’ cells can be productively infected with 
HIV-1 themselves (Kawamura et al., 2003), although these cells are CD4 negative but may 
become infected through langerin-mediated internalisation of HIV-1 (Hladik and Hope, 
2009). Inflammation of the genital tract due to sexually transmitted infections increase the 
probability of HIV-1 acquisition, most likely due to activation of antigen presenting cells 
such a Langerhans’ cells and recruitment of activated CD4+ T cells to a closer proximity to 
infectious HIV-1 (Arien et al., 2011). 
 
In heterosexual HIV-1 transmission, even though a heterogeneous viral population is 
usually present in the infected inoculum, such as semen, only a small number or most often a 
single virion establishes infection in the new host (Keele et al., 2008). There is uncertainty 
whether a single virus is selected at the mucosal site of entry or if multiple viruses breach the 
mucosal barrier but undergo positive selection in another compartment, nevertheless, in most 
circumstances the transmitted/founder virus has a particular phenotype that includes almost 
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exclusive dependence on CCR5 as the co-receptor for target cell entry, short V1-V2 loops in 
gp120 as well as fewer N-linked glycosylation sites and a higher neutralisation sensitivity 
compared to donor viruses (Arien et al., 2011). 
 
1.4.2. Pathogenesis of HIV-1 
 
The hallmark of HIV-1 pathogenesis in untreated individuals is the progressive 
depletion of CD4+ T cells over time which is coupled to an increasing impairment of adaptive 
immune responses leading to increased susceptibility to opportunistic infections. In untreated 
individuals, the typical course of infection is subdivided into three stages: acute infection 
stage, asymptomatic period and AIDS onset (Qu et al., 2008). Based on laboratory testing for 
the presence of viral RNA, viral antigens or virus-specific antibodies, the Fiebig staging 
system can further expand virological and immunological changes during each stage of 
infection (Fiebig et al., 2003). 
 
1.4.2.1. Acute infection stage 
 
Heterosexual exposure to HIV-1 does not necessarily result in productive infection, 
since in low risk settings, HIV-1 transmission ranges from 2-50 per 10,000 exposures (Arien 
et al., 2011). Symptoms of primary infection may develop after 2-3 weeks and last up to 4 
weeks (Qu et al., 2008). Exposure to HIV-1 at mucosal surfaces in susceptible hosts, permits 
virus to cross the epithelial cell barriers, most likely facilitated by Langerhans’ cells that 
transport infectious virus to local lymphoid tissues; a process that takes ~2-6 hours (Cohen et 
al., 2011). Langerhans’ cells in an activated state have been shown to mediate trans-infection 
of CD4+ T cells (Fahrbach et al., 2007) which may be related to their professional role as 
antigen-presenting cells that migrate to lymphoid tissues where they stimulate antigen-
specific T cells (Ayala-Garcia et al., 2005). There is also the possibility that Langerhans’ 
cells may become productively infected although these dendritic cells are considered CD4 
negative (Kawamura et al., 2003). 
 
Trans-infection of CD4+CCR5+ T cells leads to local production of virus in regional 
draining lymph nodes of the genital tract and dissemination of infected effector T cells to 
mucosal tissues where uninfected T cells and macrophages can become infected as well as 
dissemination to other tissues. Activated antigen-presenting cells are known to secrete 
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cytokines such as IL-1, TNF-α and IL-6, known to cause fever. This symptom, including 
others, such as pharyngitis, myalgia, lymphadenopathy, headache, diarrhoea, nausea, 
meningismus, photophobia, rash, vomiting and oropharyngeal sores, are sometimes compared 
to “flu-like” or “mononucleosis-like” illness, although not all primary infections are 
associated with these symptoms (Celum et al., 2001). A skin rash (exanthem) is reported in 
up to 70% of primary HIV-1 infections. HIV-1 dissemination to the skin and productive 
infection of skin dendritic and Langerhans’ cells has been reported in a human case study 
(Simonitsch et al., 2000) and investigations of the same phenomenon observed in the SIV-
rhesus macaque monkey model revealed the presence of SIV and infiltrates of CD4+ and 
CD8+ T cells expressing αEβ7 integrins in skin biopsies (Sasseville et al., 1998). The integrin 
αEβ7 is specific for homing of effector T cells to the skin and this may be due to overlap of 
the cutaneous and genital mucosa with regard to immune responses involving skin-resident 
Langerhans’ cells that are also present in both male and female genital squamous epithelium. 
Notably, lymphadenopathy caused by clonal expansion of antiviral CD4+ and CD8+ T cells 
leads to preferential infection of HIV-specific CD4+ T cells (Douek et al., 2002) and likely 
reflects trans-infection of responding CD4+ T cells by antigen-presenting cells that have 
captured viral antigens, such as Langerhans’ cells expressing langerin or myeloid dendritic 
cells expressing DC-SIGN (Fahrbach et al., 2007). 
 
SIV studies have shown rapid dissemination of virus to gut lymphoid tissues as early 
as 2 weeks after infection, while human studies have determined that this causes extensive 
CD4+ T cell depletion in the gastrointestinal tract (Brenchley et al., 2004). Although the path 
of HIV-1 dissemination from the genital tract to the gut is unclear, there is evidence from 
murine studies that the mesenteric lymph node may facilitate a skin and gut homing overlap 
involving retinoic acid dependent activation of langerin+ dendritic cells (Chang et al., 2008). 
This suggests that HIV-1 dissemination to the skin may mediate virus dissemination to the 
gut via trans-infection of gut homing CD4+ T cells activated in the mesenteric lymph node. 
Systemic dissemination of virus also facilitates seeding of the central nervous system (CNS) 
with HIV-1 via infected monocytes or macrophages that differentiate into microglial cells or 
perivascular brain macrophages (Gras and Kaul, 2010). These cells become reservoirs of 
HIV-1 in the brain without virus production, since immune activation is suppressed in the 
CNS, however, failure to control peripheral HIV-1 replication at AIDS onset leads to a 
breakdown of immune privilege and viral replication in the CNS causes dementia. 
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During acute infection the appearance of biological markers of HIV-1 infection 
detectable by clinical laboratory testing procedures can be listed according to a staging 
system.  According to Fiebig staging (Fiebig et al., 2003), during acute infection, plasma viral 
RNA is undetectable (eclipse phase) with ultrasensitive RNA testing assays (1-5 copies/ml) 
until ~10 days post-infection (p.i.); stage I (10-15 days p.i.) is when RNA becomes detectable 
in blood, but p24 antigen is undetectable; stage II (15-20 days p.i.) is when p24 antigen 
becomes detectable; stage III (20-24 days p.i.) is when HIV-specific IgM becomes detectable 
and it is during this seroconversion period when peak viraemia is attained and begins to 
decline; Stage IV (24-30 days p.i.) is the period where viral load continues to decline, p24 
levels decline and Western blot results are indeterminate; Stage V (30-100 days p.i.) is when 
Western blot results are positive, excluding positivity for p31 integrase and viral load reach a 
low level but continue to decline slowly as do p24 levels; Stage VI (100 days p.i.) is when 
viral load becomes stable and is said to reach a “setpoint” , p24 becomes undetectable and the 
individual enters the early chronic infection period. The staging and results of clinical 
laboratory testing procedures is shown in Figure 1.10 (Cohen et al., 2011). 
 
 
Figure 1.10. Staging, immune responses and clinical laboratory testing sensitivity during acute HIV-1 
infection. Taken from (Cohen et al., 2011). 
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1.4.2.2. Asymptomatic period 
 
The asymptomatic (also called chronic or clinical latency) period of HIV-1 infection 
is characterised by a viral load setpoint which remains relatively stable, although CD4+ T cell 
count continues to decline and the viral load setpoint is positively correlated with disease 
progression (Geskus et al., 2007). Classification of untreated individuals based on the 
duration of the asymptomatic period defines three main groups: rapid progressors, typical 
progressors and long-term non-progressors (LTNPs) (Qu et al., 2008). Rapid progressors are 
characterised by an accelerated decline in CD4+ T cell counts and progression to AIDS within 
2-5 years, although this only occurs in 5-15% of individuals in the asymptomatic period, 
while typical progressors do not develop symptoms of AIDS for 8-10 years. Another 5-15% 
of individuals in the asymptomatic period remain clinically/immunologically stable beyond 
10 years, albeit with detectable viraemia but usually at low levels, and these individuals are 
termed LTNPs. LTNPs, despite a slow decline in CD4+ T cell count and low viraemia, do 
eventually develop AIDS (Qu et al., 2008). An additional subset of LTNPs have undetectable 
levels of viraemia (<50 copies/ml) and these individuals are termed “elite controllers”, “elite 
suppressors” or “HIV controllers”, however only 0.1%-1% of infected individuals represent 
this minority group (Deeks and Walker, 2007). 
 
1.4.2.3. AIDS onset 
 
Towards the end of the asymptomatic period viral load begins to increase and this 
precedes a more rapid decline in CD4+ T cells count to <200 cells/µl that marks the onset of 
AIDS and the manifestation of opportunistic diseases (Qu et al., 2008). Due to immune 
dysregulation, opportunistic infections can also manifest before CD4+ T counts decline to 
<200 cells/µl, however the severity of infections is increased at lower CD4+ T cell counts. In 
untreated HIV-1 infection, opportunistic infections such as pulmonary tuberculosis, 
Pneumococcal pneumonia, Herpes zoster, Kaposi’s sarcoma and oropharyngeal Candidiasis 
begin to appear at CD4+ T cell counts of <500 cells/µl (Peters et al., 2013). At a CD4+ T cell 
count of <200 cells/µl, extrapulmonary Tuberculosis, Pneumocystis pneumonia, clinical 
wasting and non-Hodgkin’s lymphoma become more common. Cryptococcus, Candididal 
esophagitis and chronic Cryptosporidiosis occurs at CD4+ T cell counts <100 cells/µl. 
Disseminated Cytomegalovirus and disseminated Mycobacterium avium complex are 
common opportunistic infections at CD4+ T cell counts <50 cells/µl. 
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1.4.3. HIV-1 immunity 
 
The human immune system has two defense arms known as innate immunity and 
adaptive immunity. The innate immune system is considered non-specific in the sense that 
defense against pathogens is generalised and targeting of common elements across invading 
organisms is often employed (pattern recognition). The innate immune system is also already 
present at birth and is only up or down regulated in response to infection. Conversely, the 
adaptive immune system has to be induced when infection occurs and the response is antigen-
specific with respect to a particular pathogen. Adaptive immunity also has a memory 
component and must be more rigorously regulated to avoid autoimmune disease. 
 
The HLA class I trans-membrane protein system plays a central role in both innate 
and adaptive immunity and is also implicated in immune hypersensitivity reactions to 
pharmaceutical drugs. HLA class I molecules are expressed on most nucleated cells, but can 
be absent or expressed at very low levels on erythrocytes, neurons, sperm/egg cells and 
villous trophoblast (Niederkorn and Wang, 2005, Sabir et al., 2013). In humans, there are 
three HLA class I gene loci (HLA-A, -B and -C) that map to the major histocompatibility 
complex region on chromosome 6p21.31 (Figure 1.11) (Klein and Sato, 2000). Due to 
extensive genetic polymorphism, HLA class I genes segregate into numerous allelic variants. 
To date 2,995 HLA-A alleles, 3,760 HLA-B alleles and 2,553 HLA-C alleles have been 
documented (http://www.ebi.ac.uk/ipd/imgt/hla/stats.html).The primary function of HLA 
class I molecules is to bind small immunogenic peptide antigens sampled from proteins 
present in the cytosol (Figure 1.12).The main difference between allelic variants of HLA 
class I molecules lies in the peptide-binding specificity of the protein which is largely 
determined by the amino-acid composition of the bound peptide, particularly residues 2 and 
11 that anchor the peptide (Figure 1.13). 
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Figure 1.11. HLA class I loci mapping to chromosome 6p21.31. Taken from (Klein and Sato, 2000). 
 
 
 
Figure 1.12. HLA class I and II molecule structures.Taken from (Klein and Sato, 2000). 
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Figure 1.13. Peptide specificities for some HLA class I molecules (a) and orientation of amino acids 
of bound peptide (b). Taken from (Klein and Sato, 2000). 
 
Many viruses, including HIV-1 and certain forms of malignancy interfere with the 
surface expression of HLA class I molecules. The innate immune system has evolved a 
mechanism to detect aberrations in cell surface expression of HLA class I molecules such as 
low abundance or absence. Lymphocyte subsets known as natural killer (NK) cells perform 
this duty and have the ability to kill target cells by perforin-dependent cell lysis (discussed in 
greater detail in section 2.3.1.). The adaptive immune system also makes use of HLA class I 
expression to detect the presence of intracellular pathogens, most commonly viruses. This is 
mediated by specialised immune cells known as CD8+ cytotoxic T lymphocytes (CTLs) that 
express T cell receptors (TCR) that are capable of sensing foreign peptide antigens bound to 
HLA class I molecules (discussed in greater detail in section 2.3.3.). 
 
24 
 
1.4.3.1. Natural Killer cell biology 
 
Natural killer (NK) cells constitute ~10% of circulating lymphocytes and mediate 
innate anti-viral/anti-tumour surveillance and facilitate adaptive immune responses via 
interaction with dendritic cells and pro-inflammatory cytokine production, such as interferon-
γ and tumour necrosis factor-α (Campbell and Hasegawa, 2013). NK cells functionally kill 
targets by inducing apoptosis; either by release of lytic granules containing perforin and 
granzymes (degranulation) or by ligation of NK cell death ligands, such as Fas ligand (FasL) 
or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), with cognate death 
receptors (Deguine and Bousso, 2013, Long et al., 2013). 
 
NK cell cytotoxicity and cytokine production is regulated by soluble factors as well as 
stimulation of cell surface activating/inhibitory receptors and co-stimulatory molecules (Long 
et al., 2013). An endosomal activation pathway via endocytosis of membrane receptor/ligand 
complexes that promotes cytokine production in the absence of cytotoxicity has also been 
described for uterine NK cells (Rajagopalan, 2010). The killer-cell immunoglobulin-like 
receptors (KIRs) are a diverse family of inhibitory/activating receptors which in combination 
with cognate ligands can associate with favourable/ deleterious outcomes in a range of 
infectious diseases including HIV, HCV, CMV, influenza, Mycobacterium tuberculosis and 
Plasmodium falciparum (Jost and Altfeld, 2013, Kulkarni et al., 2008). KIR/ligand 
interaction also influences susceptibility to many autoimmune/inflammatory conditions and 
certain types of cancer (Kulkarni et al., 2008). In addition, KIRs and their ligands are thought 
to play a role in human reproduction and can associate with susceptibility to pre-eclampsia, 
recurrent miscarriage and spontaneous abortion (Kulkarni et al., 2008, Parham and Moffett, 
2013). KIR/ligand mismatched recipient NK cells contribute to solid organ transplant 
rejection (van Bergen et al., 2011), whereas in allogeneic stem cell transplantation, 
mismatched KIR/ligand donor NK cells expressing activating receptors reduce the risk of 
graft-versus-host disease and augment anti-tumour responses (Locatelli et al., 2013, Stern et 
al., 2010). In HIV discordant couples, mismatched KIR/ligand combinations between sexual 
partners associates with reduced risk of heterosexual transmission (Jennes et al., 2013) and 
conversely, discordance of KIRs between mother and infant associates with increased risk of 
vertical transmission of HIV (Hong. et al., 2013). 
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In humans, 14 KIR genes (KIR2DL1-5, KIR2DS1-5, KIR3DL1-3 and KIR3DS1) and 
two pseudogenes (KIR2DP1 and KIR3DP1) have been described and are located in the 
leukocyte receptor complex (LRC) on chromosome 19q13.4 (Figure 1.14) (Middleton and 
Gonzelez, 2010). KIRs are classified according to the presence of two (2D) or three (3D) 
extracellular immunoglobulin-like domains and either a long (L) or short (S) cytoplasmic tail 
(Uhrberg, 2005). With the exception of KIR2DL4, a long cytoplasmic tail transduces 
inhibitory signals (KIR2DL1-3, KIR2DL5 and KIR3DL1-3) mediated by two immune 
tyrosine-based inhibitory motifs (ITIMs), whereas a short cytoplasmic tail transduces 
activation signals (KIR2DS1-5 and KIR3DS1) mediated by a transmembrane positively 
charged lysine or arginine residue that recruits immune tyrosine-based activation motif 
(ITAM)-bearing DAP12 homodimers (Lanier et al., 1998). KIR2DL4 is an unusual receptor 
that shares structural features with both inhibitory and activating KIRs (i.e. a single ITIM in 
the cytoplasmic tail and a positively charged arginine in the transmembrane region) and 
functions as an activating receptor with inhibitory potential (Faure and Long, 2002). 
 
Figure 1.14. Map of the leukocyte receptor complex (LRC) depicting the KIR loci on chromosome 
19q13.4. Taken from http://www.ebi.ac.uk/ipd/kir. 
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Classical HLA class I molecules serve as ligands for KIR2DS1/4, KIR2DL1-3 and 
KIR3DL1/2, while ligands for KIR2DS2/3/5, KIR2DL5, KIR3DS1 and KIR3DL3 are 
unknown (Parham et al., 2012). KIR3DL1 binds HLA-B molecules that express the Bw4 
epitope defined by an isoleucine (HLA-Bw480I) or threonine (HLA-Bw480T) at amino acid 
position 80 (Cella et al., 1994, Gumperz et al., 1995). A subset of HLA-A molecules also 
express the HLA-Bw480I epitope (Stern et al., 2008). HLA-C molecules with an asparagine 
present at position 80 are defined as group C1 epitopes and are recognised by KIR2DL2 and 
KIR2DL3, whereas KIR2DL1 and KIR2DS1 recognise group C2 epitopes defined by the 
presence of a lysine at position 80 (Mandelboim et al., 1996). Interestingly, in comparison to 
other primate species, humans lack an activating KIR that recognises the C1 epitope (Moesta 
et al., 2010) and additionally HLA-B allotypes that express the group C1 epitope have been 
lost (Abi-Rached et al., 2010). Notably, a minority of HLA-B alleles do encode the C1 
epitope, such as HLA-B*07:13, -B*46:01:01, -B*46:01:02, -B*46:02-46:18 and -B*67:02 as 
a result of recombination and HLA-B*07:15, -B*08:15, -B*15:57, -B*18:06, -B*35:74, -
B*39:27, -B*40:73, -B*55:03 and -B*73:01 as a result of point mutations (Abi-Rached et al., 
2010). KIR2DS4 recognises subsets of HLA-C1 and HLA-C2 allotypes as well as HLA-
A*11 (Graef et al., 2009). KIR3DL2 has been shown to bind HLA-A*11 and HLA-A*03 
allotypes as well as HLA-B*27 dimers and free heavy chains (Shaw and Kollnberger, 2012, 
Wong-Baeza et al., 2013). Recent reports have broadened the functional properties of 
KIR2DS4 and KIR3DL2 by demonstration of interaction with non-classical HLA-F 
molecules and peptide free HLA class I open conformers (Goodridge et al., 2013). 
 
KIR gene expression is controlled by epistatic regulatory mechanisms, hence,  KIRs 
are expressed stochastically on the surface of clonal subpopulations of NK cells (Chan et al., 
2005). Conversely, KIR2DL4, is expressed by all NK cells and furthermore, constitutive 
internalisation of cell surface KIR2DL4 by endocytosis results in localisation of the majority 
of receptors in endosomes (Rajagopalan, 2010). The ligand for KIR2DL4 is soluble HLA-G 
(sHLA-G), a non-classical HLA class Ib molecule, which is abundantly produced at the 
maternal-infant interface (Carosella et al., 2008). Although KIR2DL4 has been shown to 
function as an activating receptor with inhibitory potential (Faure and Long, 2002), recent 
studies have demonstrated that endosomal KIR2DL4 transduces unique intracellular 
activation signals that mediates NK cell production of pro-inflammatory cytokines and pro-
angiogenic factors, but does not induce cell-mediated cytotoxicity (Rajagopalan, 2010). This 
was suggestive that NK cells may be of importance in human reproduction, however, the 
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existence of truncated KIR2DL4 receptors, commonly present in Caucasians, that are not 
expressed on the cell surface (Kikuchi-Maki et al., 2003, Gedil et al., 2005) as well as normal 
pregnancies reported in women lacking KIR2DL4 is contradictory to this possibility (Gomez-
Lozano et al., 2003, Nowak et al., 2011). 
 
KIR genotypes are diverse at an individual and population level due to variability of 
the gene content of KIR haplotypes as well as allelic variation and copy number differences. 
Two KIR haplotype groups have been defined; haplotype A contains a fixed number of genes 
(n=9) that includes the “framework” genes; KIR3DL3, -3DP1, -2DL4 and -3DL2 present in 
the majority of humans (Middleton and Gonzelez, 2010) and KIR2DL1, -2DL3, -3DL1, -
2DS4 and -2DP1; whereas haplotype B is variable in gene content and includes the 
“framework” genes as well as one or more of the following KIR genes: KIR2DL2, -2DL5, -
2DS1, -2DS2, -2DS3, -2DS5 and -3DS1 (Martin et al., 2004a). Due to a recombination 
breakpoint between KIR3DP1 and -2DL4, KIR haplotypes can be further classified according 
to the genes encoded by the centromeric (c) region, flanked by KIR3DL3 and -3DP1, and the 
telomeric (t) region, flanked by KIR2DL4 and -3DL2. Analysis of KIR haplotypes (Figure 
1.15) in Caucasian, Asian, African-American and Hispanic populations have defined four 
centromeric (cA01 and cB01-B03) and two telomeric (tA01 and tB01) motifs (Pyo et al., 
2010, Jiang et al., 2012). KIR2DL5 is encoded by two genetic loci present in the telomeric 
and centromeric region, termed KIR2DL5A and KIR2DL5B, respectively, however, 
KIR2DL5B is not transcriptionally active (Vilches et al., 2000). Similarly KIR2DS3 and 
KIR2DS5 can also be present in either the telomeric or centromeric region (Hou et al., 2012).  
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Figure 1.15. KIR haplotypes commonly found in Caucasians. Taken from (Jiang et al., 2012). 
 
KIR genes have further diversified at an allelic level with the number of variants 
described as follows: KIR2DL1 (n=48), -2DL2 (n=30), -2DL3 (n=55), -2DL4 (n=52), -2DL5 
(n=48), -2DS1 (n=16), -2DS2 (n=22), -2DS3 (n=15), -2DS4 (n=31), -2DS5 (n=18),-R3DL1 
(n=110), -3DL2 (n=112), -3DL3 (n=111), -3DS1 (n=30), -2DP1 (n=28) and -3DP1 (n=27) 
(http://www.ebi.ac.uk/ipd/kir/stats.html). The documented KIR2DL5 alleles can be further 
subdivided into KIR2DL5A (n=15), -2DL5B (n=28) and 5 unassigned allelic variants. 
Mutagenesis of several KIR allelic variants has lead to these genes encoding soluble proteins 
that are not expressed on the cell surface. For example, KIR3DP1*004 encodes a secreted 
protein as a result of recombination between the promoter of KIR2DL5A and -3DP*001 and 
is the only transcriptionally active pseudogene (Gomez-Lozano et al., 2005). Similarly, 
several allelic variants of KIR2DL4 contain a -1 frameshift mutation in the coding region of 
the cytoplasmic tail that causes the expressed protein to be truncated and soluble (Goodridge 
et al., 2007). Loss of function due retention of proteins in the endoplasmic reticulum is 
attributed to the KIR3DL1*004 allelic variant (Pando et al., 2003). A number of alleles of 
KIR2DS4 encode truncated proteins that lack membrane anchoring domains due to a 22 base-
pair deletion in exon 5 (Maxwell et al., 2002, Middleton et al., 2007). 
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In addition to diversity in KIR gene repertoires and allelic variation, individuals may 
carry variable copy numbers of KIR genes due to duplications/deletions. This has been shown 
previously for KIR2DL4 (Williams et al., 2003), KIR3DL1/S1 (Pelak et al., 2011, Williams et 
al., 2003) and more recently for other KIR genes in the Caucasian population (Jiang et al., 
2012, Vendelbosch et al., 2013). The immunological significance of increased KIR copies has 
been demonstrated for KIR2DL3 in clearance of HCV (Khakoo et al., 2004) and KIR3DL1/S1 
in the control of HIV-1 replication (Pelak et al., 2011). 
 
1.4.3.2. CD8+ cytotoxic T cell biology 
 
Effector CTLs functionally kill infected targets in an antigen-specific manner via 
induction of apoptosis (Figure 1.16); either by release of lytic granules containing perforin 
and granzymes (degranulation) or by ligation of target cell death ligands, such as Fas ligand 
(FasL) or tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) (Deguine and 
Bousso, 2013, Long et al., 2013). The mechanism of recognition of target cells involves the 
interaction between the T cell receptor (TCR) and HLA class I molecules expressed on the 
surface of the CTL and the target cell, respectively (Andersen et al., 2006). Cells productively 
infected with HIV-1 accumulate viral proteins in the cytoplasm and via constitutive 
proteolytic processing of cytosolic proteins, mediated by the proteosome, short peptide 
antigens (9-11 amino acids) are generated that bind to HLA class I molecules (Figure 1.17). 
Peptide-bound HLA class I molecules are then displayed on the cell surface for potential 
recognition by CTL’s that express a unique TCR capable of recognising the peptide antigen 
in complex with HLA class I molecules. Recognition stimulates the effector functions of the 
CTL resulting in death of the target cell. CTL detection of virus-infected cells is dependent 
on presentation of antigenic peptides derived from viral proteins bound to HLA class I A, -B 
and -C molecules displayed on the surface of target cells. 
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Figure 1.16. Induction of apoptosis in target cells by CTLs either by engagement of death receptor 
ligands (top) or release of granzyme B and perforin (bottom). Taken from (Andersen et al., 2006). 
 
Figure 1.17. Intracellular protein processing and display of antigenic peptides on HLA class I 
molecules. Taken from (Andersen et al., 2006). 
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1.4.3.3. Virus/host interaction 
1.4.3.3.1. NK cell immune evasion 
 
The antiviral efficacy of NK cells are often underappreciated in HIV-1 infection, 
however, NK cell responses precede CTL responses during acute HIV-1 infection (Alter et 
al., 2007) and KIRs in combination with cognate HLA class I ligands, such as KIR3DL1 and 
HLA-Bw480I, associate with reduced viral load (Jiang et al., 2013, Pelak et al., 2011, Martin 
et al., 2007). The synergistic or epistatic interaction between KIR3DS1 and HLA-Bw480I also 
associates with low viral load (Pelak et al., 2011, Martin et al., 2002). KIR3DS1 and 
KIR3DL1 are similar in structure in the extracellular domains, however, functional studies 
have not shown direct interaction of KIR3DS1 with HLA-Bw480I ligands (Carr et al., 2007, 
Gillespie et al., 2007, O'Connor et al., 2007). Interestingly, CTLs also express KIRs, such as 
KIR3DL1 and KIR3DS1, and a recent report shows that KIR3DS1-positive CTLs are 
effective in targeting HIV-infected cells (Zipperlen et al., 2014). 
 
Although contact between KIRs and HLA class I molecules does not span the peptide 
binding site and hence KIR-ligand interaction is essentially antigen-independent, there is an 
enhancing or inhibitory effect on binding affinity mediated by the peptide antigen (Figure 
1.18). Mutations in viral proteins such as Gag, Vpr, Tat, Vpu, Env and Nef escape NK cell 
recognition by KIR2DS1/2/3/5, KIR2DL2/3 and KIR3DS1(Alter et al., 2011). Since KIRs 
can be activating or inhibitory, a plausible explanation for this finding is that mutations in 
HLA restricted viral epitopes either strengthen the inhibitory signal or dampen activation 
signals, thereby reducing NK cell activation potential. Sequence variation in the YL9 epitope 
in p24Gag restricted by HLA-C*03:04 have been found to influence binding to KIR2DL2 
inhibitory receptors (van Teijlingen et al., 2014), and similar studies in HLA-B*57 and 
KIR3DL1 have shown the same effects of amino acid substitutions in the p24Gag TW10 
epitope (Brackenridge et al., 2011). 
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1.4.3.3.2. CD8+ cytotoxic T cell immune evasion 
 
In HIV-1 infection, it is known that control of viral replication is primarily mediated 
by virus-specific CD8+ cytotoxic T lymphocytes (CTLs) (Borrow et al., 1994). This is further 
supported by SIV studies showing that depletion of CTLs results in increased viraemia 
(Schmitz et al., 1999). Due to the extensive genetic variation in HLA class I A, -B and -C 
alleles, differences in HIV-1 antigenic peptide binding specificities, has lead to the 
observation that some HLA class I alleles can be protective or deleterious. Immunogenetic 
studies in HIV-1 subtype C infected Black South African individuals have established that 
particular HLA class I alleles, such as HLA-B*57, -B*58:01, -B*81:01, -A*02:05, -C*04:01 
and -B*42:01 are significantly associated with lower viral loads, higher CD4+ T cell counts 
and slower disease progression, whereas the opposite is true for deleterious alleles such as 
HLA-B*45:01, -B*58:02, -B*18 and -C*06:02 (Kiepiela et al., 2004). One explanation for 
this observation is that protective HLA class I molecules bind immunogenic peptides derived 
from conserved viral protein domains which are less tolerant of mutations and therefore a 
sustained antiviral CTL response maintains a low viral load. Deleterious HLA class I 
molecules on the other hand target variable protein domains that mutate and allow escape 
from CTL surveillance. This is supported by work showing that CTL responses directed 
towards conserved proteins, such as Gag, are associated with lower viral loads than responses 
  
 
Figure 1.18. HLA class I molecule showing the KIR and TCR binding sites. Taken from 
(Parham et al., 2012). 
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to epitopes derived from variable proteins such as Env (Kiepiela et al., 2007, Wang et al., 
2009, Masemola et al., 2004a). It was demonstrated that Gag-specific HLA-B*58:01-
restricted CTLs could be identified in individuals controlling HIV-1 replication, whereas, in 
non-controlling individuals, HLA-B*58:02-restricted CTLs were directed towards Env, and 
furthermore, selection pressure on viral epitopes was reduced in HLA-B*58:02, but not in 
HLA-B*58:01 carriers (Ngumbela et al., 2008). Although similar in structure HLA-B*58:01 is 
a protective allele, but HLA-B*58:02 is a deleterious allele. 
 
It has also been observed that the protective benefits of HLA class I alleles, such as 
HLA-B*57 and -B*58:01 can be due to fitness costs imposed on replicating virus when CTL 
escape mutations are introduced into conserved proteins (Crawford et al., 2007). This is 
further supported by the observation that escape mutations often revert to wild-type when 
virus is transmitted to HLA mismatched hosts (Leslie et al., 2004). Unfortunately, it has also 
been shown that the benefits of early escape mutations that reduce viral replicative capacities 
can be overcome by compensatory mutations that develop during the chronic stage of 
infection (Brockman et al., 2010, Gijsbers et al., 2013). This has been documented in HLA-
B*58:01 carriers with subtype C HIV-1 infection in South Africa (Chopera et al., 2011). Over 
time this effect may also become established at a population level as evidenced by a lack of 
the protective benefits of HLA-B*57/58:01 in Botswana compared to South Africa due to the 
longer duration of the epidemic in Botswana (Payne et al., 2014). 
 
Recent data has shown that the timing of epitope presentation to CTLs may be of 
importance for long-term control of HIV-1 replication. Protective HLA alleles not only target 
conserved viral proteins, but also target p24Gag epitopes derived from incoming capsid 
proteins delivered to the cytoplasm following envelope fusion (Kloverpris et al., 2013a). This 
was first noted in SIV studies where early CTL responses to Gag where observed prior to 
integration and viral protein expression (Sacha et al., 2007). Following integration of the 
HIV-1 genome, due to Rev-dependent regulation of transcription, Rev, Tat and Nef proteins 
are expressed early in the replication cycle, while Gag and Pol are expressed at late stages 
(Karn and Stoltzfus, 2012). Expression of Env is also late and additional RNA splicing events 
are required. Attempts to relocate Gag epitopes from late to early proteins in integrated forms 
of virus showed variability in the timing of epitope presentation, meaning that it was not 
possible to confirm that lower viral loads associate with CTL responses before Nef-mediated 
down-regulation of HLA-A and -B molecules (Balamurugan et al., 2013). It therefore seems 
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likely that CTL targeting of HIV-1 core proteins derived from infecting virions is critical for 
long term control of virus. Interestingly, HIV-1 Nef proteins are incorporated into the virion 
by interaction with the p6Pol transframe protein, which may be an attempt to interfere with 
HLA class I presentation of antigens derived from core components of the infecting virion 
(Costa et al., 2004). 
 
In addition, an important finding in infected individuals carrying protective HLA 
alleles is that immune pressure by other HLA alleles in the individual’s repertoire, are co-
operative or additive in the overall control of viral replication (Matthews et al., 2012, Leslie 
et al., 2010). Particular haplotypes, such as HLA-C*04:01-B*81:01, -C*12:03-B*39:10, -
A*74:01-B*53:03 associate with improved viral control compared to the individual alleles 
(Leslie et al., 2010). Slow disease progression based on CD4+ T cell count associates with 
haplotypes HLA-A*74:01-B*15:03, -B*14:02-C*08:02 and -A*74:01-B*15:03-C*02:02, 
while accelerated disease progression associates with haplotypes HLA-A*30:02-B*45:01, -
A*30:02-C*16:01, -B*53:01-C*04:01, -B*15:10-C*03:04 and -B*58:01-C*03:02 
(Sampathkumar et al., 2014). 
 
1.4.4. HIV-1 treatment 
 
1.4.4.1. Antiretroviral drug therapy 
 
 The development of antiretroviral drugs (ARVs) for the treatment of HIV-1 infection 
has made the largest impact in the limiting of viral transmission. Although ARVs are only 
suppressive and do not cure HIV-1 infection, the development of different classes of 
compounds that target different aspects of the viral replication cycle (Figure 1.19) has 
provided a large repertoire of combinational therapies that has changed the status of HIV-1 
infection from an untreatable fatal disease to a manageable chronic illness (Cohen et al., 
2008). The first drug approved for HIV-1 treatment was zidovudine, a nucleoside reverse 
transcriptase inhibitor (NRTI), belonging to a class of compounds known as DNA chain 
terminators. To date there are 7 approved NRTIs including lamivudine (3TC), emtricitabine 
(FTC), stavudine (d4T), didanosine (ddI), abacavir (ABC), zidovudine (AZT) and zalcitabine 
(ddC), although ddC is no longer marketed. 
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 These drugs require intracellular phosphorylation to generate a nucleotide 
triphosphate that serves as a substrate for reverse transcriptase. The first nucleotide reverse 
transcriptase inhibitor (NtRTI) to be developed, tenofovir (TDF), already contains the first 
phosphate group and hence only requires double phosphorylation for activity. Collectively 
there are 8 nucleotide/nucleoside reverse transcriptase inhibitors (nRTIs) currently approved 
by the FDA (http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm). 
The early use of NRTIs in monotherapeutic and dual therapy settings lead to the discovery of 
drug resistance mutations that rendered decreased sensitivity to therapy. Due to the error 
prone nature of reverse transcription, randomly generated nucleotide substitutions in the 
reverse transcriptase gene were able to select for amino acid substitutions in the enzyme 
capable of either discriminating analogue molecules from normal nucleotides or facilitating 
excision of incorporated analogues (Arts and Hazuda, 2012). 
 
 The development of other classes of antiretroviral therapy such as the non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) lead to the 
development of combinational therapy known as highly active antiretroviral therapy 
(HAART) that was able to suppress virus replication sufficiently in order to limit the 
emergence of resistant virus. Currently 5 NNRTIs are licensed for use including delavirdine 
(DLV), efavirenz (EFV), nevirapine (NVP), etravirine (ETR) and rilpivirine (RPV) 
(http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm). ETR and 
RPV are second generation NNRTIs that are insensitive to some of the resistance mutations 
common to the first generation drugs. Licensed PIs include lopinavir (LPV), amprenavir 
(APV), fosamprenavir (FOS-APV), ritonovir (RTV), atazanavir (ATV), indinivir (IDV), 
nelfinavir (NFV), saquinavir (SQV), darunavir (DRV) and tipranavir (TPV), although FOS-
APV and APV are no longer marketed 
(http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm). 
 
Other targets in the viral replication cycle include inhibition of proviral integration 
mediated by integrase and viral entry facilitated by the interaction of gp41 with host 
membrane and interaction of gp120 with the co-receptor CCR5. Two licensed integrase 
inhibitors; raltegravir (RAL) and dolutegravir (DTG) are currently approved 
(http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm). The entry 
inhibitor, enfuvirtide (T-20), targets the mechanism of action of gp41 mediated fusion of viral 
envelope with the cell membrane, while the co-receptor antagonist, Maraviroc, inhibits CCR5 
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co-receptor binding to gp120 spike proteins that precedes envelope fusion 
(http://www.fda.gov/ForPatients/Illness/HIVAIDS/Treatment/ucm118915.htm). 
 
 
Figure 1.19. Drug targets in the viral replication cycle (a), relative time frame of drug action (b) and list 
of approved and investigational drugs targeting the viral life cycle (c). Taken (Arts and Hazuda, 2012). 
 
1.4.4.2. Immune hypersensitivity reaction 
 
Although ARV therapy has reduced morbidity and mortality associated with HIV-1 
infection, treatment success can be compromised by toxicity, resistance and immune 
complications such as immune reconstitution inflammatory syndrome (IRIS) and immune 
hypersensitivity reaction (IHR). In susceptible individuals, IHR develops rapidly following 
administration of the ABC or NVP. IHR is potentially life-threatening due to excessive 
activation of autoimmune CTLs and increased production of pro-inflammatory cytokines 
(Pompeu et al., 2012). Symptoms include fever, rash, nausea, vomiting, diarrhoea, abdominal 
pain, dyspnoea, sore throat, cough and malaise (Yuen et al., 2008). In extreme circumstances, 
failure to withdraw the drug, or re-initiation of therapy, can lead to multiple organ failure and 
death. ABC IHR associates with the presence of HLA-B*57:01, although, not all carriers 
develop a response (Hetherington et al., 2002, Mallal et al., 2002, Martin et al., 2004b, 
Phillips et al., 2005). Similarly, NVP IHR associates with the presence of HLA-B*35:05 in 
Thai populations (Chantarangsu et al., 2009, Yuan et al., 2011); HLA-C*04 in Thai, Chinese 
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and African populations (Likanonsakul et al., 2009, Gao et al., 2012, Yuan et al., 2011); 
HLA-C*08 in Japanese populations (Gatanaga et al., 2007) and HLA-B*14-C*08 haplotypes 
in Caucasian populations (Littera et al., 2006). Recently, the HLA-C*04:01 allelic variant was 
specifically associated with NVP IHR in an African population (Carr et al., 2013a). An 
association of HLA class II alleles, such as HLA-DRB1*01 (Vitezica et al., 2008) and HLA-
DRB1*0101 (Martin et al., 2005), with cutaneous rash/hepatotoxicity in Caucasians treated 
with NVP, has also been described and more recently, a study in South African populations 
has linked NVP hepatotoxicity with HLA-DRB1*0102 as well as HLA-B*58:01 (Phillips et 
al., 2013).  
 
The immunopathogenetic mechanism for ABC IHR is well characterised and 
demonstrates that drug-specific CTLs are activated in response to ABC exposure as shown 
experimentally by incubation of drug-treated HLA-B*57:01-expressing target cells with 
donor CTLs from HLA-B*57:01 carriers (Chessman et al., 2008). Furthermore, key residues 
114D and 116S, located in the peptide-binding pocket of HLA-B*57:01, determine the HLA 
class I allele specificity, since closely related HLAs, such as HLA-B*57:02 or HLA-
B*57:03, contain 114N and 116Y residues and are insensitive to ABC (Chessman et al., 
2008). Subsequent crystallographic studies revealed that ABC binds to HLA-B*57:01 via 
chemical interaction with residues 114D and 116S (Figure 1.20), with the latter position 
playing a dominant role (Illing et al., 2012, Norcross et al., 2012, Ostrov et al., 2012, 
Chessman et al., 2008). In what is termed the “altered peptide repertoire” mechanism, the 
presence of ABC in the HLA-B*57:01 peptide-binding pocket modifies the antigen 
specificity, leading to the presentation of self-peptides to autoimmune CTLs (Pompeu et al., 
2012). An alternative and not necessarily mutually exclusive mechanism, known as the 
“hapten” model, suggests that drug metabolites covalently linked to host proteins leads to the 
presentation of drug-modified self-peptides restricted by HLA-B*57:01 (Pompeu et al., 
2012). Indeed, ABC-modified proteins generated through aldehyde intermediates have been 
identified (Grilo et al., 2013) and furthermore, drug-specific CTL clones can be activated by 
overnight incubation of antigen presenting cells with ABC, but not following short-duration 
exposure, suggesting that an alternative pathway dependent on drug metabolism and antigen 
processing may exist (Bell et al., 2013). It remains to be determined whether similar 
mechanisms are involved in the development of NVP IHR. 
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Figure 1.20. Interaction of abacavir (orange and blue) with amino acid residues 114D and 116S ( 
purple and red) and immunogenic peptide (light and dark blue with red) located in the peptide binding 
cleft of HLA-B*57:01 determined by X-ray crystallography. Taken from (Illing et al., 2012). 
 
1.5. Problem statement 
 
Differences in host genetics can play modulatory roles in disease outcome in 
individuals and populations. HLA class I molecules are central in modulating both innate and 
adaptive immune responses to HIV-1exposure, via respective NK cell and CTL activities. In 
turn, the effectiveness of these responses influences both HIV-1 susceptibility to infection as 
well as disease progression and associated transmission risk. Due to the extensive 
polymorphism in HLA class I genes at a population and individual level, the efficacy of the 
immune response is dependent on inherited HLA class I repertoires, since particular alleles 
can be classified as protective or deleterious. Immunogenic peptides derived from viral 
proteins are restricted by particular HLA class I molecules that mediate immune detection of 
infected cells by CTLs and also influence NK cell surveillance via stimulation of KIRs. The 
KIR family of receptors are also highly polymorphic at population and individual levels and 
notably KIRs and HLAs assort to different chromosomes and are not necessarily inherited in 
complementary pairs. The effectiveness of NK cell responses is further complicated by 
variability in KIR gene repertoires, allelic variation and gene copy number variation. Both 
NK cell and CTL activities are also affected by the propensity of HIV-1 to induce mutations 
in immunogenic peptides that are restricted by HLA class I molecules that in turn affects both 
CTL and NK cell responses. Lastly, particular HLA class I alleles are also implicated in the 
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development of adverse events during treatment of HIV-1 infection with antiretroviral drugs 
via the development of immune-mediated hypersensitivity reactions. 
 
HIV-1 infection has a low prevalence in South African (SA) Caucasian (SAC), Indian 
(SAI) and Mixed ancestry (SAM) populations, but is high in SA Black (SAB) populations. 
This raises the possibility that, in part, genetic factors may contribute to HIV-1 susceptibility 
or transmission risk. SAB and SAC populations are well characterised, but little data on KIR 
and HLA class I genotypes are available for the SAI and SAM populations. A subset of HLA 
class I alleles are also associated with immune hypersensitivity reactions to antiretroviral 
drugs such as Abacavir and Nevirapine that are in use in South Africa. This PhD study aims 
to generate HLA class I and KIR genotypic data for healthy controls in the understudied 
populations for subsequent analysis and comparison to data available from SAB and SAC 
populations. Viral factors such as immune escape from virus-specific HLA class I restricted 
CTL detection and NK cell surveillance are also of importance, however, due to the low 
prevalence of HIV-1 in SAI and SAM populations, an investigation of evolution in HIV-1 
Gag epitopes from infected SAB individuals will be included and analysed in the context of 
KIR and HLA class I allele repertoires. 
 
The three main hypotheses that this study will address are as follows: 
 
1.  That the differential HIV-1 prevalence rates in SAI, SAM, SAC and SAB populations 
 may be affected, in part, by differences in HLA class I and KIR genotypes associated 
 with HIV-1 susceptibility and transmission risk that can be extrapolated from 
 genotypic data obtained from studies of healthy individuals from these populations. 
 
2. That the frequencies of HLA class I alleles associated with immune 
 hypersensitivity reaction to Abacavir and Nevirapine determined for healthy SAI, 
 SAM, SAC and SAB populations are significant and justifies the need for pre-
 treatment screening. 
 
3. That viral evolution in HIV-1 Gag contributes to disease progression in infected 
 individuals carrying different HLA class I alleles due to viral immune escape 
 from CTL and NK cell responses. 
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1.6. Study objectives 
 
To test these hypotheses the following study objectives will be met. 
 
1. Sequence based typing methods will be used to determine HLA class I A, -B and -C allelic 
variants present in healthy SAI and SAM populations for comparison to available data for 
SAB and SAC populations (Chapter 3). 
 
2. To develop and/or optimise qualitative rapid real-time AS-PCR based methods for the 
determination of HLA ligand and KIR genotype profiles in healthy controls from SAI and 
SAM populations for comparison to available data for SAB and SAC populations (Chapter 
3). 
 
3. To optimise quantitative real-time AS-PCR based methods for the determination of gene 
copy number variation for KIR3DL1/S1 and KIR2DS4f/v in SAI and SAM population 
(Chapter 3). 
 
4. To develop rapid real-time AS-PCR based screening assays to identify HLA class I alleles 
associated with Abacavir and Nevirapine immune hypersensitivity reaction, apply the method 
to healthy controls in SAI and SAM populations, and with SAC and SAC data included, 
determine the potential number of individuals who are at risk (Chapter 4). 
 
5. To compare and analyse the population data generated for SAI and SAM, with SAB and SAC 
data included, with respect to genotypes associated with HIV-1 acquisition and transmission 
to generate a hypothesis that host genetic factors might influence the HIV-1 prevalence in 
South Africa (Chapter 5). 
 
6. To design RT-PCR and sequencing methods to characterise the evolution of Gag over time in 
HIV-1-positive SAB individuals and to assess the contribution of viral immune escape 
mutations from CTL and NK cell responses in the context of KIR and protective/deleterious 
HLA class I alleles (Chapter 6). 
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Chapter 2:                                                              
Materials and Methods 
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2.1. Study cohorts 
 
2.1.1.  ESKOM cohort 
 
 Buffy coats stored at -80◦C were available for healthy individuals of SAM (n=40) and 
SAI (n=22) ethnicity from the ESKOM cohort recruited in a previous study (Paximadis et al., 
2012). Additional volunteers were recruited prospectively from staff/students at the National 
Institute for Communicable Diseases (NICD), the University of the Witwatersrand (WITS) 
Medical School and academic hospital in Johannesburg, to make up totals of 50 individuals 
for the SAI and SAM populations. Signed consent was obtained from each participant and 
ethics approval for the study was granted by the Human Research Ethics Committee 
(Medical) of the WITS medical faculty. Clearance certificate M130873 appears in Appendix 
A. 
 
2.1.2. Progressor cohort 
 
 HLA class I A, -B and -C genotypes, CD4+ T cell counts and viral load data were 
available for individuals (n=113) classified as progressors, based on CD4+ T cell counts 
declining to <350 cells/µl prior to initiation of treatment. These participants were part of a 
larger cohort of untreated HIV-1-positive SAB individuals recruited from Soweto, 
Johannesburg, for a previous study (Martinson et al., 2014). Based on HLA class I genotypic 
data, 9/113 (8.0%) progressors were HLA-B*58:01 carriers and 22/113 (19.5%) were HLA-
B*58:02 carriers. Baseline and follow up plasma samples stored at -80◦C, taken prior to 
initiation of treatment, were available for HLA-B*58:01 carriers (n=5) and for -B*58:02 
carriers (n=13). Ethics approval for the study was granted by the Human Research Ethics 
Committee (Medical) of the WITS medical faculty. Clearance certificate M130873 appears in 
Appendix A. 
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2.2. Methods 
 
2.2.1. DNA extraction 
 
 Genomic DNA was extracted from buffy coats or whole blood using the QiaAmp 
DNA blood mini kit (Qiagen, Hilden, Germany) as per the manufacturer’s instructions and 
quantified using a Nanodrop spectrophotometer instrument (Thermo Scientific, Waltham, 
USA). 
 
2.2.2. KIR genotyping assay 
 
 A real-time AS-PCR assay developed previously (Hong et al., 2011) was used in 
combination with additional PCR primers to generate KIR genotype profiles. The assay was 
enhanced by inclusion of a second set of primers designed to target KIR2DL3, -2DS1 and -
3DP1, since the original assay used a single set of primers for detection of these KIRs, but 
dual primer sets for all other KIRs. The use of dual primer sets for detection of all the KIRs 
improves coverage of allelic variants. The new KIR3DP1 primer sets were designed to 
include detection of allelic variants KIR3DP1*00902 and -3DP1*004 that were missed by the 
original KIR3DP1 primer set. All PCR primers were designed using KIR alignments available 
at the Immuno Polymorphism Database (IPD) (Robinson et al., 2013a). The internal control 
gene, GALC (Galactosylceramidase), was found to be compatible in multiplex with the new 
KIR primer sets. (A complete list of the dual sets of PCR primers used in the assay as well as 
KIR allelic variants missed or detectable by some primers appears in Table 2.1. 
 
 Real-time AS-PCR amplification was performed in 96-microwell PCR plates on an 
ABI7500 real-time PCR instrument (Life Technologies, Carlsbad, USA). Reaction volumes 
were 5 µl containing 5 ng of genomic DNA, 2X Universal SYBRgreen Mastermix (Roche, 
Mannheim, Germany), 0.5 µM KIR and 0.5 µM GALC forward/reverse primers (Inqaba 
Biotec, Pretoria, South Africa). Cycling conditions were an initial incubation of 95◦C for 10 
minutes followed by 30 cycles of 95◦C for 15s and 60◦C for 60s. Melting curve analysis was 
performed to determine the presence/absence of the gene of interest (Figure 2.1). True 
negatives showed the presence of control amplicon only due to a lower melting temperature. 
If no melting curves were present the sample was repeated. 
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Table 2.1. PCR primer sets used for the KIR real-time AS-PCR genotyping assay 
Well Primer name Primer sequence (5’-3’) KIR alleles not detected 
1 2DL1 f11 GTTGGTCAGATGTCATGTTTGAA *013N 
2DL1 r11 GGTCCCTGCCAGGTCTTGCG  
2 2DL1 f21 TGGACCAAGAGTCTGCAGGA *005 
2DL1 r21 TGTTGTCTCCCTAGAAGACG *0040102 
3 2DL2 f11 CTGGCCCACCCAGGTCG *004,*00601,*00602 
2DL2 r11 GGACCGATGGAGAAGTTGGCT *00303,*004 
4 2DL2 f22 AAACCTTCTCTCTCAGCCCA  
2DL2 r22 GCCCTGCAGAGAACCTACA *009 
5 2DL3 f12 AGACCCTCAGGAGGTGA  
2DL3 r12 CAGGAGACAACTTTGGATCA *010,*017 
6 2DL3 f24 GGCCCAGAAGTGCCCTCT  
2DL3 r24 ATTGGAGCTGGCAACCCA  
7 2DL4 f11 CAGGACAAGCCCTTCTGC  
2DL4 r11 CTGGGTGCCGACCACT  
8 2DL4 f21 ACCTTCGCTTACAGCCCG  
2DL4 r21 CCTCACCTGTGACAGAAACAG  
9 2DL5 f11 GCGCTGTGGTGCCTCG  
2DL5 r11 GACCACTCAATGGGGGAGC  
10 2DL5 f21 TGCAGCTCCAGGAGCTCA  
2DL5 r21 GGGTCTGACCACTCATAGGGT  
11 2DS1 f1a2 TCTCCATCAGTCGCATGAG  
2DS1 f1b2 TCTCCATCAGTCGCATGAA  
2DS1 r12 GGTCACTGGGAGCTGAC  
12 2DS1 f24 CCGCTCTTGAGCGAGCAA  
2DS1 r24 CAACTCCACCTCCAGGCCTATATA  
13 2DS2 f11 TTCTGCACAGAGAGGGGAAGTA  
2DS2 r11 GGGTCACTGGGAGCTGACAA  
14 2DS2 f21 CGGGCCCCACGGTTT *00104 
2DS2 r21 GGTCACTCGAGTTTGACCACTCA  
15 2DS3 f13 AAACCTTCTCTCTCAGCCCA  
2DS3 r13 GCATCTGTAGGTTCCTCCT  
16 2DS3 f21 CTATGACATGTACCATCTATCCAC  
2DS3 r21 AAGCAGTGGGTCACTTGAC  
17 2DS4 f11 CTGGCCCTCCCAGGTCA  
2DS4 r11 TCTGTAGGTTCCTGCAAGGACAG  
18 2DS4 f21 GTTCAGGCAGGAGAGAAT  
2DS4 r21 GTTTGACCACTCGTAGGGAGC 
19 2DS5 f11 TGATGGGGTCTCCAAGGG  
2DS5 r11 TCCAGAGGGTCACTGGGC *003 
20 2DS5 f21 ACAGAGAGGGGACGTTTAACC  
2DS5 r21 ATGTCCAGAGGGTCACTGGG  
21 2DP1 f11 GTCTGCCTGGCCCAGCT  
2DP1 r11 GTGTGAACCCCGACATCTGTAC  
22 2DP1 f21 CCATCGGTCCCATGATGG  
2DP1 r21 CACTGGGAGCTGACAACTGATG  
23 3DL1 f11 CGCTGTGGTGCCTCGA *009;*042;*057 
3DL1 r11 GGTGTGAACCCCGACATG  
24 3DL1 f1a2 CCATCGGTCCCATGATGCT *054 
3DL1 f1b2 CCATTGGTCCCATGATGCT *054 
3DL1 f1c2 TCCATCGGTCCCATGATGTT *054 
3DL1 r22 CCACGATGTCCAGGGGA  
25 3DL2 f11 CAAACCCTTCCTGTCTGCCC *01301;*01302;*014; 
*024;*025;*037;*040; 
*046;*052;*054 
3DL2 r11 GTGCCGACCACCCAGTGA  
26 3DL2 f21 CCCATGAACGTAGGCTCCG  
3DL2 r21 CACACGCAGGGCAGGG *018 
27 3DL3 f11 GTCAGGACAAGCCCTTCCTC  
3DL3 r11 GAGTGTGGGTGTGAACTGCA  
28 3DL3 f21 TTCTGCACAGAGAGGGGATCA  
3DL3 r21 GAGCCGACAACTCATAGGGTA  
29 3DS1 f11 AGCCTGCAGGGAACAGAAG  
3DS1 r11 GCCTGACTGTGGTGCTCG  
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30 3DS1f 2a2 CATCGGTTCCATGATGCG  
3DS1f 2b2 CATCAGTTCCATGATGCG  
3DS1 r22 CCACGATGTCCAGGGGA  
31 3DP1 f12 GTACGTCACCCTCCCATGATGTA *00902;*004 
3DP1 r14 GCACTCCCTCCCTCTATTCCT  
32 3DP1 f24 CATCCTCCTCTCTAAGGTGGC  
3DP1 r22 GAAAACGGTGTTTCGGAATAC  
All GALC f3 TTACCCAGAGCCCTATCGTTCT  
GALC r3 GTCTGCCCATCACCACCTATT  
GALC, galactosylceramidase; KIR, killer-cell immunoglobulin-like receptor; PCR, polymerase chain reaction; AS-PCR, 
allele-specific PCR. 1Primers taken from (Martin and Carrington, 2008); 2Primers taken from (Vilches et al., 2007); 3Primers 
taken from (Alves et al., 2009); 4Primers designed for this study. 
 
 
 
 
                   
Figure 2.1. Melting curve analysis of KIR gene of interest and GALC control gene. 
 
 
 
 
 
GALC 
KIR 
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2.2.3. HLA-Bw480I/Bw480T/C1/C2 ligand genotyping assay 
 
 A real-time AS-PCR assay developed previously (Hong et al., 2011) was used with 
additional primer modifications to generate HLA-Bw480I/Bw480T/C1/C2 ligand profiles based 
on genetic variation at codon-80. A complete list of the PCR primers used in the assay 
appears in Table 2.2. Further optimisation and enhancement of the HLA ligand assay was 
done by modifying the PCR primers as follows: (i) the HLA-A non-Bw480T reverse primer 
was extended to 20 bases, (ii) the HLA-B specific forward primers were replaced with a 
single re-designed common forward primer, (iii) the HLA-B Bw680N reverse primer was 
extended to 19 bases, (iv) the HLA-B Bw480TA reverse primer was extended to 20 bases and 
(v) optional HLA-B C180N reverse primers were included to pair with the common HLA-B 
specific forward primer to detect the rare subset of HLA-B alleles that encode HLA-C1 
epitopes. The assay makes use of 3’locked nucleic acid (LNA) modification to the primers 
(indicated by [ ] in Table 2.2) to reduce false-positive amplification due to mispriming. The 
redesigned common HLA-B forward primer when paired with the HLA-Bw480TA reverse 
primer showed improvement in the correct identification of two HLA-B*38:02-positive DNA 
samples obtained from the International Histocompatibility Working Group (IHWG) 
(www.ihwg.org) that had previously failed to type correctly in the original assay (Hong et al., 
2011). Detection of HLA-B allelic variants encoding C1 epitopes were successfully tested 
using three HLA-B*46 positive samples obtained from the IHWG, however, due to a 
nucleotide polymorphism in HLA-B*73:01, we included an additional reverse primer to 
detect this variant, but no control sample was available for testing. 
 
 Since HLA class I genotyping was done at a later time (discussed in Section 2.2.7.1.), 
all real-time AS-PCR results were confirmed to be in agreement with HLA typing results. 
However, we did notice a potential false positive result for two samples that were 
homozygous for HLA-B Bw480TA, where a small melting peak was visible when HLA-B 
Bw480IA primers were used. The HLA-B Bw480IA and HLA-B Bw480TA primers differ by a single 
base at the 3’end, and even though 3’LNA modified primers are used, a small amount of 
misprimed product may be generated in the presence of two copies of HLA-B Bw480TA. This 
was not seen in samples with a single copy of HLA-B Bw480TA and the false-positive peak 
height is considerably smaller than a true HLA-B Bw480IA result. Since the melting curve peak 
height is different for each primer set, we recommend that analysis is also done comparing all 
samples positive for the same primer set so that a false-positive call can be avoided. 
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Table 2.2. PCR primer sets used for the determination of genetic variability at codon-80 of HLA-ABC. 
Well Primer name Primer sequence (5’-3’) 
1 HLA-A Bw480I f11 CCATTGGGTGTCGGGTTTC[C] 
HLA-A/B Bw480I r11 CTCTGGTTGTAGTAGCGGAGCGCG[A] 
2 HLA-A non-Bw480T f11 AATCAGTGTCGTCGCGGTC[G] 
HLA-A non-Bw480T r12 GTTGTAGTAGCCGCGCAGG[G] 
3 HLA-B f12 GCGAGGGGACCGCAGGC[G] 
HLA-B Bw680N r12 TTGTAGTAGCCGCGCAGG[T] 
4 HLA-B f12 GCGAGGGGACCGCAGGC[G] 
HLA-A/B Bw480I r11 CTCTGGTTGTAGTAGCGGAGCGCG[A] 
5 HLA-B f12 GCGAGGGGACCGCAGGC[G] 
HLA-B Bw480TA r12 GTTGTAGTAGCGGAGCGCG[G] 
6 HLA-B f12 GCGAGGGGACCGCAGGC[G] 
HLA-B Bw480TL r11 CTCTGGTTGTAGTAGCGGAGCAGG[G] 
7 HLA-C C180N f11 AGCCAATCAGCGTCTCCGC[A] 
HLA-C C180N r11 GCTCTGGTTGTAGTAGCCGCGCAG[G] 
8 HLA-C C280K f11 CCATTGGGTGTCGGGTTCT[A] 
HLA-C C280K r11 GCTCTGGTTGTAGTAGCCGCGCAG[T] 
9 HLA-B f12 GCGAGGGGACCGCAGGC[G] 
HLA-B C180N r12 GCAGGTTCCGCAGGCTC[A] 
HLA-B C180N r22 GCAGGTTCCGCAGGCCC[A] 
All ALB f11 TCGATGAGAAAACGCCAGTAA 
ALB r11 ATGGTCGCCTGTTCACCAA 
ALB, albumin; HLA, human leukocyte antigen; PCR, polymerase chain reaction; AS-PCR, allele-specific PCR; [ ] denotes 3’ 
locked nucleic acid (LNA) base modification. 1Primers taken from (Hong et al., 2011); 2Primers modified or designed for 
this study. 
 
 Real-time AS-PCR amplification was performed in 96-microwell PCR plates on an 
ABI7500 real-time PCR instrument (Life Technologies, Carlsbad, USA). Reaction volumes 
were 5 µl containing 5 ng of genomic DNA, 2X Universal SYBRgreen Mastermix (Roche, 
Mannheim, Germany), 0.5 µM HLA ligand and 0.5 µM ALB control gene forward/reverse 
primers (Inqaba Biotec, Pretoria, South Africa). Cycling conditions were an initial incubation 
of 95◦C for 10 minutes followed by 35 cycles of 95◦C for 15s, 62◦C for 15s and 72◦C for 30s. 
Melting curve analysis was performed after generation of HLA ligand amplicons to determine 
the presence/absence of the gene of interest. True negatives showed the presence of control 
amplicon only due to a lower melting temperature compared to the gene of interest. 
 
2.2.4. CCR5/CCR5Δ32 genotyping assay. 
 
 CCR5/CCR5Δ32 genotypes were determined by a real-time AS-PCR threshold cycle 
(Ct) shift assay. Allele-specific forward primers CCR5WTf and CCR5Δ32f and a common 
reverse primer CCR5r were designed (Table 2.3) to amplify the full-length wild-type and 
32bp-deletion variant of CCR5 using genomic sequences available in Genbank 
(www.ncbi.nlm.nih.gov/genbank). Genomic DNA samples representing homozygous CCR5, 
homozygous CCR5Δ32 and heterozygous CCR5/CCR5Δ32 genotypes, previously 
characterised by DNA sequencing (Picton et al., 2010), were available as controls and for 
evaluation of the assay. Additional confirmation of results was done using an agarose gel-
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based amplicon size discrimination method. Briefly, genomic DNA was amplified with PCR 
primers spanning the 32bp-deletion, CCR5F and CCR5R (Table 2.3), followed by 2% 
agarose gel electrophoresis, ethidium bromide staining and visualisation of amplicons under 
UV light. 
 
Table 2.3. PCR primers used to determine CCR5/CCR5Δ32 genotypes 
Primer name Primer sequence (5’-3’) 
CCR5WTf TGCAGCTCTCATTTTCCATACAGTC 
CCR5Δ32f TGCAGCTCTCATTTTCCATACATTA 
CCR5r GATTCCCGAGTAGCAGATGACC 
CCR5F GTGGTGGCTGTGTTTGCGT 
CCR5R CATTTCGACACCGAAGCAGAG 
 
 Real-time AS-PCR amplification was performed in 96-microwell PCR plates using an 
ABI7500 real-time PCR instrument (Life Technologies, Carlsbad, USA). Reaction volumes 
were 5 µl containing 5 ng of genomic DNA, 2X Universal SYBRgreen Mastermix (Roche, 
Mannheim, Germany) and 0.5 µM CCR5 forward/reverse primers (Inqaba Biotec, Pretoria, 
South Africa). Cycling conditions were an initial incubation of 95◦C for 10 minutes followed 
by 45 cycles of 95◦C for 15s, 62◦C for 5s and 72◦C for 30s and results were determined by 
analysis of relative shifts of threshold cycle (Ct) values (Figure 2.2). 
 
 
Figure 2.2. Schematic representation of real-time PCR amplification curves of the CCR5 gene and 
CCR5∆32 allelic variant. The SYBRgreen amplification plots of the threshold cycle (Ct) shift assay 
were designed to discriminate wild-type CCR5 from the CCR5∆32 deletion mutant. (a) Homozygous 
CCR5 wild-type, primer mispriming results in amplifying 10 cycles later; (b) CCR5/CCR5∆32 
heterozygous, no primer mispriming and similar Ct values; (c) Homozygous CCR5∆32 mutant, primer 
mispriming results in amplification 6 cycles later. ΔRn; derivative of reporter. 
2.2.5. Copy number variation assay for KIR2DS4f/v and KIR3DL1/S1 
 
 Published primers and probe specific for KIR2DS4f/v (Jiang et al., 2012) and 
KIR3DL1/S1 (Pelak et al., 2011) were used in combination with the primers and probe 
specific for the human beta-globin (BGB) reference gene (Shostakovich-Koretskaya et al., 
   (a) (b) (c) 
Δ
R
n 
 
Cycle  number 
Δ
R
n 
 
Cycle  number 
Δ
R
n 
 
Cycle  number 
49 
 
2009) in a probe hydrolysis-based relative quantification real-time AS-PCR assay to 
determine gene copy number variation. A complete list of the PCR primers and probes used 
in the copy number variation assay are listed in Table 2.4. To facilitate target and reference 
gene multiplexing, KIR-specific probes were labelled at the 5’-end with the fluorochrome 
VIC, while BGB probes were labelled with the fluorochrome FAM. Standard curves were 
generated in two-fold dilution steps over a range of 20 - 0.625 ng of genomic DNA. The 
control DNA for the KIR2DS4f/v assay was derived from a haplotype AA1 donor carrying a 
single copy each of KIR2DS4f and KIR2DS4v, while DNA extracted from the CEPH cell 
lines GM11840 and GM12752, containing single copies of KIR3DL1 and -3DS1 was used for 
the KIR3DL1/S1 assay (Pelak et al., 2011). 
 
Table 2.4. List of PCR primers and probe sequences used for real-time quantitative AS-PCR copy 
number determination of KIR3DL1/S1 and KIR2DS4f/v. 
Well Primer name Primer sequence (5’-3’) 
1 KIR3DL1 f11 GCCTCGTTGGACAGATCCA[T] 
KIR3DL1 r11 TAGGTCCCTGCAAGGGCA[A] 
KIR3DL1/S1 probe1 VIC-GGGTCTCCAAGGCCAATTTCTCCAT-MGB 
2 KIR3DS1 f11 CTCGTTGGACAGATCCATG[A] 
KIR3DS1 r11 GTCCCTGCAAGGGCA[C] 
KIR3DL1/S1 probe1 VIC-GGGTCTCCAAGGCCAATTTCTCCAT-MGB 
3 KIR2DS4f f12 CCGGAGCTCCTATGACATG 
KIR2DS4f/v r12 TGACGGAAACAAGCAGTGG[A] 
KIR2DS4f/v probe2 VIC-AACATTCCAGGCCGACTTTCCTCTG-MGB 
4 KIR2DS4v f12 CCTTGTCCTGCAGCTCCAT 
KIR2DS4f/v r12 TGACGGAAACAAGCAGTGG[A] 
KIR2DS4f/v probe2 VIC-AACATTCCAGGCCGACTTTCCTCTG-MGB 
All BGB f13 TCGCTTTCTTGCTGTCCAATTTCTA 
BGB r13 ATGCTCAAGGCCCTTCATAATATCC 
BGB probe3 FAM-CCTAAGTCCAACTACTAAACTG-MGB 
VIC and FAM, probe reporter fluorescent dyes; MGB, minor groove binding protein (non-fluorescent quencher); AS-PCR, 
allele-specific PCR; BGB, human beta-globin, [ ] denotes 3’ locked nucleic acid (LNA) base modification. 1Primers/probes 
taken from (Pelak et al., 2011); 2Primers taken from (Jiang et al., 2012); 3Primers/probes taken from (Shostakovich-
Koretskaya et al., 2009). 
 
 Real-time AS-PCR amplification was performed in 96-microwell PCR plates using an 
ABI7500 real-time PCR instrument (Life Technologies, Carlsbad, USA). Reaction volumes 
were 5 µl containing 5 ng of genomic DNA, 2X Lightcycler 480 probes Mastermix (Roche, 
Mannheim, Germany), 0.5 µM KIR3DL1/S1 or KIR2DS4f/v forward/reverse primers (Inqaba 
Biotec, Pretoria, RSA), 0.5 µM BGB forward/reverse primers (Inqaba Biotec, Pretoria, RSA), 
0.1 µM VIC-labelled KIR3DL1/S1 or KIR2DS4f/v probe and 0.1 µM FAM-labelled BGB 
probe (Life Technologies, Carlsbad, USA). Cycling conditions were an initial incubation of 
95◦C for 10 minutes followed by 40 cycles of 95◦C for 15s and 60◦C for 60s. Gene copy 
numbers were estimated from the ratio of the relative amounts of target and reference genes. 
All samples were run in duplicate and repeated if the copy numbers were not in agreement. 
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2.2.6. Determination of HLA-C 3’UTR +263 insertion/deletion variants 
 
 The HLA-C 3’UTR was amplified by conventional PCR using published primers 
(Kulkarni et al., 2011). PCR cycling conditions were 94◦C for 2 minutes followed by 30 
cycles of 94◦C for 15s, 65◦C for 30s and 72◦C for 90s and a final extension of 72◦C for 7 
minutes. PCR products were purified using Agencourt Ampure XP magnetic bead separation 
(Becton-Dickenson, Franklin lakes, USA). Sequence products were generated using a 
published reverse primer (Gentle et al., 2013) and the BigDye terminator v3.1 cycle 
sequencing kit (Life Technologies, Carlsbad, USA). Sequence products were purified using 
ethanol-sodium acetate precipitation and resolved on an ABI3100 PRISM Genetic Analyser 
instrument (Life Technologies, Carlsbad, USA). DNA sequences were analysed using 
Sequencher v4.5 software (Gene Codes Corporation, Ann Arbor, USA). 
 
2.2.7. High resolution HLA class I ABC genotyping 
 
2.2.7.1. ESKOM cohort 
 
 The SBT resolver kit (Conexio Genomics, Fremantle, Australia) was used to generate 
HLA class I A, B and C amplicons for DNA sequencing as described by the manufacturers. 
PCR products were purified using Agencourt Ampure XP magnetic bead separation (Becton-
Dickenson, Franklin lakes, USA). Sequence products were generated using the BigDye 
terminator v3.1 cycle sequencing kit (Life Technologies, Carlsbad, USA), purified using 
ethanol-sodium acetate precipitation and resolved on an ABI3100 PRISM Genetic Analyser 
instrument (Life Technologies, Carlsbad, USA). Alleles were assigned using ASSIGN-SBT 
v4.7 software (Conexio Genomics, Fremantle, Australia). When encountered, ambiguous 
HLA class I genotypes were resolved using a “common” allele predictive approach based on 
allele frequency data available from the same population or ancestral populations. 
Ambiguities for the SAI population were resolved using data available from a previous HLA 
class I study of SAI individuals (n=51) as well as data available from studies in mainland 
India (Gonzalez-Galarza et al., 2011). Ambiguities found in the SAM population were 
resolved by referring to published HLA class I alleles detected in this population (Salie et al., 
2014) as well as referring to HLA class I allele frequency data available for two of the 
ancestral populations, SAC and SAB (Paximadis et al., 2012). In addition, since HLA-A, -B 
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and -C alleles were determined for each sample, common HLA class I  haplotypes could be 
used to support the linkage of specific alleles (Gonzalez-Galarza et al., 2011). 
 
2.2.7.2. Progressor cohort 
 
 High resolution HLA class I genotypes were determined for the study participants 
using the Roche 454 GS FLX next-generation sequencing platform (Roche Diagnostics, 
Indianapolis, USA). This work was outsourced to the HLA typing service available at the 
Mallal Laboratory, Institute for Immunology and Infectious Diseases, Murdoch University, 
Western Australia. Briefly, genomic DNA was used to generate DNA sequences spanning 
exons 2 and 3 of HLA-A, -B and -C alleles by PCR simultaneously incorporating DNA 
adaptor molecules. Amplicons were purified, quantified by fluorimetry, diluted and subjected 
to emulsion PCR. Sequence data was then generated on a Roche 454 GS FLX instrument as 
per instructions by the manufacturers. Alleles were assigned by matching exon consensus 
sequences to a reference library. 
 
2.2.8. Determination of HLA-B signal peptide p2-M/T variants 
 
 The presence of methionine or threonine at position-2 of the HLA-B signal peptide 
was determined by sequence analysis of exon 1 that is available through amplicon sequencing 
results from the HLA-B SBT typing method 
 
2.2.9. Statistical analysis 
 
 Gene frequencies were determined by direct counting. Significance values and odds 
ratios were calculated using the two-tailed Fisher’s exact test or the Mann-Whitney test 
available in GraphPad Prism v4.02 software (GraphPad software, San Diego, USA). Due to 
the hypothesis-generating nature of this study, correction for multiple testing was not applied, 
since, given the complex and multifactorial nature of HIV-1 susceptibility/transmission, we 
considered it more important to identify potential factors that may play a role in HIV-1 
acquisition and donor infectivity rather than simply dismissing these leads as due to chance 
variations brought about by multiple comparisons. 
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2.2.10. Phylogenetic analysis 
 
 Neighbour-joining phylogenetic trees were constructed using the Kimura 2-parameter 
model and n=1000 bootstrap settings available in the software MEGA v5 (Tamura, Dudley, 
Nei and Kumar., 2007). 
 
2.2.11. HLA class I IHR real-time AS-PCR assay development 
 
 Due to the extensive genetic polymorphism in HLA-B*57 allelic variants (n=85), the 
design of AS-PCR primers capable of direct discrimination of alleles of HLA-B*57:01 (n=16) 
from other HLA-B*57 alleles necessitated the use of a novel strategy. In order to detect the 
presence of any HLA-B*57 allele, two group-specific primer sets were designed. Two primer 
sets were included to detect the presence of HLA-B*57 alleles encoding amino-acid residues 
114D and 116S. It has been shown that these two key amino-acid residues located in the 
peptide-binding pocket of HLA-B*57:01 determine the HLA class I allele specificity in ABC 
IHR, since closely related HLA molecules, such as HLA-B*57:02 and -B*57:03, that contain 
114N and 116Y, are insensitive to ABC (Chessman et al., 2008). A final primer set to 
identify the guanine (G) variant of the HCP5 rs2395029 single nucleotide polymorphism 
(SNP), also termed “HCP5 568G”, was also included, since HCP5 568G is known to be in 
strong linkage disequilibrium with HLA-B*57:01 (Colombo et al., 2008, Rodriguez-Novoa et 
al., 2010). A positive PCR amplification for all five primer sets is highly indicative of the 
presence of HLA-B*57:01. However, since linkage between HCP5 568G and HLA-B*57:01 
is not absolute (Badulli et al., 2012, Colombo et al., 2008), it is useful to confirm the presence 
of HLA-B*57 as well as codons 114D and 116S in cases where HCP5 568G occurs in HLA-
B*57:01-negative individuals or is absent in HLA-B*57:01-positive individuals. 
 
 The primers used to detect alleles of HLA-B*57 (n=85) and -B*35:05 (n=3) were 
designed using sequence alignments of HLA-B alleles (n=3,089) available in the International 
Immunogenetics project (IMGT)/HLA database (Robinson et al., 2013b), last updated in 
October 2013 (Table 2.6). To detect the presence of codons 114D and 116S in HLA-
B*57:01, a common forward primer B57E was designed to pair with two allele-specific 
reverse primers 114D and 116Sa (Table 2.6). Due to a sequence polymorphism in codon 
116S in HLA-B*57:01:02, an additional reverse primer 116Sb was also included. Notably, 
other HLA alleles also encode 114D and 116S, hence, the B57E primer was designed to 
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selectively target HLA-B*57 specifically, however HLA-B*57:11 is missed. This does not 
affect detection of HLA-B*57:01, however, codons 114D and 116S are also present in other 
HLA-B*57 alleles and it is not certain whether these alleles also associate with ABC IHR, 
although, these residues are present in HLA-B*58:01 molecules, which is insensitive to ABC. 
As a precaution, individuals testing positive for the presence of other HLA-B*57 alleles that 
encode 114D and 116S should either be excluded from ABC therapy or be closely monitored 
for early signs of clinical development of IHR. The primers used to detect alleles of HLA-
C*04 (n=221) and -C*08 (n=121) were designed using sequence alignments of HLA-C alleles 
(n=2,032) available in the IMGT/HLA database (Robinson et al., 2013b), last updated in 
October 2013 (Table 2.6). Although attempts were made to avoid false-positive PCR 
amplifications, due to the large number of HLA-B and -C alleles documented, it was 
inevitable that a small number of alleles would be co-amplified by the primer sets used in the 
assay (Table 2.7). The number of alleles co-amplified was minimized to 21/3089 (0.7%), 
12/3089 (0.4%), 18/2032 (0.9%) and 9/2032 (0.4%) for HLA-B*57, -B*35:05, -C*04 and -
C*08, respectively. 
 
 The real-time AS-PCR assay was performed in 96-microwell PCR plates using an 
ABI7900HT real-time PCR instrument (Life Technologies, Carlsbad, USA). Reaction 
volumes of 5 µl containing 5 ng of genomic DNA, 2X universal SYBRgreen mastermix with 
ROX passive reference dye (Roche, Mannheim, Germany), 0.5 µM HLA gene-specific 
forward/reverse primers and 0.5 µM ALB forward/reverse primers (Inqaba Biotec, Pretoria, 
RSA). Cycling conditions were an initial denaturation of 95◦C for 10 minutes followed by 35 
cycles of 95◦C for 15s, 65◦C for 5s and 72◦C for 60s. Melting curve analysis was performed to 
determine the presence/absence of the gene of interest. The presence of a melting peak 
corresponding to the positive control gene (ALB) and absence of a melting peak 
corresponding to the gene of interest was considered a true negative (Figure 2.2). The sample 
was repeated if no melting peaks were visible at all. 
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Table 2.5. PCR primers used to identify HLA class I alleles associated with ABC and NVP IHR 
Well Primer name Primer sequence (5-3’) 
1 B57A (sense) CGCGAGTCCGAGGATGG[C] B57B (antisense) TCTCGGTAAGTCTGCGCGG[A] 
2 B57C (sense) GAGACACGGAACATGAAGGCCT[C] B57D (antisense) CCACGTCGCAGCCATACATCA[C] 
3 B57E (sense) GGGTCTCACATCATCCAGG[T] B57114D (antisense) CCGTCGTAGGCGGACTGGT[C] 
4 
B57E (sense) GGGTCTCACATCATCCAGG[T] 
116Sa (antisense) TAATCCTTGCCGTCGTAGGCG[G] 
116Sb (antisense) TAATCCTTGCCGTCGTAGGCA[G] 
5 HCP5GF (sense) GGCCTTGGGAAATTACCTGG HCP5GR (antisense) TACACATTACAGCTGCC[C] 
6 B3505F (sense) CGGGTCTCACACCCTCCAGAG[C] B3505R (antisense) CGGAGGAGGCGCCCGTC[G] 
7 C04A (sense) AGCGACGCCGCGAGTCC[A] C04B (antisense) GCGGTCCAGGAGCGCAG[A] 
8 C04C (sense) TGAGGTATTTCTCCACATCCGTGTCC[T] C04D (antisense) GCCGTCGTAGGCGAACTGGT[T] 
9 C08A (sense) ACGACACGCAGTTCGTG[C] C08B (antisense) CGCAGGTTCCGCAG[G] 
10 C08C (sense) AGGCACAGACTGACCGAGTG[A] C08D (antisense) GGTCCAGGAGCGCAGGTCCT[C] 
All ALBF (sense) TCGATGAGAAAACGCCAGTAA ALBR (antisense) ATGGTCGCCTGTTCACCAA 
[ ] denotes 3’Locked Nucleic Acid (LNA) modification; AS-PCR, allele-specific PCR; HLA, human leukocyte antigen; 
ABC, abacavir; NVP, nevirapine; IHR, immune hypersensitivity reaction. 
 
 
Table 2.6. HLA class I alleles predicted to be missed or co-amplified by the AS-PCR primers used 
Primer set HLA alleles missed HLA alleles co-amplified 
B57A/B B*57:16; -57:45; 57:51 B*15:16:01-03; 15:17:01:01; 15:17:01:02; 15:17:02; 
15:67; 15:95; 15:162; 15:168; 15:177; 15:196; 15:208; 
15:216; 15:222; 15:230; 15:254; 15:268; 15:273; 58:36 
B57C/D B*57:05; 57:11 B*58:14 
B57E/114D B*57:11 B*35:208; 55:14; 58:14 
B57E/116S B*57:11 B*35:208; 55:14; 58:14 
B3505F/R none B*35:58; 35:66; 35:72; 35:89; 35:97; 35:114; 35:232; 
40:02:08; 40:24; 41:04; 53:14; 58:18 
C04A/B C*04:01:05; 04:01:07; 04:01:09; 
04:01:23; 04:04:02; 04:160; 04:94:02 
C*03:04:25; 08:01:07; 08:02:07; 08:33:02; 12:03:20; 
14:02:03; 14:03; 14:08; 14:10; 14:22; 14:35N; 14:38; 
14:41; 14:53; 14:54; 15:77; 16:01:06 
C04C/D C*04:03:01; 04:03:02; 04:06; 04:16; 
04:23; 04:42; 04:54; 04:80; 04:100; 
04:103; 04:107; 04:108; 04:140; 04:147; 
04:160 
C*05:78 
C08A/B C*08:10; 08:13; 08:16:01; 08:16:02; 
08:25; 08:94 
C*01:43; 07:101; 07:148; 07:161 
C08C/D C*08:10; 08:01:06; 08:01:07; 08:02:04; 
08:02:07; 08:33:01; 08:33:02 
C*01:34; 03:87; 07:02:35; 07:41; 12:02:07 
HLA, human leukocyte antigen; AS-PCR, allele-specific PCR 
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Figure 2.3. Melting curve analysis of HLA gene of interest and ALB control gene. 
 
2.2.12. Cumulative analysis of protective/deleterious factors 
 
2.2.12.1. HIV-1 acquisition 
 
 A cumulative analysis of factors associated with HIV-1 acquisition was done for each 
individual by assigning equal weighting to protective factors known to be associated with 
resistance including KIR2DL2/3+HLA-C1/C2, KIR3DL1/S1+HLA-Bw4, specific HLA-ABC 
alleles and HLA-B p2-T/T phenotypes; while deleterious factors known to be associated with 
susceptibility included KIR2DL2/3+HLA-C1/C2, KIR3DL1/S1+HLA-Bw4, HLA-B p2-M/M 
phenotypes and specific HLA-ABC alleles. KIR-HLA ligand combinations associated with 
HIV-1 acquisition have been reported (Guerini et al., 2011, Habegger de Sorrentino et al., 
2013, Jennes et al., 2006) and include KIR2DL2(+)/KIR2DL3(+)/HLA-C2/C2(+), 
KIR3DL1(+)/KIR3DS1(-)/HLA-B Bw6/Bw6(+), KIR3DL1(-)/KIR3DS1(+)/HLA-B Bw480I(+), 
KIR3DL1(+)/KIR3DS1(+)/HLA-B Bw480I(+)/Bw6(+) and KIR3DL1(+/-)/KIR3DS1(+)/HLA-
A/B Bw480I(+) that associate with resistance and KIR2DL3(+)/KIR2DL2(-)/HLA-C1/C2(+) 
ALB 
HLA 
D
er
iv
at
iv
e 
Temperature (◦C) 
56 
 
and KIR3DL1(+)/KIR3DS1(-)/HLA-A/B Bw480I/80T(+) that associate with susceptibility. Due 
to some KIR3DL1/S1 and HLA-Bw4 ligand combinations having overlapping profiles, a 
single protective KIR-HLA ligand genotype was assigned to an individual when more than 
one protective combination was present. HLA-B signal peptide p2-T/T phenotypes were 
counted as resistance factors, while the HLA-B signal peptide p2-M/M phenotype was 
counted as a susceptibility factor (Merino et al., 2013, Merino et al., 2012). Although 
heterozygous HLA-B signal peptide p2-M/T phenotypes have been shown to confer an 
intermediate degree of protection from HIV-1 acquisition (Merino et al., 2012), we did not 
include heterozygotes in our analysis. A number of studies have reported associations of 
individual HLA class I A, -B and -C alleles with heterosexual HIV-1 acquisition and where 
possible, taking all 6 alleles into account, these data were used to determine whether an 
individual had an overall resistance or susceptible HLA class I profile scoring the total 
number of protective vs. deleterious alleles. The relevant HLA class I alleles found in this 
study are listed alongside references in Appendix B. In this analysis, individuals with equal 
numbers of protective and deleterious HLA alleles or with alleles that were not associated 
with acquisition were considered neutral. In some cases contradictory reports on associations 
of HLA class I alleles and HIV-1 acquisition were observed, most likely due to population or 
viral subtype differences. In these cases, we opted for reports in populations closest in match 
to our populations under study or if there was an excess of studies in favour of an association. 
2.2.12.2. HIV-1 viral load setpoint 
 
 A similar cumulative analysis of factors associated with HIV-1 viral load setpoint 
(VLS) was done for each individual by assigning equal weighting to known protective factors 
associated with low VLS including CCR5/CCR5Δ32 heterozygosity (van Manen et al., 2011), 
KIR3DL1/S1+HLA-Bw4, HLA-C 3’UTR +263-del/del genotypes and specific HLA-ABC 
alleles; while deleterious factors associated with high VLS included KIR3DL1/S1+HLA-Bw4, 
KIR2DS4f (Merino et al., 2011, Merino et al., 2014), HLA-C 3’UTR +263 ins/ins genotypes 
and specific HLA-ABC alleles. Reported KIR-HLA ligand combinations associated with VLS 
(Pelak et al., 2011, Jiang et al., 2013) were used in the cumulative analysis and included 
KIR3DL1(+/-)/KIR3DS1(+)/HLA-B Bw480I(+), KIR3DL1(+)/KIR3DS1(+)/HLA-B Bw480I(+) 
and KIR3DL1(+)/KIR3DS1(-)/HLA-B Bw480I(+) associated with low VLS and 
KIR3DL1(+)/KIR3DS1(+/-)/HLA-B Bw480I(-) and KIR3DL1(+)/KIR3DS1(-)/HLA-B Bw480I(-) 
associated with high VLS. Since the genotypes involving KIR3DL1/S1 and HLA-Bw4 had 
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overlapping profiles, an overall analysis per individual was done by only counting a 
protective genotype once, even if there was more than one protective genotype present. HLA-
C 3’UTR +263-ins/ins homozygosity was counted as a protective factor associated with low 
VLS, while HLA-C 3’UTR +263 del/del homozygosity was counted as a deleterious factor 
associated with high VLS (Kulkarni et al., 2011). Although HLA-C 3’UTR +263 ins/del 
heterozygosity has been shown to exert an intermediate influence in reducing VLS, we only 
considered homozygotes in our analysis. A number of studies have reported associations of 
individual HLA class I A, -B and -C alleles with VLS following heterosexual HIV-1 
acquisition and these data were used to determine whether an individual had an overall low or 
high VLS HLA class I profile by adding up the total number of protective vs. deleterious 
alleles. The relevant HLA class I alleles found in this study and references are listed in 
Appendix C. Individuals with equal numbers of protective and deleterious alleles or with 
alleles that have not been shown to associate with VLS were considered neutral. Again, in 
some cases contradictory reports on associations of HLA class I alleles and HIV-1 VLS were 
observed, most likely due to population or viral subtype differences. In these cases, we opted 
for reports in populations closest in match to our populations under study or if there was an 
excess of studies in favour of an association. 
 
2.2.13. HIV-1 RNA isolation, reverse transcription and gag sequencing 
 
 A set of nested PCR primers and internal sequencing primers were designed to 
amplify and sequence near full-length gag genes encompassing partial p17Gag coding regions 
to the Gag stop codon (Table 2.5). PCR and sequencing primers were optimally designed 
using alignments of sub-Saharan subtype C gag sequences available at the Los Alamos HIV 
Database (http://www.hiv.lanl.gov). Viral RNA was extracted from 500 µl of plasma using 
the high performance MagNA Pure LC total nucleic acid isolation kit and a MagNA Pure LC 
instrument (Roche Diagnostics, Indiapolis, USA). The elution volume was set to 50 µl and 
viral RNA was stabilised by addition of MS2 carrier RNA (Roche Diagnostics, Indiapolis, 
USA) to a final concentration of 10 ng/µl. Complementary DNA (cDNA) was synthesised 
using the outer reverse primer, gagoutR. An initial primer annealing step was performed by 
adding 50 pmol of gagoutR in 0.5 µl to 12.5 µl of viral RNA and heating to 65◦C for 10 
minutes before cooling on ice for 2 minutes.  The annealed RNA mixture was made up to a 
20 µl reaction volume by addition of 0.5 µl of reverse transcriptase enzyme and 4 µl of 5X 
buffer from the Transcriptor cDNA kit (Roche Diagnostics, Indiapolis, USA), 2 µl of 10 mM 
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dNTP mix (Roche Diagnostics, Indiapolis, USA) and 0.5 µl of Protector RNAse inhibitor 
(Roche Diagnostics, Indiapolis, USA). The cDNA reaction was incubated at 50◦C for 1 hour 
and inactivated at 80◦C for 5 minutes. 
 
 A 25 µl first-round PCR amplification was carried out using the FastStart High-
Fidelity PCR system (Roche Diagnostics, Indiapolis, USA) by addition of 3 µl of cDNA to 
22 µl of PCR mastermix containing 2.5 µl 10X buffer, 0.5 µl of 10 mM dNTP mix, 0.25 µl 
DNA polymerase, 1 µl containing 30 pmol of outer forward primer (gagoutF), 1 µl 
containing 30 pmol of outer reverse primer (gagoutR) and 16.75 µl of PCR grade water. 
Cycling conditions were 95◦C for 2 minutes followed by 40 cycles of 95◦C for 30sec, 55◦C for 
30s and 72◦C for 3 minutes. A 50 µl second-round PCR amplification was carried out using 
the FastStart High-Fidelity PCR system (Roche Diagnostics, Indiapolis, USA) by addition of 
5 µl of PCR product to 45 µl of PCR mastermix containing 5 µl 10X buffer, 1 µl of 10 mM 
dNTP mix, 0.5 µl DNA polymerase, 2 µl containing 30 pmol of inner forward primer 
(gaginF), 2 µl containing 30 pmol of inner reverse primer (gaginR) and 34.5 µl of PCR grade 
water. Cycling conditions were 95◦C for 2 minutes followed by 40 cycles of 95◦C for 30s, 
58◦C for 30s and 72◦C for 3 minutes. 
 
 Second-round PCR products were purified using Agencourt Ampure XP magnetic 
bead separation (Becton-Dickenson, Franklin lakes, USA) and eluted in 50 µl water. 
Sequence products were generated using 2 µl of purified amplicon in a 10 µl reaction volume 
containing 5 pmol of sequencing primer in 1 µl, 0.5 µl of BigDye terminator v3.1 cycle 
sequencing mastermix (Life Technologies, Carlsbad, USA), 1.75 µl of 5X sequence reaction 
buffer (Life Technologies, Carlsbad, USA) and 4.75 µl of PCR grade water. The two inner 
PCR primers and six overlapping internal sequencing primers were used to generate gag 
sequences. Cycling conditions were 96◦C for 60s followed by 25 cycles of 96◦C for 10s, 52◦C 
for 10s and 60◦C for 4 minutes. Sequence products were purified using ethanol-sodium 
acetate precipitation and resolved on an ABI3100 PRISM Genetic Analyser instrument (Life 
Technologies, Carlsbad, USA). DNA sequences were analysed using Sequencher v4.5 
software (Gene Codes Corporation, Ann Arbor, USA). 
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Table 2.7. PCR primers used for RT-PCR amplification and sequencing of HIV-1 gag. 
 
2.2.14. Gag sequence analysis 
 
 A total of 18 participants were included in the analysis of the gag sequences generated 
which comprised of 16 sequences at baseline, 16 sequences at the 6 month time-point and 10 
sequences at the 12 month time-point. Sequences were aligned to a consensus South African 
subtype C reference sequence using BioEdit software v7.0.9.0 (Hall, T.A.  1999.  BioEdit: a 
user-friendly biological sequence alignment editor and analysis program for Windows 
95/98/NT.  Nucl. Acids. Symp. Ser. 41:95-98.). Deduced amino acid sequences were used to 
determine the presence of relevant polymorphisms cited in the literature. CTL escape 
mutations in known HLA class I-restricted epitopes for HLA-B*58:01 as well as in other 
epitopes restricted by other HLA molecules in the participant’s HLA repertoire were also 
determined.  
 
 
 
 
 
 
 
 
Primer name Primer sequence (5’-3’) 
gagoutF TGTTAAAACACTTAGTATGGGCAAG 
gagoutR TTACTTTGATAAAACCTCCAATTCC 
gaginF TTGCACTTAACCCTGGCCTTTTAGA 
gaginR ATTTATTTCTTCTAATACTGTATCATCTGC 
gagsegF1 GCTCTTCAGACAGGAACAGA 
gagsegF2 GGACATCAAGCAGCCATGCA 
gagsegF3 GAAGAAATGATGACAGCATG 
gagsegR1 CCTGCTATGTCACTTCCCCT 
gagsegR2 TTTCCACATTTCCAACAGCC 
gagsegR3 GACAAGGGGTCGCTGCCAAA 
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Chapter 3:                                                    
Immunogenetic characterisation of healthy 
individuals of South African Indian, Mixed ancestry, 
Caucasian and Black ethnicity 
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3.1. Introduction 
 
The South African (SA) resident population is extensive in size (n=52,982,000) and 
ethnically diverse; consisting of individuals of SA Black (SAB), SA mixed ancestry (SAM), 
SA Caucasian (SAC) and SA Indian/Asian (SAI) ethnicities that respectively represent 
79.8%, 9.0%, 8.7% and 2.5% of the total population 
(www.statssa.gov.za/publications/P0302/P03022013.pdf). The SAC population has its origins 
in the Western Cape region ~360 years ago when Dutch sailors established a refreshment 
station in Cape Town in 1652, while the SAM population has its origins around the same 
time period due to admixture of multiple ethnic groups incorporating Caucasian, Black 
African, South Asian and Indonesian ancestry (de Wit et al., 2010, Patterson et al., 2010). 
The SAI population was established ~150 years ago in the KwaZulu-Natal region by a 
founder population of immigrants from mainland India (www.sahistory.org.za). 
 
There is a high HIV-1 burden in South Africa with a national HIV-1 prevalence of 
12.2% estimated in 2012, however prevalence rates are not proportionate among the different 
SA populations. In 2008, the prevalence of HIV-1 was estimated at 0.3%, 0.3%, 1.7% and 
13.6% in SAI, SAM, SAC and SAB populations, respectively 
(www.mrc.ac.za/pressreleases/2009/sanat.pdf). In 2012, these estimates changed to 0.8%, 
3.1%, 0.3% and 15.0% in SAI, SAM, SAC and SAB populations, respectively 
(www.hsrc.ac.za/en/research-outputs/view/6871), indicating differential influences on HIV-1 
spread within each population, which could reflect potential host genetic differences. 
 
Immunogenetic studies in different local populations are important in terms of 
immunity in HIV-1 infection (Martin and Carrington, 2013) as well as the effect of immune 
genes on prevention/treatment options, such as immune hypersensitivity reactions to 
antiretroviral drug therapy (Bharadwaj et al., 2012). Of particular importance is the role 
played by human leukocyte antigen (HLA) class I molecules found on the surface of most 
nucleated cells, that regulate both adaptive and innate immune responses following exposure 
to intracellular pathogens, via activation of CD8+ cytotoxic T cell (CTLs) and natural killer 
(NK) cells. The three HLA class I genes, (HLA-A, -B and -C) are encoded by a highly 
polymorphic gene cluster mapping to the major histocompatibility complex (MHC) on 
chromosome 6 (Robinson et al., 2013b). NK cell activity is dependent on interaction with 
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HLA class I molecules via killer-cell immunoglobulin-like receptors (KIRs); a specific 
family of cell-surface activating/inhibitory molecules mapping to the leukocyte receptor 
complex (LRC) on chromosome 19 (Middleton and Gonzelez, 2010). Extensive genetic 
variation exists within both the HLA class I and KIR genes due to unequal distribution of 
HLA class I allelic variants and KIR haplotypes within different populations. It is therefore 
necessary to identify the presence of genetic variants associated with disease susceptibility 
and outcome, particularly in the context of HIV-1 infection, in different South Africa 
populations where the HIV-1 prevalence is high. 
 
HLA class I genotyping has been done in SAB and SAC populations (Paximadis et al., 
2012) but limited information on KIR genotypes is available in these populations, with one 
KIR genotyping study published for the SAB population (Hong et al., 2011). Furthermore, in 
terms of HLA class I and KIR genotypes, the SAM and SAI populations are relatively 
understudied in comparison to SAB and SAC populations. The purpose of the current study 
was to characterise several immunogenetic factors in healthy individuals of SAI (n=50) and 
SAM (n=50) ethnicity and to include data generated by others for the SAC (n=94) and SAB 
(n=159) populations. Real-time allele-specific PCR (AS-PCR) assays were used to determine 
CCR5/CCR5Δ32, KIR and HLA-Bw480I/Bw480T/C1/C2 genotypes, while relative 
quantification real-time AS-PCR assays were used to determine copy number variation of 
KIR3DL1/S1 and KIR2DS4f/v. HLA-ABC genotyping was done using commercial sequence-
based typing (SBT) methods and HLA-B signal peptide p2-M/T variants were determined 
from these sequences. HLA-C 3’UTR +263-ins/del variants were determined by direct DNA 
sequencing. For detailed methodologies, see Chapter 2. 
 
3.2. Results 
 
3.2.1. KIR genotyping 
 
3.2.1.1. Analysis of KIR frequencies 
 
 The presence/absence of each KIR gene was determined by real-time AS-PCR assay 
for SAM and SAI populations. Results for SAC and SAB populations, generated using the 
same assay, were provided by Ms. Nikki Gentle. A comparison of KIR gene frequencies 
between the four populations as well as significant differences are shown in Figure 3.1. The 
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frequencies of KIR2DL1, -2DL4, -3DL2, -3DL3, -DS5 and -3DP1 were similar between the 
four populations. KIR2DL2 was found at the lowest frequency in the SAC population 
(58.5%). KIR2DL3, -3DL1, -2DS4 and -2DP1 frequencies were lowest in the SAI population 
(64.0%, 88.0%, 88.0% and 94.0%, respectively) and the difference was significant for 
KIR2DL3 in comparison to the other populations. KIR2DL5, -2DS1, -2DS2 and -2DS3 were 
found at the highest frequencies in the SAI population (84.0%, 66.0%, 78.0% and 56.0%) 
respectively) and the difference was significant for KIR2DS1 and -2DS3 in comparison to the 
other populations. Low frequencies of KIR2DS1 and -3DS1 (12.6% and 6.9%, respectively) 
and the difference was significant for KIR3DS1 in comparison to the other populations. The 
framework genes (KIR2DL4, -3DL2, -3DL3 and -3DP1) were present in all individuals in all 
populations except one SAI individual shown to lack KIR2DL4. 
 
 
 
 
 
 
*Inter-population gene frequency comparisons showing significance (p<0.05): 
KIR2DL2 SAI vs. SAC  p=0.0101  KIR3DL1 SAC vs. SAI p=0.0211  KIR2DS3 SAI vs. SAM  p=0.0042  
KIR2DL3 SAM vs. SAI p=0.0198   SAB vs. SAI  p=0.0008   SAI vs. SAC  p=0.0002  
 SAC vs. SAI  p=0.0007  KIR2DS1 SAI vs. SAM  p=0.0268   SAI vs. SAB  p=0.0003  
 SAB vs. SAI  p=0.0196   SAI vs. SAC  p=0.0049  KIR2DS4 SAC vs. SAI  p=0.0211  
KIR2DL5 SAI vs. SAC p=0.0001   SAI vs. SAB  p<0.0001   SAB vs. SAI  p=0.0027  
 SAI vs. SAB  p=0.0033   SAM vs. SAB  p<0.0001  KIR3DS1 SAI vs. SAB  p<0.0001 
    SAC vs. SAB p<0.0001   SAM vs. SAB  p<0.0001  
   KIR2DS2 SAI vs. SAC  p=0.0173   SAC vs. SAB  p<0.0001  
    SAI vs. SAB  p=0.0418  KIR2DP1 SAB vs. SAI  p=0.0433  
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Figure 3.1. Frequency (%) of KIR (killer-cell immunoglobulin-like receptor) genes determined for SAI, South 
African Indian (n=50); SAM, South African Mixed ancestry (n=50); SAC, South African Caucasian (n=94) 
and SAB, South African Black (n=159) populations; Bold KIRs are framework genes; KIR2DL4 is listed as 
an inhibitory gene although this may not be true at a functional level. 
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3.2.1.2. Analysis of KIR genotype frequencies 
 
KIR genotype designations were assigned for individuals genotyped for the 
presence/absence of the 16 KIRs in all four populations (Table 3.1) according to the 
classification system used by the allele frequency database (Gonzalez-Galarza et al., 2011). 
Overall, 55 different KIR genotypes were identified, including 5 undocumented KIR 
genotypes (three found in the SAI population, one in the SAM population and one in the SAC 
population). In SAI, SAM, SAC and SAB populations 21, 18, 24 and 32 different KIR 
genotypes, respectively, were observed. KIR genotypes unique to one population or shared 
between two, three or all of the populations are depicted in Figure 3.2. Predominant KIR 
genotypes detected at frequencies >10% were detected as follows: Bx6 (12.0%), Bx73 
(12.0%) and Bx71 (10.0%) in SAI individuals; AA1 (22.0%), Bx2 (10.0%) and Bx21 (16%) in 
SAM individuals; AA1 (26.6%), Bx4 (16.0%), Bx2 (11.7%) and Bx3 (10.6%) in SAC 
individuals and AA1 (25.8%), and Bx21 (11.3%) in SAB individuals. Statistical differences 
were evaluated in populations where the same KIR genotype was present and are listed in 
Table 3.2. 
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Table 3.1. Frequency (%) of KIR genotypes determined for SAI (n=50), SAM (n=50), SAC (n=94) and 
SAB (n=159) populations 
KIR 
geno-
types 
Inhibitory KIR genes Activating KIR geness KIR pseudogenes Populations* 
2D
L1
 
2D
L2
 
2D
L3
 
2D
L
4 
2D
L5
 
3D
L1
 
3D
L
2 
3D
L
3 
2D
S1
 
2D
S2
 
2D
S3
 
2D
S4
 
2D
S5
 
3D
S1
 
2D
P1
 
3D
P1
 
SAI SAM SAC SAB 
AA1                 8.0 22.0 26.6 25.8 
Bx2                 6.0 10. 11.7 0.6 
Bx3                 4.0 2.0 10.6 0.6 
Bx4                 6.0 8.0 16.0 9.4 
Bx5                 6.0 8.0 2.1 9.4 
Bx6                 12.0 6.0 6.4 3.1 
Bx7                 2.0 4.0 2.1 0.6 
Bx9                 6.0 4.0 0.0 3.8 
Bx10                 0.0 0.0 1.1 0.0 
Bx11                 0.0 0.0 0.0 0.6 
Bx13                 0.0 0.0 2.1 0.0 
Bx15                 0.0 0.0 1.1 0.0 
Bx19                 0.0 0.0 0.0 0.6 
Bx20                 0.0 0.0 0.0 5.0 
Bx21                 0.0 16.0 1.1 11.3 
Bx24                 0.0 0.0 1.1 0.0 
Bx25                 0.0 0.0 0.0 0.6 
Bx30                 0.0 0.0 0.0 0.6 
Bx31                 0.0 0.0 0.0 1.3 
Bx32                 0.0 0.0 0.0 1.9 
Bx44                 0.0 0.0 0.0 0.6 
Bx48                 0.0 0.0 1.1 0.6 
Bx51                 0.0 0.0 0.0 1.9 
Bx58                 0.0 0.0 1.1 0.0 
Bx62                 0.0 0.0 0.0 0.6 
Bx64                 2.0 0.0 1.1 0.0 
Bx68                 2.0 0.0 0.0 0.0 
Bx69                 4.0 0.0 0.0 0.0 
Bx70                 0.0 0.0 2.1 0.0 
Bx71                 10.0 0.0 3.2 4.4 
Bx73                 12.0 4.0 1.1 0.6 
Bx76                 0.0 2.0 0.0 0.0 
Bx78                 0.0 2.0 0.0 0.0 
Bx81                 4.0 0.0 0.0 0.6 
Bx88                 0.0 2.0 0.0 0.0 
Bx89                 0.0 0.0 3.2 0.6 
Bx91                 0.0 2.0 0.0 0.0 
Bx92                 0.0 2.0 1.1 0.6 
Bx112                 0.0 0.0 0.0 3.1 
Bx113                 2.0 0.0 0.0 0.0 
Bx169                 0.0 0.0 0.0 0.6 
Bx172                 2.0 0.0 1.1 0.6 
Bx175                 0.0 0.0 0.0 0.6 
Bx188                 0.0 2.0 0.0 0.0 
Bx228                 0.0 2.0 1.1 7.5 
Bx270                 0.0 0.0 0.0 0.6 
Bx337                 2.0 0.0 0.0 0.0 
Bx382                 0.0 0.0 1.1 0.0 
Bx393                 0.0 0.0 0.0 0.6 
Bx429                 2.0 0.0 0.0 0.0 
BxN1                 2.0 0.0 0.0 0.0 
BxN2                 4.0 0.0 0.0 0.0 
BxN3                 2.0 0.0 0.0 0.0 
BxN4                 0.0 2.0 0.0 0.0 
BxN5                 0.0 0.0 1.1 0.0 
KIR, killer-cell immunoglobulin-like receptor, SAI, South African Indian, SAM, South African Mixed ancestry, SAC, South 
African Caucasian; SAB, South African Black. Grey tiles indicate the presence of a KIR gene; Bold KIRs are framework 
genes; KIR2DL4 is listed as an inhibitory gene although this may not be true at a functional level. 
 
*Inter-population KIR genotype comparisons showing significance (p<0.05): 
Bx2 SAI vs. SAB p=0.0433 Bx6 SAI vs. SAB p=0.0244 
 SAM vs. SAB p=0.0033 Bx21 SAM vs. SAC p=0.0009 
 SAC vs. SAB p=0.0001  SAB vs. SAC p=0.0022 
Bx3 SAC vs. SAB p=0.0003 Bx73 SAI vs. SAC p=0.0073 
Bx5 SAB vs. SAC p=0.0348  SAI vs. SAB p=0.0008 
   Bx228 SAB vs. SAC p= 0.0351 
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Figure 3.2. Distribution of shared and unique KIR, killer-cell immunoglobulin-like receptor genotypes 
determined for SAI, South African Indian (n=50), SAM, South African Mixed ancestry (n=50), SAC, 
South African Caucasian (n=94) and SAB, South African Black (n=159) populations. 
 
3.2.2. HLA-Bw480I/Bw480T/C1/C2 ligand genotyping 
 
HLA-Bw480I/Bw480T/C1/C2 genotypes were initially determined by real-time AS-PCR 
assay for SAI and SAM populations and confirmed to be correctly assigned by analysis of 
HLA class I genotype data that was generated later. HLA-Bw480I/Bw480T/C1/C2 genotypes for 
the SAC and SAB populations were determined from published HLA-ABC data (Paximadis et 
al., 2012) and additional HLA-ABC data was provided by Ms. Nikki Gentle. Identification of 
genetic variability at codon-80 of HLA-A, -B and -C loci was used to define combinations of 
HLA ligand genotypes present in all four populations. HLA ligand frequencies and significant 
differences are shown in Figure 3.2. 
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For HLA-A, Bw480I homozygotes were absent in the SAC population and found at low 
frequencies in the SAI, SAM and SAB populations (4.0%, 4.0% and 1.3%, respectively).  
The highest frequency of non-Bw480T homozygotes was found in SAB population (77.4%) 
and the frequency of Bw480I/non-Bw480T heterozygotes were highest in the SAI populations 
(38.0%). 
 
At the HLA-B locus, the frequency of Bw680N homozygotes and Bw480I/Bw680N 
heterozygotes was highest the SAB population (38.4% and 40.9%, respectively. Low 
frequencies of Bw680N/Bw480TL heterozygotes were observed in SAI, SAM and SAC 
populations (10.0%, 4.0% and 6.4%, respectively), while this genotype was absent in the 
SAB population. The frequency of Bw680N/Bw480TA heterozygotes was highest in the SAC 
population (20.2%). Low frequencies of Bw480I/Bw480TA heterozygotes, Bw480I homozygotes 
and Bw480TA/Bw480TL heterozygotes were detected in all populations, but highest in the SAI 
population (8.0%, 6.0% and 8% respectively).  The frequency of Bw480TA homozygotes was 
low in all populations (2.0%, 4.0%, 2.1% and 0.6%, respectively). Bw480TA/Bw480TL 
heterozygotes were absent in the SAB population, Bw480I/Bw480TL heterozygotes were absent 
in both the SAI and SAB populations and no Bw480TL homozygotes were deteced in any of 
the populations. Notably, HLA-B alleles that encode the C1 epitope are prevalent in Asian 
populations (Abi-Rached et al., 2010) and could potentially be present in SAI and SAM 
populations, however, none were detected in this study. 
 
For HLA-C, the frequency of C1 homozygotes was highest in the SAC population 
(42.6%), while the frequency of C2 homozygotes was highest in the SAB population 
(31.4%). All populations had similar frequencies of C1/C2 heterozygotes ranging from 46.0% 
to 48.9%.  
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*Inter-population HLA-ABC ligand frequency comparisons showing significance (p<0.05): 
 
3.2.3. Analysis of known KIR-HLA ligand pairs 
 
 Since KIRs and HLAs are encoded by different chromosomes (19 and 6, respectively), 
KIRs and cognate HLA ligands are not necessarily inherited together. The frequencies of 
known KIR-HLA ligand pairs were calculated for the SAI, SAM, SAC and SAB populations 
using the available KIR and HLA-Bw480I/Bw480T/C1/C2 ligand genotypes as well as specific 
HLA class I alleles using HLA class I high-resolution typings. KIR-HLA ligand pair 
frequencies and significant differences are shown in Table 3.3. 
 
 The frequency of KIR3DL1+HLA-B Bw480T, KIR2DL2+HLA-C1 and 
KIR2DS1+HLA-C2 was highest in the SAI population (40.0%, 66.0% and 48.0%, 
respectively) with a significant difference in the frequency of KIR2DS1+HLA-C2 in 
comparison to the other three populations. The SAM population showed the highest 
frequency of KIR3DL1+HLA-A/B Bw480I (68.0%), while in the SAC population the 
frequency of KIR2DL3+HLA-C1 was highest (80.9%) and significantly different in 
HLA-A 80T/80T SAC vs. SAI p=0.0371 HLA-B 80N/80TA SAC vs. SAM p=0.0281 
 SAB vs. SAI p=0.0105  SAC vs. SAB p=0.0048 
HLA-A 80I/80T SAI vs. SAB p=0.0250 HLA-C C1/C1 SAI vs. SAB p=0.0233 
HLA-B 80I/80N SAB vs. SAC p=0.0009  SAC vs. SAB p=0.0003 
HLA-B 80N/80N SAC vs. SAI p=0.0260 HLA-C C2/C2 SAB vs. SAI p=0.0454 
 SAB vs. SAI p=0.0171  SAM vs. SAC p=0.0205 
    SAB vs. SAC p<0.0001 
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Figure 3.3. Frequency (%) of HLA-A, -B and -C ligand profiles determined for SAM, South African Mixed 
ancestry (n=50); SAC, South African Caucasian (n=94); SAI, South African Indian (n=50) and SAB, South 
African Black (n=159) populations; HLA, human leukocyte antigen; HLA-A locus 80I = Bw4, 80T = non-Bw4; 
At the HLA-B locus 80I, 80TA and 80TL = Bw4, 80N = Bw6. 
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comparison to the other three populations. KIR3DL1+HLA B Bw480I and KIR2DL2+HLA-C2 
were highest in frequency in the SAB population (52.8% and 78.6%, respectively). 
 
 The real-time AS-PCR HLA ligand assay does not determine the presence of specific 
HLA class I alleles, however, since high-resolution HLA class I genotypes were also 
determined by SBT, it was possible to analyse KIR and HLA allele-specific ligand pairs for 
the four populations (Table 3.2). KIR2DS4+HLA-A*11 and KIR3DL2+HLA-A*11 was found 
at the highest frequency in the SAI population (28.0% and 32.0%, respectively) and 
significantly different in comparison to the other three populations. KIR3DL2+HLA-A*03 
was found at the highest frequency in the SAC population (24.5%) and significantly different 
in comparison to the other three populations. 
 
 KIR2DS4 is also known to bind subsets of HLA-C1 and -C2 allotypes with varying 
affinities (Graef et al., 2009) and the corresponding KIR-HLA ligand genotypes were 
analysed in the four populations. KIR2DS4+HLA-C*01:02, KIR2DS4+HLA-C*03:02 and 
KIR2DS4+HLA-C*14:02 were found at the highest frequencies in the SAI population (8.0%, 
10.0% and 10.0%, respectively). The SAC population showed the highest frequencies of 
KIR2DS4+HLA-C*02:02 and KIR2DS4+HLA-C*05:01 (11.7% and 10.6%, respectively), 
while KIR2DS4+HLA-C*04:01 and KIR2DS4+HLA-C*16:01 was found at the highest 
frequency in the SAB population (24.5% and 13.8%, respectively). 
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Table 3.2. Frequency (%) of known KIR-HLA ligand pairs determined for SAI (n=50); SAM (n=50); 
SAC (n=94) and SAB (n=159) populations 
KIR-HLA ligand pairs Populations* SAI SAM SAC SAB 
KIR3DL1+HLA-A Bw480I 36.0 36.0 14.9 22.6 
KIR3DL1+HLA-B Bw480I 38.0 46.0 29.8 52.8 
KIR3DL1+HLA-A/B Bw480I 58.0 68.0 44.7 65.4 
KIR3DL1+HLA-B Bw480T 40.0 20.0 37.2 13.8 
KIR2DL1+HLA-C2 62.0 68.0 56.4 78.6 
KIR2DL2+HLA-C1 66.0 50.0 51.1 49.1 
KIR2DL3+HLA-C1 54.0 64.0 80.9 56.6 
KIR2DS1+HLA-C2 48.0 24.0 21.3 9.4 
KIR2DS4+HLA-A*11 28.0 8.0 11.7 1.9 
KIR3DL2+HLA-A*03 8.0 10.0 24.5 10.7 
KIR3DL2+HLA-A*11 32.0 10.0 11.7 1.9 
KIR2DS4+HLA-C*01:02 8.0 4.0 4.3 0.0 
KIR2DS4+HLA-C*02:02 0.0 8.0 11.7 1.9 
KIR2DS4+HLA-C*03:02 10.0 2.0 0.0 3.1 
KIR2DS4+HLA-C*04:01 10.0 18.0 17.0 24.5 
KIR2DS4+HLA-C*05:01 0.0 4.0 10.6 0.6 
KIR2DS4+HLA-C*14:02 10.0 2.0 2.1 1.3 
KIR2DS4+HLA-C*16:01 2.0 8.0 12.8 13.8 
KIR, killer-cell immunoglobulin-like receptor, HLA, human leukocyte antigen; SAI, South African Indian; SAM, South 
African Mixed ancestry; SAC, South African Caucasian; SAB, South African Black. 
 
 
*Inter-population KIR-HLA ligand frequency comparisons showing significance (p<0.05): 
 
KIR3DL1+HLA-A Bw480I SAI vs. SAC p=0.0058 KIR2DS4+HLA-A*11 SAI vs. SAM p=0.0174 
 SAM vs. SAC p=0.0058  SAI vs. SAC p=0.0202 
KIR3DL1+HLA-B Bw480I SAB vs. SAC p=0.0004  SAI vs. SAB p<0.0001 
KIR3DL1+HLA-A/B Bw480I SAM vs. SAC p= 0.0088  SAC vs. SAB p=0.0027 
 SAB vs. SAC p=0.0016 KIR3DL2+HLA-A*03 SAC vs. SAI p=0.0234 
KIR3DL1+HLA-B Bw480T SAI vs. SAM p=0.0486  SAC vs. SAM p=0.0462 
 SAI vs. SAB p=0.0002  SAC vs. SAB p=0.0068 
 SAC vs. SAM p=0.0387 KIR3DL2+HLA-A*11 SAI vs. SAM p=0.0128 
 SAC vs. SAB p<0.0001  SAI vs. SAC p=0.0062 
KIR2DL1+HLA-C2 SAB vs. SAI p=0.0250  SAI vs. SAB p<0.0001 
 SAB vs. SAC p=0.0003  SAM vs. SAB p=0.0204 
KIR2DL3+HLA-C1 SAC vs. SAI p=0.0010  SAC vs. SAB p=0.0027 
 SAC vs. SAM p=0.0421 KIR2DS4+HLA-C*02:02 SAC vs. SAB p=0.0027 
 SAC vs. SAB p<0.0001 KIR2DS4+HLA-C*04:01 SAB vs. SAI p=0.0291 
KIR2DS1+HLA-C2 SAI vs. SAM p=0.0213 KIR2DS4+HLA-C*05:01 SAC vs. SAB p=0.0003 
 SAI vs. SAC p=0.0013 KIR2DS4+HLA-C*14:02 SAI vs. SAC p=0.0494 
 SAI vs. SAB p<0.0001  SAI vs. SAB p=0.0094 
 SAM vs. SAB p=0.0137 KIR2DS4+HLA-C*16:01 SAC vs. SAI p=0.0343 
 SAC vs. SAB p=0.0134  SAB vs. SAI p=0.0185 
 
 
3.2.4. Copy number variation of KIR3DL1/S1 and KIR2DS4f/v 
 
A probe hydrolysis-based relative quantification real-time AS-PCR assay was used to 
estimate copy numbers of KIR2DS4f/v and KIR3DL1/S1 relative to the BGB gene in the four 
populations. The frequency of copy number variants and significant differences detected 
within the four populations is shown in Figure 3.4. 
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3.2.4.1. Copy number variation of KIR3DL1/S1 
 
The absence of KIR3DL1/S1 was only found in the SAI population (2.0%). The 
frequency of KIR3DL1/S1 copy variants 0/1, 1/0, and 1/1 was highest in SAI population 
(8.0%, 14.0% and 48%, respectively), while the frequency of KIR3DL1/S1 copy variants 0/2, 
1/2 and 2/1 was highest in the SAC population (2.1%, 4.3% and 3.2%, respectively). A low 
frequency of KIR3DL1/S1 copy variant 1/1 was found in the SAB population (6.3%) and the 
difference was significant in comparison to the other three populations. The KIR3DL1/S1 
copy variant 2/0 was highest in frequency in the SAB population (83.6%) and the difference 
was significant in comparison to the other three populations. The KIR3DL1/S1 copy variants 
0/1 were absent in the SAM and SAC populations, while KIR3DL1/S1 copy variant 1/2 was 
not detected in the SAM and SAB populations. The KIR3DL1/S1 copy variants 0/2 and 2/1 
were not present in the SAB population. The detection of KIR3DL1/S1 copy variants 0/0, 0/1 
and 1/0 is suggestive of deletions at the KIR3DL1/S1 locus. Similarly, the detection of 
KIR3DL1/S1 copy variants 1/2 and 2/1 is suggestive of a duplication at the KIR3DL1/S1 
locus. 
 
3.2.4.2. Copy number variation KIR2DS4f/v 
 
For KIR2DS4f/v copy number variation, the absence of KIR2DS4 was detected in all 
populations, but the highest frequency was found in the SAI population (12.0%) and the 
difference was significant in comparison to the other three populations. The KIR2DS4f/v copy 
variant 0/1 was found at the highest frequency in the SAB population (61.7%) and the 
difference was significant in comparison to the other three populations. The KIR2DS4f/v copy 
variant 2/0 was absent in the SAC and SAB populations and detected at the highest frequency 
in the SAI population (22.0%). The KIR2DS4f/v copy variants 1/0 and 1/1 was present at the 
highest frequency in the SAB population (50.3% and 34.6%, respectively) and a significant 
difference was observed in frequency of KIR2DS4f/v copy variants 1/0 in comparison to the 
other three populations. The KIR2DS4f/v copy variant 0/2 was absent in the SAC and SAB 
populations and present at the highest frequency in the SAM population (12.0%). 
 
 
 
72 
 
 
 
 
 
 
*Inter-population KIR3DL1/S1 and KIR2DS4f/v copy number frequency comparisons showing significance (p<0.05): 
 
KIR3DL1/S: 0/1 SAI vs. SAC p=0.0134 KIR2DL4f/v: 0/0 SAI vs. SAC p=0.0211 
  SAI vs. SAB p=0.0122   SAI vs. SAB p=0.0027 
 1/1 SAI vs. SAB p<0.0001  0/1 SAI vs. SAM p=0.0440 
  SAM vs. SAB p<0.0001   SAI vs. SAB p=0.0004 
  SAC vs. SAB p<0.0001   SAC vs. SAI p=0.0085 
 1/2 SAC vs. SAB p=0.0183   SAC vs. SAM p<0.0001 
 2/0 SAM vs. SAI p=0.0253   SAC vs. SAB p<0.0001 
  SAC vs. SAI p=0.0081  0/2 SAI vs. SAC p<0.0001 
  SAB vs. SAI p<0.0001   SAI vs. SAB  p<0.0001 
  SAB vs. SAM p<0.0001   SAM vs. SAC p=0.0005 
  SAB vs. SAC p<0.0001   SAM vs. SAB p<0.0001 
     1/0 SAB vs. SAI p<0.0001 
      SAB vs. SAM p=0.0005 
      SAB vs. SAC p<0.0001 
     1/1 SAM vs. SAI p=0.0128 
      SAB vs. SAI p=0.0006 
      SAB vs. SAC p=0.0470 
     2/0 SAM vs. SAC p=0.0014 
      SAM vs. SAB p=0.0001 
 
 
3.2.5. CCR5/CCR5Δ32 genotyping 
 
 The presence/absence of the CCR5Δ32 variant (Mt) was determined in SAI, SAM and 
SAC individuals by real-time AS-PCR Ct-shift assay, however, this was not done for the 
SAB population due to the known absence of the CCR5Δ32 variant in South African African 
individuals (Picton et al., 2010). The frequencies of CCR5 wild-type (WT) and Mt genotypes 
and significant differences detected within the populations are shown in Figure 3.5. Low 
frequencies of WT/Mt heterozygotes were detected in the SAI and SAM populations (4.0% 
and 6.0%, respectively), while the highest frequency was present in the SAC population 
(17.0%). A low frequency of Mt homozygotes was found in the SAC population (1.1%), 
while this genotype was absent in the SAI and SAM populations. The frequency of WT/Mt 
heterozygotes and Mt homozygotes was assumed to be 0.0% in the SAB population. 
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Figure 3.4. Frequency (%) of copy number variants for (A) KIR3DL1/S1 and (B) KIR2DS4f/v genotypes 
determined for SAI, South African Indian (n=50), SAM, South African Mixed ancestry (n=50); SAC, South 
African Caucasian (n=94) and SAB, South African Black (n=159) populations. 
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3.2.6. HLA-B signal peptide p2-M/T variants 
 
The presence of a methionine (M) or threonine (T) residue at position-2 (p2) of the 
HLA-B signal peptide was determined by analysis of exon 1 coding sequences generated by 
commercial HLA-B genotyping or from HLA class I sequences available in the International 
Histocompatibility Working Group (IHWG) (www.ihwg.org). The frequencies of HLA-B p2-
M/T genotypes and significant differences detected within the populations are shown in 
Figure 3.5. HLA-B p2-M/M homozygotes were absent in the SAI population, present at low 
frequencies in the other three populations and highest in the SAB population (8.8%). HLA-B 
p2-M/T heterozygotes were present at the highest frequency in the SAC population (47.9%). 
The highest frequency of HLA-B p2-T/T homozygotes was found in the SAI population 
(78.0%) and was significantly different in comparison to the other three populations. 
 
3.2.7. HLA-C 3’UTR +263 Ins/Del variants 
 
 The insertion (Ins) or deletion (Del) of a single guanine (G) residue at position +263 
in the HLA-C 3’untranslated region (3’UTR) was determined for the SAI and SAM 
populations by direct sequencing and genotypes were inferred from these results. Genotypic 
data for the SAC and SAB populations was provided by Ms. Nikki Gentle. The frequencies 
of HLA-C 3’UTR +263 Ins/Del genotypes and significant differences detected within the 
populations are shown in Figure 3.5. HLA-C 3’UTR +263 Del/Del homozygotes were the 
least common genotypes detected in all populations with the highest frequency found in the 
SAM population (20%). HLA-C 3’UTR +263 Ins/Ins homozygotes were found at the highest 
frequency in the SAC population (52.1.0%), while HLA-C 3’UTR +263 Ins/Del 
heterozygotes were the most common in the SAI population (60.0%). 
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Figure 3.5. Frequency (%) of genotypes for (A) CCR5Δ32 WT/Mt, (B) HLA-B p2-M/T and (C) HLA-C 
+263 Ins/Del determined for SAI, South African Indian (n=50), SAM, South African Mixed ancestry 
(n=50); SAC, South African Caucasian (n=94) and SAB, South African Black (n=159) populations. 
 
*Inter-population frequency comparisons for CCR5Δ32, HLA-Bp2-M/T2 and HLA-C +263 Ins/Del showing significance (p<0.05): 
 
3.2.8. HLA class I A, -B and -C allelic variation 
 
HLA-ABC alleles were determined for SAI and SAM individuals by commercial SBT 
methods. HLA-ABC genotypes for the SAC and SAB populations were derived from 
published data (Paximadis et al., 2012) and additional typings were done by Ms Nikki Gentle. 
 
3.2.8.1. Alleles at the HLA-A locus 
 
The allele frequencies (f) of HLA-A allelic variants detected and significant 
differences found within the populations are shown in Table 3.3. Overall, a total of 42 
different alleles were detected in the four populations with 19, 24, 25 and 31 different alleles 
identified in SAI, SAM, SAC and SAC populations, respectively. HLA-A alleles unique to 
one population or shared between two, three or all of the populations are depicted in Figure 
3.6. The most common HLA-A allele detected in each population was HLA-A*11:01 (f=0.17), 
-A*02:01 (f=0.21), -A*02:01 (f=0.255) and -A*30:01 (f=0.11) in SAI, SAM, SAC and SAC 
populations, respectively. The frequency of individuals who were homozygous at the HLA-A 
locus was 16.0%, 8.0%, 12.8% and 9.4% in the SAI, SAM, SAC and SAB populations, 
respectively. 
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3.2.8.2. Alleles at the HLA-B locus 
 
The allele frequencies of HLA-B allelic variants detected and significant differences 
found within the populations are shown in Table 3.4. Overall, a total of 61 different alleles 
were detected in the four populations with 30, 41, 38 and 29 different alleles identified in 
SAI, SAM, SAC and SAC populations, respectively. HLA-B alleles unique to one population 
or shared between two, three or all of the populations are depicted in Figure 3.7. The most 
common HLA-B allele detected in each population was HLA-B*40:06 (f=0.14), -B*07:02 
(f=0.08), -B*07:02 (f=0.154) and -B*58:02 (f=0.094) in SAI, SAM, SAC and SAC 
populations, respectively. The frequency of individuals who were homozygous at the HLA-B 
locus was 4.0%, 6.0%, 5.3% and 5.0% in the SAI, SAM, SAC and SAB populations, 
respectively. 
 
3.2.8.3.  Alleles at the HLA-C locus 
 
The allele frequencies of HLA-C allelic variants detected and significant differences 
found within the populations are shown in Table 3.5. Overall, a total of 38 different alleles 
were detected in the four populations with 20, 24, 26 and 27 different alleles identified in 
SAI, SAM, SAC and SAC populations, respectively. HLA-C alleles unique to one population 
or shared between two, three or all of the populations are depicted in Figure 3.8. The most 
common HLA-C allele detected in each population was HLA-C*06:02 (f=0.14), -C*06:02 
(f=0.12), -C*07:01 (f=0.176) and -C*06:02 (f=0.157) identified in SAI, SAM, SAC and SAC 
populations, respectively. The frequency of individuals who were homozygous at the HLA-C 
locus was 6.0%, 8.0%, 6.4% and 9.4% in the SAI, SAM, SAC and SAB populations, 
respectively. 
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Table 3.3. Allele frequencies of HLA-A alleles determined for SAI (n=50), SAM (n=50), SAC (n=94) 
and SAB (n=159) populations. 
 
 Populations* 
HLA-A SAI SAM SAC SAB 
A*01:01 0.130 0.130 0.207 0.019 
A*01:03    0.003 
A*02:01 0.040 0.210 0.255 0.075 
A*02:02   0.011 0.025 
A*02:03  0.010   
A*02:05 0.010  0.005 0.072 
A*02:06 0.030    
A*02:11 0.040 0.020   
A*02:14    0.003 
A*02:17   0.005  
A*03:01 0.030 0.060 0.122 0.053 
A*03:02 0.010    
A*11:01 0.170 0.060 0.053 0.006 
A*11:03 0.020    
A*11:12   0.005 0.003 
A*23:01 0.010 0.040 0.016 0.085 
A*24:02 0.160 0.090 0.069 0.019 
A*24:07 0.030 0.040 0.005  
A*25:01  0.020 0.005  
A*26:01 0.020 0.020 0.021 0.009 
A*29:01    0.003 
A*29:02  0.030 0.064 0.063 
A*29:11    0.028 
A*30:01  0.040 0.016 0.110 
A*30:02 0.010 0.050 0.005 0.107 
A*30:04  0.020 0.027 0.022 
A*31:01 0.020 0.010 0.016  
A*32:01 0.030 0.010 0.027 0.016 
A*33:01   0.011 0.003 
A*33:03 0.150 0.010 0.005 0.022 
A*34:01  0.010   
A*34:02  0.030 0.021 0.031 
A*36:01    0.013 
A*43:01  0.020  0.041 
A*66:01  0.010  0.006 
A*66:02    0.003 
A*68:01 0.070 0.020 0.016 0.035 
A*68:02 0.020 0.040 0.005 0.072 
A*68:27    0.003 
A*69:01   0.005  
A*74:01    0.041 
A*80:01    0.006 
HLA, human leukocyte antigen; SAI, South African Indian; SAM, South African Mixed ancestry; SAC, South African 
Caucasian; SAB, South African Black; Allele frequency defined as n/2 x number of individuals. 
 
*Inter-population frequency comparisons for HLA-A alleles showing significance (p<0.05): 
 
HLA-A*01:01 SAI vs. SAB p<0.0001 HLA-A*23:01 SAB vs. SAI p=0.0054 
 SAM vs. SAB p<0.0001  SAB vs. SAC p=0.0014 
 SAC vs. SAB p<0.0001 HLA-A*24:02 SAI vs. SAC p=0.0223 
HLA-A*02:01 SAM vs. SAI p=0.0004  SAI vs. SAB p<0.0001 
 SAC vs. SAI p<0.0001  SAM vs. SAB p=0.0025 
 SAM vs. SAB p=0.0004  SAC vs. SAB p=0.0064 
 SAC vs. SAB p<0.0001 HLA-A*30:01 SAB vs. SAM p=0.0466 
HLA-A*02:05 SAB vs. SAI p=0.0233  SAB vs. SAC p<0.0001 
 SAB vs. SAC p=0.0003 HLA-A*30:02 SAB vs. SAI p=0.0008 
HLA-A*03:01 SAC vs. SAI p=0.0088  SAM vs. SAC p=0.0204 
 SAC vs. SAB p=0.0097  SAB vs. SAC p<0.0001 
HLA-A*11:01 SAI vs. SAM p=0.0249 HLA-A*33:03 SAI vs. SAM p=0.0003 
 SAI vs. SAC p=0.0023  SAI vs. SAC p<0.0001 
 SAI vs. SAB p<0.0001  SAI vs. SAB p<0.0001 
 SAM vs. SAB p=0.0030 HLA-A*68:02 SAB vs. SAC p=0.0003 
 SAC vs. SAB p=0.0013    
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Figure 3.6. Distribution of shared and unique HLA, human leukocyte antigen class I A alleles 
determined for SAI, South African Indian (n=50), SAM, South African Mixed ancestry (n=50), SAC, 
South African Caucasian (n=94) and SAB, South African Black (n=159) populations. 
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Table 3.4. Allele frequency of HLA-B alleles determined for SAI (n=50), SAM (n=50), SAC (n=94) and 
SAB (n=159) populations. 
 Populations* 
HLA-B SAI SAM SAC SAB 
B*07:02 0.040 0.080 0.154 0.050 
B*07:05 0.010    
B*07:06   0.005 0.016 
B*08:01 0.020 0.020 0.133 0.057 
B*13:01 0.040 0.010   
B*13:02   0.011 0.022 
B*14:01 0.010 0.020 0.005 0.022 
B*14:02  0.020 0.016 0.019 
B*15:01  0.030 0.090 0.006 
B*15:02 0.010 0.010 0.005  
B*15:03  0.020 0.005 0.085 
B*15:08 0.020    
B*15:10 0.020 0.020 0.005 0.066 
B*15:13  0.020 0.005  
B*15:16  0.010 0.005 0.016 
B*15:17 0.010  0.011  
B*15:25 0.010    
B*18:01 0.010 0.070 0.053 0.028 
B*27:02   0.005  
B*27:05  0.030 0.043  
B*27:07 0.010    
B*35:01 0.050 0.010 0.064 0.016 
B*35:02  0.020   
B*35:03 0.050 0.030   
B*35:05  0.020 0.005  
B*35:08   0.011  
B*37:01 0.080 0.010 0.011  
B*38:01 0.010 0.010 0.011  
B*38:02  0.010   
B*39:06  0.010   
B*39:10  0.020  0.022 
B*40:01 0.030 0.040 0.021 0.003 
B*40:02  0.020 0.011  
B*40:06 0.140 0.040   
B*41:01 0.010 0.020 0.005 0.013 
B*42:01  0.050  0.079 
B*42:02    0.016 
B*42:06    0.003 
B*44:02 0.010  0.053  
B*44:03 0.130 0.040 0.074 0.053 
B*44:04   0.005  
B*44:05  0.020 0.011  
B*44:27   0.005  
B*44:29  0.010   
B*45:01  0.020 0.005 0.079 
B*45:07    0.006 
B*47:01  0.010   
B*48:01 0.020    
B*49:01  0.030 0.005 0.006 
B*50:01 0.010  0.005  
B*51:01 0.040 0.040 0.048 0.009 
B*51:19 0.010    
B*52:01 0.060 0.020 0.011  
B*53:01  0.010  0.050 
B*55:01 0.020  0.016  
B*57:01 0.060 0.040 0.043  
B*57:02  0.010  0.013 
B*57:03    0.025 
B*58:01 0.050 0.020 0.021 0.088 
B*58:02 0.010 0.050 0.005 0.094 
B*81:01  0.010  0.038 
HLA, human leukocyte antigen; SAI, South African Indian; SAM, South African Mixed ancestry; SAC, South African 
Caucasian; SAB, South African Black; Allele frequency defined as n/2 x number of individuals. 
79 
 
*Inter-population frequency comparisons for HLA-B alleles showing significance (p<0.05): 
 
HLA-B*07:02 SAC vs. SAI p=0.0032 HLA-B*40:01 SAI vs. SAB p=0.0441 
 SAC vs. SAB p=0.0001  SAM vs. SAB p=0.0127 
HLA-B*08:01 SAC vs. SAI p=0.0011 HLA-B*40:06 SAI vs. SAM p=0.0238 
 SAC vs. SAM p=0.0011 HLA-B*44:03 SAI vs. SAM p=0.0398 
 SAC vs. SAB p=0.0045  SAI vs. SAB p=0.0142 
HLA-B*15:01 SAC vs. SAB p<0.0001 HLA-B*45:01 SAB vs. SAM p=0.0365 
HLA-B*15:03 SAB vs. SAM p=0.0238  SAB vs. SAC p<0.0001 
 SAB vs. SAC p<0.0001 HLA-B*51:01 SAC vs. SAB p=0.0117 
HLA-B*15:10 SAB vs. SAC p=0.0005 HLA-B*52:01 SAI vs. SAC p=0.0227 
HLA-B*35:01 SAC vs. SAM p=0.0385 HLA-B*58:01 SAB vs. SAM p=0.0241 
 SAC vs. SAB p=0.0083  SAB vs. SAC p=0.0022 
HLA-B*37:01  SAI vs. SAM p=0.0349 HLA-B*58:02 SAB vs. SAI p=0.0034 
 SAI vs. SAC p=0.0039  SAM vs. SAC p=0.0204 
    SAB vs. SAC p<0.0001 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Distribution of shared and unique HLA, human leukocyte antigen class I B alleles 
determined for SAI, South African Indian (n=50), SAM, South African Mixed ancestry (n=50), SAC, 
South African Caucasian (n=94) and SAB, South African Black (n=159) populations. 
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Table 3.5. Allele frequencies HLA-C alleles determined for SAI (n=50), SAM (n=50), SAC (n=94) and 
SAB (n=159) populations. 
 
 Populations* 
HLA-C SAI SAM SAC SAB 
C*01:02 0.060 0.020 0.021  
C*02:02  0.050 0.059 0.009 
C*02:05   0.005 0.003 
C*02:10  0.010  0.085 
C*03:02 0.050 0.010  0.016 
C*03:03  0.010 0.059  
C*03:04 0.030 0.070 0.059 0.041 
C*03:16   0.005  
C*04:01 0.090 0.090 0.090 0.129 
C*04:03 0.040 0.010   
C*04:04    0.003 
C*04:08   0.005  
C*05:01  0.020 0.053 0.003 
C*06:02 0.140 0.120 0.069 0.157 
C*06:06    0.003 
C*06:11   0.011  
C*07:01 0.120 0.080 0.176 0.069 
C*07:02 0.060 0.090 0.149 0.066 
C*07:04 0.010 0.040 0.011 0.013 
C*07:06 0.020  0.021 0.041 
C*07:11    0.003 
C*07:18   0.016 0.044 
C*07:26 0.010    
C*08:01 0.020 0.040 0.005 0.003 
C*08:02 0.010 0.040 0.021 0.019 
C*08:03 0.010    
C*08:04   0.011 0.031 
C*12:02 0.070 0.020 0.011  
C*12:03 0.070 0.060 0.021 0.016 
C*14:02 0.050 0.010 0.011 0.006 
C*15:02  0.030 0.027 0.003 
C*15:05  0.010  0.006 
C*15:07 0.010    
C*16:01 0.010 0.040 0.069 0.075 
C*16:02 0.010  0.011  
C*17:01  0.070 0.005 0.110 
C*18:01  0.030  0.016 
C*18:02  0.030  0.028 
HLA, human leukocyte antigen; SAI, South African Indian; SAM, South African Mixed ancestry; SAC, South African 
Caucasian; SAB, South African Black; Allele frequency defined as n/2 x number of individuals. 
 
*Inter-population frequency comparisons for HLA-C alleles showing significance (p<0.05): 
 
HLA-C*02:02 SAM vs. SAB p=0.0215 HLA-C*12:03 SAI vs. SAB p=0.0101 
 SAC vs. SAB p=0.0031  SAM vs. SAB p=0.0262 
HLA-C*02:10 SAB vs. SAM p=0.0054 HLA-C*14:02 SAI vs. SAB p=0.0100 
HLA-C*05:01 SAC vs. SAB p=0.0003 HLA-C*15:02 SAM vs. SAB p=0.0441 
HLA-C*06:02 SAB vs. SAC p=0.0034  SAC vs. SAB p=0.0286 
HLA-C*07:01 SAM vs. SAC p=0.0329 HLA-C*16:01 SAC vs. SAI p=0.0396 
 SAC vs. SAB p=0.0003  SAB vs. SAI p=0.0139 
HLA-C*07:02 SAC vs. SAB p=0.0030 HLA-C*17:01 SAM vs. SAC p=0.0030 
HLA-C*08:01 SAM vs. SAB p=0.0127  SAB vs. SAC p<0.0001 
HLA-C*12:02 SAI vs. SAC p=0.0096    
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Figure 3.8. Distribution of shared and unique HLA, human leukocyte antigen class I C alleles 
determined for SAI, South African Indian (n=50), SAM, South African Mixed ancestry (n=50), SAC, 
South African Caucasian (n=94) and SAB, South African Black (n=159) populations. 
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3.3. Discussion 
 
An extensive immunogenetic characterisation of healthy individuals of SAI, SAM, 
SAC and SAB ethnicity was achieved and the background frequencies of HLA-ABC alleles, 
KIR genotypes, KIR-HLA combinations, KIR3DL1/S1 and KIR2DS4f/v copy number 
variation as well as the prevalence of CCR5Δ32, HLA-B signal peptide p2-M/T and HLA-C 
3’UTR +263-ins/del variants were determined. The four way comparison of frequencies of 
genes important in innate and adaptive immunity between the SAI, SAM, SAC and SAB 
populations revealed, as expected, a large number of differences, many of which reached 
statistical significance which have been reported in the results section. 
 
 A few differences of interest were observed in the distribution of KIR genes that was 
most divergent between the SAI population and the other three populations. The highest 
frequencies of the activating KIRs, KIR2DS1 (66.0%), KIR2DS2 (78.0%) and KIR2DS3 
(56.0%), KIR2DS5 (56.0%) and KIR3DS1 (54.0%), although lower frequencies of KIR2DS4 
(88.0%) and the pseudogene KIR2DP1 (94.0%) was observed in the SAI population 
comparison to the three other populations. Similarly, the inhibitory KIRs, KIR2DL2 (80.0%) 
and KIR2DL5 (84.0%) had the highest frequencies, except for KIR2DL3 (64.0%) which had 
the lowest frequency in the SAI population. A rare individual from the SAI population was 
identified with the framework gene KIR2DL4 absent. Low frequencies of KIR2DL4 negative 
individuals have been reported previously in studies from Brazil, China (Gonzalez-Galarza et 
al., 2011), Equatorial Guinea (Gomez-Lozano et al., 2003, Gonzalez-Galarza et al., 2011) and 
Poland (Nowak et al., 2011). The SAB population had very low frequencies of the activating 
KIRs, KIR2DS1 (12.6%) and KIR3DS1 (6.9%) in comparison to the other three populations. 
KIR3DS1 is known to be present at low frequencies in African populations (Norman et al., 
2007). 
 
 The copy numbers of KIR3DL1 and KIR3DS1 were quantified and showed that the 
SAM and SAC populations were the most similar in the distribution of copy number variants, 
however the SAI and SAB populations had divergent profiles of copy number variants. The 
SAI population was the only population with one individual lacking both KIR3DL1 and 
KIR3DS1 entirely. Individuals with only a single copy of KIR3DS1 were rare or absent in the 
other populations, but present in 8.0% of individuals in the SAI population. Approximately a 
third of SAI, SAM and SAC populations carried one copy each of KIR3DL1 and KIR3DS1, 
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but a significantly low frequency of individuals in the SAB populations carried this copy 
number variant (6.3%). The majority of SAB individuals carried 2 copies of KIR3DL1 in the 
absence of KIR3DS1 (83.6%) which is expected considering the lack of KIR3DS1 in this 
population. There was evidence of duplication of KIR3DS1 or KIR3DL1 in the SAI, SAM 
and SAC populations, but not in the SAB population. Evidence for deletion of KIR3DS1 or 
KIR3DL1 was found in the SAI and SAB populations, but not in the SAM and SAC 
populations. Duplication and deletion of KIR3DL1/S1 has been reported in minority of 
Caucasian individuals (Jiang et al., 2012, Pelak et al., 2011). 
 
 The copy numbers of full-length KIR2DS4f and truncated KIR2DS4v were also 
measured. The absence of both KIR2DS4f and KIR2DS4v was at a low frequency and similar 
in the SAM, SAC and SAB populations, but significantly higher in the SAI population 
(12.0%). All of the individuals who did not carry KIR2DS4 were in fact KIR2DS1-positive; 
hence the absence of KIR2DS4 is unlikely to be due to a deletion. This is because KIR2DS4 
and KIR2DS1, although not present at the same locus, are inherited in a mutually exclusive 
pattern (Hsu et al., 2002). However, in some cases deletion of KIR2DS4 can occur and has 
been described in a minority of Caucasian individuals (Jiang et al., 2012). In the SAC 
population 61.7% of SAC individuals had only a single copy of KIR2DS4v. Since KIR2DS4v 
encodes a truncated protein, this is large number of individuals without a functional 
activating receptor. The SAI population also showed high frequencies of individuals carrying 
a non-functional KIR2DS4, with 38% and 22% in individuals carrying single and double 
copies of KIR2DS4v, respectively, in the absence of KIR2DS4f. 
 
In all populations, collectively, 55 different KIR genotypes could be identified. This 
included 5 new genotypes (BxN1-N5) that have not been reported before, three of which 
were identified in the SAI population (BxN1-N3), while one each was detected in the SAM 
and SAC population (BxN4 and BxN5, respectively). For each individual population, the 
number of KIR genotypes detected was 21, 18, 24 and 32 for SAI, SAM, SAC and SAB 
populations, respectively. The most common KIR genotypes detected in SAI populations 
were Bx6 and Bx76 both at frequencies of 12.0%, while the AA1 genotype was the most 
common in the other three populations at 22.0%, 26.6% and 25.8% in the SAM, SAC and 
SAB populations, respectively. 
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The frequencies of HLA ligands were different in the four populations. For HLA-A, 
HLA-A Bw480I homozygosity was rare in SAI, SAM and SAB populations and absent in the 
SAC population. HLA-A non-Bw4 homozygosity was the most common genotype in all 
populations, but lowest in the SAI population (58.0%). For HLA-B, HLA-B Bw480I/Bw6 
heterozygotes and HLA-B Bw6 homozygotes were the most common genotypes detected in 
all populations. All permutations of HLA-B ligands were detectable in the overall analysis, 
however, interestingly, no HLA-B Bw4TL homozygotes were found in any of the populations 
studied. At the HLA-C locus, all populations had similar frequencies of HLA-C1/C2 
heterozygotes approaching 50% of the population. SAI and SAC populations had higher 
frequencies of HLA-C1 homozygotes compared to SAM and SAB populations, while in SAM 
and SAB populations the frequencies of HLA-C2 homozygotes were higher. 
 
Since the genes that encode the KIRs and HLA ligands are present on separate 
chromosomes (6 and 19, respectively), KIR-HLA ligand pairs are not necessarily inherited 
together. The SAB and SAM populations had the highest frequencies of the KIR3DL1/HLA-B 
Bw480I combination (52.8% and 46.0%, respectively). The SAB and SAM populations also 
had the lowest frequencies of the KIR3DL1/HLA-B Bw480T combination (13.8% and 20.0%, 
respectively). The frequency of KIR2DL1/HLA-C2 was significantly higher in the SAB 
population (78.6%) compared to the other three populations, while KIR2DL3/HLA-C1 was 
significantly higher in the SAC population (80.9%) compared to the other populations.  A 
very low frequency of the KIR2DS1/HLA-C2 combination was detected in the SAB 
population (9.4%). 
 
The prevalence of the CCR5Δ32 variant was previously unknown in the SAI and 
SAM population and was shown to be present at low frequencies in both the SAI (4.0%) and 
SAM (6.0%) population. This result was not unexpected, however, since CCR5Δ32 has been 
detected at low frequencies (1.5%) in mainland Indian populations (Verma et al., 2007) and 
due to SAC ancestry within the SAM population, it was predicted that CCR5Δ32 would also 
be present in this population. Notably, none of the carriers of CCR5Δ32 detected in the SAI 
and SAM populations were homozygous, however, a single individual was detected in the 
SAC population who was homozygous for CCR5Δ32. A high frequency of CCR5Δ32 
heterozygotes was determined in the SAC population (17.0%). This is higher than generally 
reported for Caucasian populations in Europe (~10%) (Martinson et al., 1997), however this 
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result is in agreement with a frequency of 14.3% reported for SAC individuals in another 
study (Picton et al., 2010). 
 
HLA class I genotyping revealed extensive diversity at all three loci, with some alleles 
shared amongst all populations and many unique alleles only found in a single population. 
Overall, 141 different HLA class I alleles were detected consisting of 42 different HLA-A 
alleles, 61 different HLA-B alleles and 38 different HLA-C alleles. For HLA-A, 19, 24, 25 and 
31 different alleles were identified in SAI, SAM, SAC and SAC populations, respectively. 
HLA-A*02:01 was the most common in both the SAM and SAC populations (f=0.210 and 
f=0.255, respectively while HLA-A*11:01 (f=0.170) and -A*30:01 (f=0.110) were the most 
common alleles in the SAI and SAB populations, respectively. For HLA-B, 30, 41, 38 and 29 
different alleles were identified in SAI, SAM, SAC and SAC populations, respectively. HLA-
B*07:02 was the most common allele in both the SAM and SAC populations (f=0.08 and 
f=0.154, respectively), while HLA-B*40:06 (f=0.140) and -B*58:02 (f=0.094) was the most 
common allele in the SAI and SAB populations, respectively. Overall, 38 different HLA-C 
alleles were detected in the four populations with 20, 24, 26 and 27 different alleles identified 
in SAI, SAM, SAC and SAC populations, respectively. For HLA-C, HLA-C*06:02 was the 
most common allele found in three populations (SAI, SAM and SAB population) at 
frequencies of f=0.14, f=0.12 and f=0.157, respectively, while HLA-C*07:01 was the most 
common allele in the SAC population (f=0.176). 
 
 In conclusion, Chapter 3 has contributed important host genetic background 
information, previously unavailable for the SAI and SAM populations, with additional 
information added for the SAC and SAB populations for comparative purposes. This chapter 
thus serves as the basis for subsequent chapters that will address the HLA class I-mediated 
immune hypersensitivity reaction to antiretroviral drugs (Chapter 4) and the potential role of 
host genetic factors associated with HIV-1 acquisition and transmission (Chapter 5). 
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Chapter 4:                                                          
Frequencies of immune hypersensitivity reaction-
associated HLA class I alleles in healthy South 
African Indian and Mixed ancestry populations 
determined by a novel real-time PCR assay 
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4.1. Introduction 
 
 Antiretroviral (ARV) therapy reduces morbidity and mortality associated with HIV-
1infection; however, treatment success is often compromised by drug toxicity, viral 
resistance development and immune complications such as immune reconstitution 
inflammatory syndrome (IRIS) and immune hypersensitivity reaction (IHR). In susceptible 
individuals, IHR develops rapidly following the administration of the nucleoside reverse 
transcriptase inhibitor (NRTI), Abacavir (ABC) or the non-nucleoside reverse transcriptase 
inhibitor (NNRTI), Nevirapine (NVP). IHR is potentially life-threatening due to excessive 
activation of autoimmune CD8+ cytotoxic T cells (CTLs) and increased production of pro-
inflammatory cytokines, such as interferon-γ (Pompeu et al., 2012). Symptoms include fever, 
rash, nausea, vomiting, diarrhoea, abdominal pain, dyspnoea, sore throat, cough and malaise 
(Yuen et al., 2008). In extreme circumstances, failure to withdraw the drug, or re-initiation of 
therapy after a period of discontinuation, can lead to multiple organ failure and death of the 
patient. 
 
 ABC IHR associates with the presence of human leukocyte antigen (HLA)-B*57:01, 
although, some carriers do not develop a response (Hetherington et al., 2002, Mallal et al., 
2002, Martin et al., 2004b, Phillips et al., 2005). Similarly, NVP IHR associates with the 
presence of HLA-B*35:05 documented in Thai populations (Chantarangsu et al., 2009, Yuan 
et al., 2011); HLA-C*04 in Thai, Chinese and African populations (Likanonsakul et al., 2009, 
Gao et al., 2012, Yuan et al., 2011); HLA-C*08 in Japanese populations (Gatanaga et al., 
2007) and HLA-B*14-C*08 haplotypes in Caucasian populations (Littera et al., 2006). 
Recently, the HLA-C*04:01 allelic variant was specifically associated with NVP IHR in a 
Black African population (Carr et al., 2013a). An association of HLA class II alleles, such as 
HLA-DRB1*01 (Vitezica et al., 2008) and HLA-DRB1*0101 (Martin et al., 2005), with 
cutaneous rash/hepatotoxicity in Caucasians treated with NVP, has also been described and 
more recently, a study in South African populations has linked NVP hepatotoxicity with the 
presence of HLA-DRB1*0102 as well as HLA-B*58:01 (Phillips et al., 2013). The current 
study has focused on HLA class I alleles only, although detection of HLA-B*58:01 has not 
been included. 
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HLA-B*57:01 is uncommon in individuals of Black African descent, but is present at 
an allele frequency of 7.1% in Caucasians and 8.2% in individuals from the Indian 
subcontinent (Gonzalez-Galarza et al., 2011). The allele frequency of HLA-B*35:05 is 10.2% 
in South America and 4.2% in Oceania, but is rarely detected in individuals of European 
descent and absent in South Asian and sub-Saharan African populations 
(www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi). The prevalence of HLA-B*35:05 is high 
in Indonesia (16.5%) and the Philippines (12.0%) (Gonzalez-Galarza et al., 2011). The allele 
frequency of HLA-C*04 ranges from 9.4% in North-East Asia to 39.9% in Australia; while 
HLA-C*08 is present in approximately 5% of European and sub-Saharan African individuals 
and is common in Oceania at an allele frequency of 18.2% 
(www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi). 
 
Diverse populations reside in South Africa and comprise of individuals of SA Black 
(SAB), SA Caucasian (SAC) and SA Indian (SAI) ethnicity as well as SA individuals of 
Mixed ancestry (SAM). HLA class I allele frequencies for the SAC and SAB population have 
been reported in a previous study; however, the SAI and SAM population was not included in 
this work (Paximadis et al., 2012). Individuals of the SAM population carry complex genetic 
admixtures derived from at least four lineages (European, Black African, South Asian and 
Indonesian) (de Wit et al., 2010, Patterson et al., 2010); hence, the presence of HLA class I 
alleles associated with ABC and NVP IHR is likely. A cohort of healthy SAI individuals was 
also included in this study, although a small study (n=51) reporting HLA class I allele 
frequencies in this population is available (Gonzalez-Galarza et al., 2011). 
 
Prospective HLA-B*57:01 screening has been successfully implemented in developed 
countries such as Australia and the USA (Rauch et al., 2006, Mallal et al., 2008) and recent 
HLA-B*35:05 genotyping was shown to reduce the occurrence of NVP IHR in Thailand 
(Kiertiburanakul et al., 2013). Currently, this intervention is not in practice in resource-
limited settings, such as countries in Africa, where NVP is widely used and ABC may have 
been introduced in some regions. ABC and NVP is prescribed in South Africa, where one of 
the largest national ARV treatment programs in the world is in operation, with two million 
HIV-positive individuals accessing treatment in October 2012 
(www.doh.gov.za/docs/presentations/2013/Antenatal_Sentinel_survey_Report2012_final.pdf
). There are limited reports, however, that describe the occurrence of IHR following exposure 
to ABC and NVP in South Africa. A 3.5% prevalence of NVP-associated rash in a local 
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national mother-to-child HIV-1 transmission prevention program has been reported (Black et 
al., 2008), while a sub-Saharan HIV-1 treatment study that included three local sites, reported 
the development of cutaneous rash of any grade in 54.0% of women receiving NVP twice-
daily (Dong et al., 2012). A frequency of 6.0% of individuals developed hypersensitivity 
reactions to ABC within the first 28 days of treatment in a multisite study that included one 
local site (Wood et al., 2004), while in a multisite paediatric HIV-1 treatment study that 
included 4 sites in South Africa, 9/109 (8.3%) children developed suspected ABC-
hypersensitivity reactions (Fortuny et al., 2014). 
 
 Several molecular and serological methods have been described previously for the 
detection of HLA-B*57:01 (Stocchi et al., 2012). There was also the suggestion that detection 
of the guanine (G) variant of the HCP5 (HLA complex protein 5) rs2395029 single 
nucleotide polymorphism (SNP), also termed “HCP5 568G”, known to be in strong linkage 
disequilibrium with HLA-B*57:01 (Colombo et al., 2008, Rodriguez-Novoa et al., 2010) 
could be used solely as a predictor of HLA-B*57:01 carriage. The current study has used a 
novel strategy to determine the presence of HLA-B*57:01 alleles using a real-time allele-
specific PCR (AS-PCR) assay and also included the detection of HLA-B*35:05, -C*04 and -
C*08. Although a recent real-time AS-PCR assay for the detection of HLA-B*57:01 has been 
published (Dello Russo et al., 2014), the detection strategy used in the current assay was 
different and more informative. To our knowledge, no real-time AS-PCR detection assays for 
HLA-B*35:05, -C*04 and -C*08 are available. The advantages of using real-time AS-PCR 
assays includes less template DNA required, lower cost of reagents and consumables and a 
faster turn-around time when compared to conventional sequence-based typing (SBT) 
methods. The assay was first developed and evaluated using DNA samples previously HLA 
class I genotyped by SBT, then subsequently applied to a cohort of healthy individuals of 
SAM and SAI ethnicity. Results were combined with the reported population frequencies of 
HLA class I alleles detected in the SAC and SAB population. In addition, South African 
demographic data was used to estimate the number of HIV-1 positive individuals potentially 
at risk of developing ABC and NVP IHR, who may benefit from the assay. 
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4.2. Results 
 
4.2.1. Real-time AS-PCR assay development and validation 
 
 DNA samples of known HLA class I genotype (n=120) were available from SAB and 
SAC individuals from a previous study (Paximadis et al., 2012). Samples representing alleles 
of interest were selected for development and evaluation of the AS-PCR primers as follows: 
HLA-B*57:01 (n=8), -B*57:02 (n=6), -B*57:03 (n=9), -B*35:05 (n=1), -C*04:01 (n=65), -
C*04:04 (n=2), -C*04:08 (n=1), -C*08:01 (n=2), -C*08:02 (n=14) and -C*08:04 (n=12). 
Each primer set was tested with all 120 samples to also assess false positive/negative 
amplification potential. The HLA-B*57 group-specific primers were evaluated with positive 
control samples representing HLA-B*57:01, -B*57:02 and -B*57:03. The presence of HLA-
B*57 was correctly detected in these samples and was also negative for all other HLAs tested. 
The primers specific for detection of coding sequences for residues 114D and 116S correctly 
identified the presence of these codons in HLA-B*57:01 samples only and not in the samples 
that contained HLA-B*57:02 and -B*57:03. HCP5 568G was detected in HLA-B*57:01 
samples only and not in samples containing HLA-B*57:02 and -B*57:03 or in samples 
containing other HLAs. Figure 4.1 shows the difference in raw data plots between samples 
positive for HLA-B*57:01, HLA-B*57:02 and HLA-B*57:03. The HLA-B*35:05-specific 
primers correctly amplified HLA-B*35:05 with no observed false positive amplification of 
other HLAs tested. The HLA-C*04 group-specific primers were tested successfully with 
samples representing HLA-C*04:01, -C*04:04 and -C*04:08, while the HLA-C*08 group-
specific primers were tested successfully with samples representing HLA-C*08:01, -C*08:02 
and -C*08:04. No false positives were observed for other HLAs tested for HLA-C*04 and -
C*08. 
 
 For additional evaluation purposes, a panel of DNA samples (n=30) representative of 
more diverse global populations, available from the International Histocompatibility Working 
Group (IHWG), was included in the validation of the real-time AS-PCR assays and included 
the following relevant alleles: HLA-B*35:01 (n=2), -B*35:03 (n=1), -B*35:05 (n=1), -
B*57:03 (n=2), -C*04:01 (n=6), -C*08:01 (n=2) and -C*08:02 (n=2). The HLA-B*57 
primers detected HLA-B*57:03 and did not show the presence of 114D/116S or HCP5 568G. 
HCP5 568G was not detected in any of the samples tested. HLA-B*35:05 was correctly 
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identified and no amplification was observed for HLA-B*35:01 or -B*35:03. The HLA-C*04 
primers correctly identified HLA-C*04:01 and likewise, the HLA-C*08 primers correctly 
identified HLA-C*08:01 and -C*08:02 with no false positive amplifications observed. 
 
Figure 4.1. Melting curve analysis of (a) HLA-B*57:01-positive; (b) HLA-B*57:02-positive and (c) HLA-
B*57:03-positive samples showing the presence of melting peak for ALB control gene and HLA-B*57 
group-specific primers in all samples, however, the presence of melting peaks corresponding to the 
HCP5 598G variant and residues 114D/116S are only present in HLA-B*57:01-positive samples. 
4.2.2. Real-time AS-PCR detection of HLA-B*57:01, -B*35:05, -C*04 and -C*08 
 
HLA-B*57:01 was detected in 8.0% and 12.0% of individuals in the SAM and SAI 
population, respectively (Table 4.1), which was similar to the frequency of 8.2% calculated 
for SAC populations (Paximadis et al., 2012). HCP5 568G was present in all HLA-B*57:01 
samples; however, HCP5 568G was also detected in one individual of SAM ethnicity, who 
was negative for HLA-B*57:01 by the AS-PCR assay. HLA class I genotyping by SBT 
confirmed that this individual was not an HLA-B*57:01 carrier and therefore HCP5 568G 
detection cannot be used as an absolute predictor of HLA-B*57:01 positivity in the SAM 
population. HLA-B*35:05 was not detected in SAI individuals, but was present in SAM 
individuals at a frequency of 6.0% (Table 4.1). HLA-B*35:05 has not been reported in SAB 
or SAI populations and has a low population frequency of 1.0% in SAC individuals 
(Paximadis et al., 2012, Gonzalez-Galarza et al., 2011). HLA-C*04 was detected at 
frequencies of 22.0% and 24.0% of individuals in the SAM and SAI population, respectively 
(Table 4.1), which was similar to the calculated population frequencies for SAC (18.6%) and 
SAB (23.7%) individuals (Paximadis et al., 2012). HLA-C*08 was detected in 10.0% of SAM 
individuals and 8.0% of SAI individuals (Table 4.1) which was similar to the calculated 
frequencies for SAC (6.9%) and SAB (10.2%) populations (Paximadis et al., 2012). To 
confirm the validity of results generated by the AS-PCR assay, all SAI and SAM samples 
were HLA class I genotyped by SBT. 
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Table 4.1. Frequency of individuals carrying HLA class I alleles associated with ABC and NVP 
immune hypersensitivity reaction for healthy SAI, SAM, SAC and SAB populations. 
HLA class I genotype SAI SAM SAC SAB 
HLA-B*57:01 6/50(12.0%) 4/50(8.0%) 8/97(8.2%) 0/196(0.0%) 
HLA-B*35:05 0/50(0.0%) 3/50(6.0%) 1/96(1.0%) 0/196(0.0%) 
HLA-C*04 12/50(24.0%) 11/50(22.0%) 19/102(18.6%) 47/198(23.7%) 
HLA-C*08 4/50(8.0%) 5/50(10.0%) 7/102(6.9%) 20/197(10.2%) 
HLA, human leukocyte antigen; ABC, Abacavir; NVP, Nevirapine; SAI, South African Indian; SAM, South African Mixed ancestry; SAC, 
South African Caucasian; SAB, South African Black 
 
4.2.3. Hypothetical analysis of individuals potentially at risk of ABC and NVP IHR 
 
The most recent South African national census (2013) provides estimates of the 
number of individuals per population 
(http://www.statssa.gov.za/publications/P0302/P03022013.pdf) as follows: SAB 
(n=42,284,100), SAC (n=4,602,400), SAM (n=4,766,200) and SAI (n=1,329,300). Updated 
HIV-1 prevalence rates stratified by population are not available, however, a national survey 
conducted in 2012 estimated rates of 0.8%, 3.1%,  0.3% and 15.0% in SAI, SAM, SAC and 
SAB populations, respectively (http://www.mrc.ac.za/pressreleases/2009/sanat.pdf). These 
figures were used to estimate that 14,235 HIV-positive individuals would potentially be at 
risk of developing IHR in response to ABC exposure and 2,212,700 HIV-positive individuals 
would potentially be at risk of developing IHR in response to NVP therapy (Table 4.2). 
 
Table 4.2. Estimated numbers of South African individuals based on HIV-1 status and carriage of at 
least one HLA class I allele associated with ABC or NVP immune hypersensitivity reaction. 
 
HLA class I genotype 
HIV-1 status 
SAI 
n=1,329,300 
SAM 
n=4,766,200 
SAC 
n=4,602,400 
SAB 
n=42,284,100 
Total 
n=52,982,000 
HIV-1(+) 10,634 147,752 13,807 6,342,615 6,514,808 
HLA-B*57:01(+) 159,516 381,296 379,579 0 920,391 
HLA-B*57:01(+) HIV-1(+) 1,276 11,820 1,139 0 14,235 
HLA-B*35:05(+) 0 285,972 47,447 0 333,419 
HLA-B*35:05(+) HIV-1(+) 0 8,865 142 0 9,007 
HLA-C*04(+) 319,032 1,048,564 857,310 10,037,135 12,262,041 
HLA-C*04(+) HIV-1(+) 2,552 32,505 2,572 1,505,570 1,543,199 
HLA-C*08(+) 106,344 476,620 315,851 4,292,802 5,191,617 
HLA-C*08(+) HIV-1(+) 851 14,775 948 643,920 660,494 
HLA, human leukocyte antigen; ABC, Abacavir; NVP, Nevirapine; HIV-1(+); HIV-1 positive; SAI, South African Indian; SAM, South 
African Mixed ancestry; SAC, South African Caucasian; SAB, South African Black 
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4.3. Discussion 
 
HLA-B*57:01 is absent in SAB individuals, but is present in 8.2% of SAC individuals 
(Paximadis et al., 2012) and has been reported in SAI individuals at an allele frequency of 
10.2% (Gonzalez-Galarza et al., 2011). The presence and frequency of HLA-B*57:01 in the 
SAM population is not known; however, using a novel real-time AS-PCR assay, 8.0% of 
individuals in this population were found to be carriers. Similarly, HLA-B*57:01 was 
detected in 12.0% of SAI individuals. Furthermore, all samples identified as HLA-B*57:01 
positive by the AS-PCR assay also tested positive for HCP5 568G, in agreement with 
previous observations that these genetic loci are in strong linkage disequilibrium (Colombo et 
al., 2008, Rodriguez-Novoa et al., 2010). However, HCP5 568G was also detected in one 
HLA-B*57:01-negative individual of SAM ethnicity. Similar observations have been made in 
two Caucasian studies (Badulli et al., 2012, Rodriguez-Novoa et al., 2010) where 3/66 (4.5%) 
and 1/15 (6.7%) individuals with HCP5 568G were HLA-B*57:01 negative. HCP5 568G can 
also be absent in HLA-B*57:01 carriers as observed in 6/104 (5.8%) and 2/119 (1.7%) 
individuals from two Caucasian studies (Badulli et al., 2012, Colombo et al., 2008). In the 
current study, however, none of the HLA-B*57:01 positive individuals were negative for 
HCP5 568G, suggesting that in the SAM and SAI populations, detection of HCP5 568G 
alone was positive predictor for exclusion from ABC treatment. However, as in one 
individual from the SAM population, the presence of HCP5 568G in the absence of HLA-
B*57:01 would deny eligibility for ABC treatment. The inclusion of HLA-B*57 group-
specific and 114D/116S primers can be used to resolve this situation. 
 
HLA-B*35:05 is absent in the SAI and SAB population and has a low frequency of 
1.0% in the SAC population (Paximadis et al., 2012, Gonzalez-Galarza et al., 2011). Using 
the AS-PCR assay, HLA-B*35:05 was not detected in SAI individuals, in agreement with the 
previous report (Gonzalez-Galarza et al., 2011), but was observed at a relatively high 
frequency of 6.0% in SAM individuals. This was an unexpected finding that questioned the 
origin of HLA-B*35:05 in the SAM population considering the scarcity of this allele in the 
SAB and SAC populations, that are shared lineages. HLA-B*35:05 is not found in Southern 
Asia, but is prevalent in South America and is also present in Oceania 
(http://www.ncbi.nlm.nih.gov/projects/gv/mhc/ihwg.cgi). Oceania includes Indonesia where 
a high population frequency (16.5%) of HLA-B*35:05 has been reported (Gonzalez-Galarza 
et al., 2011). Since the SAM population is known to have Indonesian ancestry (de Wit et al., 
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2010, Patterson et al., 2010), there is a likelihood that HLA-B*35:05 may be derived from the 
Indonesian lineage, although a Caucasian influence cannot be excluded. 
 
HLA-C*04 is present in 18.6% of SAC and 23.7% of SAB individuals (Paximadis et 
al., 2012) and was detected at similar frequencies of 22.0% and 24.0% in SAM and SAI 
populations, respectively, by the AS-PCR assay. Notably, a recent African study identified 
the HLA-C*04:01 allelic variant as a risk factor for the development of NVP IHR (Carr et al., 
2013b). The real-time AS-PCR assay does not differentiate this allele from other HLA-C*04 
alleles, but does include its detection. HLA-C*08 is present in 6.9% of SAB individuals and 
10.2% of SAC individuals (Paximadis et al., 2012). An allele frequency of 4.2% has also 
been reported for the SAI population (Gonzalez-Galarza et al., 2011). Similar frequencies of 
HLA-C*08 were detected by the AS-PCR assay in SAM and SAI populations (10.0% and 
8.0%, respectively). A Caucasian study identified the HLA-B*14-C*08 haplotype as a risk 
factor for NVP IHR (Littera et al., 2006), however, the role of HLA-B*14 is uncertain due to 
the high linkage disequilibrium between HLA-B*14 and -C*08 known for this population 
(Sardinia). This strong linkage disequilibrium has also been reported in the SAC and SAB 
population (Paximadis et al., 2012). Since, HLA-C*08 has been reported as an independent 
risk factor for NVP IHR, albeit in a Japanese population (Gatanaga et al., 2007) where HLA-
B*14 is uncommon (Gonzalez-Galarza et al., 2011), it was decided to omit detection of HLA-
B*14 in the current assay, even though HLA-B*14 is prevalent in the SAB and SAC 
population at allele frequencies of 3.3% and 2.6%, respectively (Paximadis et al., 2012). 
 
The current study has used South Africa an example to illustrate the potential benefits 
of a pre-screening assay by estimating the number of individuals potentially at risk of 
developing IHR. Two million individuals were accessing treatment in October 2012, making 
the South African national antiretroviral treatment program one of the largest in the world 
and currently, the South African Department of Health (DOH) recommends ABC for the 
treatment of adolescent and paediatric HIV-1 infection, while NVP is recommended for adult 
HIV-1 treatment when efavirenz is contra-indicated 
(www.doh.gov.za/docs/policy/2013/ART_Treatment_Guidelines_Final_25March2013.pdf). 
Using population statistics, HIV-1 prevalence data and the reported/measured frequencies of 
HLA class I alleles, the number of HLA-B*57:01 carriers who are HIV-1 positive equates to 
14,235 individuals. Notably, HLA-B*57:01 has not been reported in the SAB population, 
although, low frequencies have been detected in individuals from other African countries, 
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including Zimbabwe, Kenya, Uganda, Sudan and Zambia (Gonzalez-Galarza et al., 2011). It 
can therefore be assumed that the risk of ABC IHR will be negligible in the SAB population. 
HLA-B*35:05 was estimated to be present in 9,007 HIV-1 positive individuals. Notably, 
HLA-B*35:05 is absent in the SAI and SAB populations and should not pose a risk for these 
individuals. It was estimated that HLA-C*04 alleles would be present in 1,543,199 HIV-1 
positive individuals and similarly, HLA-C*08 alleles would be present in 660,494 HIV-1 
positive individuals. The risk of NVP IHR is highly significant in the SAB population due to 
a large population size (n=42,284,100), high frequency of HLA-C*04 (23.7%) and -C*08 
(10.2%) as well as a high HIV-1 prevalence (15.0%). Furthermore, the HLA-C*04:01 allelic 
variant, associated with NVP IHR, is common in this population with a reported allele 
frequency of 11.9% and is also present at allele frequencies of 8.5% in SAC individuals 
(Paximadis et al., 2012) and 4.2% in SAI individuals (Gonzalez-Galarza et al., 2011). The 
allele frequency of HLA-C*04:01 was determined at 9.0 % in the SAM population using HLA 
class I genotyping data. In total, an estimated 14,235 and 2,212,700 HIV-1 positive 
individuals are potentially at risk of developing IHR in response to ABC and NVP exposure, 
respectively. Based on these estimates, a substantial number of South African individuals 
would benefit from the availability of a pre-screening assay before starting treatment, as 
exemplified by prospective HLA-B*57:01 and -B*35:05 genotyping in Australia and 
Thailand. 
 
Pre-screening of HIV-positive patients for the presence of HLA class I alleles 
associated with ABC and NVP IHR can markedly reduce the risk of morbidity and mortality, 
however, the implementation of cheaper and quicker molecular tests to substitute 
conventional HLA class I genotyping methods are needed to facilitate this intervention. This 
study presents the development of a real-time AS-PCR assay to achieve this aim and in 
addition the previously unknown percentages of HLA class I alleles associated with ABC and 
NVP IHR (HLA-B*57:01, -B*35:05, -C*04 and -C*08) in healthy SAM and SAI individuals 
was determined. Limitations of the assay include the potential of detection of a small subset 
of false positive alleles that are inevitable due to the large number of HLA class I alleles 
currently described. It is recommended that if the assay was implemented in populations 
where HLA class I alleles that produce false positive results are prevalent, that the contra-
indicated drug was not necessarily withheld based on the results, but used with close 
monitoring for early clinical signs of IHR. Using South Africa as an example, it was 
estimated that a substantial number of individuals accessing antiretroviral therapy may be at 
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risk of IHR and would therefore benefit from a genetic pre-screening assay. The assay may 
also be of use in populations, such as Australia, USA and Thailand, where these alleles are 
prevalent and ABC and NVP are in use for HIV-1 treatment.  
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Chapter 5:                                                           
Prevalence of protective/deleterious genotypes 
associated with HIV-1 acquisition/transmission in 
healthy individuals of South African Indian, Mixed 
ancestry, Caucasian and Black ethnicity 
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5.1. Introduction 
 
 Host genetic factors can modulate the rate of spread of HIV-1 within a population due 
to the influence of individual genes or gene combinations on susceptibility/resistance to HIV-
1 infection. In addition, HIV-1 transmission, which predominantly occurs via a heterosexual 
route, can also be influenced by genetic determinants of infectivity, such as high viral load. A 
primary example of a gene variant consistently associated with both resistance to HIV-1 
infection and a low viral load setpoint (VLS) is the 32bp-deletion variant of C-C chemokine 
receptor type 5, CCR5Δ32 (Barmania et al., 2013). CCR5Δ32 homozygotes (Liu et al., 1996), 
but not heterozygotes (Liu et al., 2012), are resistant to CCR5-tropic HIV-1 acquisition, while 
heterozygotes have a low VLS that mediates slow disease progression and lower infectivity 
(van Manen et al., 2011). 
 
 Other mediators of HIV-1 acquisition/transmission include cell-surface HLA class I 
molecules that regulate both adaptive and innate antiviral immune responses following HIV-1 
exposure, via activation of CD8+ cytotoxic T cell (CTLs) and natural killer (NK) cells. 
Specific alleles of HLA class I genes are known to associate with VLS (Carlson et al., 2012, 
Leslie et al., 2010, Frahm et al., 2005, Geldmacher et al., 2007, Honeyborne et al., 2007, 
Frahm et al., 2006, Tang et al., 2002, Tang et al., 2010, Kiepiela et al., 2004). Susceptibility 
and resistance to HIV-1 acquisition has also been associated with particular HLA class I 
alleles (Raghavan et al., 2009, Umapathy et al., 2007, Koehler et al., 2010, Peterson et al., 
2013, Song et al., 2011). 
 
 CTLs respond to immunogenic peptides derived from cytosolic proteins produced by 
intracellular pathogens, such as HIV-1. Peptide antigens bind to HLA class I molecules 
expressed on the cell surface. Three related subclasses of HLA class I molecules are 
expressed (HLA-A, -B and -C) that are encoded by three separate genes present in a highly 
polymorphic gene cluster mapping to the major histocompatibility complex (MHC) on 
chromosome 6 (Robinson et al., 2013b). NK cells are regulated in part, by killer-cell 
immunoglobulin-like receptors (KIRs); a specific family of cell-surface activating/inhibitory 
molecules mapping to the leukocyte receptor complex (LRC) on chromosome 19 (Middleton 
and Gonzelez, 2010). KIRs, in combination with cognate HLA class I ligands, are involved in 
detection and destruction of HIV-1-infected target cells by activated NK cells (Carrington 
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and Alter, 2012). NK cell responses precede the development of antiviral CTLs following 
HIV-1 exposure, underlining the importance of innate immune responses in preventing 
infection (Alter et al., 2007). 
 
 Studies in HIV-1 exposed seronegative (HESN) individuals, such as female sex 
workers, and uninfected partners in serodiscordant couples, have identified specific KIR-HLA 
combinations that associate with resistance/susceptibility to heterosexual HIV-1 acquisition. 
KIR-HLA combinations including KIR2DL2(+)KIR3DL3(+)HLA-C1(-)HLA-C2(+); 
KIR3DL1(+)KIR3DS1(-)HLA-Bw4(-)HLA-Bw6(+);KIR3DL1(-)KIR3DS1(+)HLA- 
Bw480I/T(+); KIR3DL1(+)KIR3DS1(+)HLA-B Bw480I/T(+)HLA-Bw6(+) and KIR3DL1(+/-
)KIR3DS1(+)HLA-A/B Bw4(+) associate with resistance to HIV-1 infection, while 
KIR2DL3(+)KIR2DL2(-)HLA-C1(+)HLA-C2(+) and KIR3DL1(+)KIR3DS1(-)HLA-A/B 
Bw4(+) associate with susceptibility to HIV-1 infection (Jennes et al., 2006, Guerini et al., 
2011, Habegger de Sorrentino et al., 2013). 
 
 Once infected by HIV-1, specific KIR-HLA combinations can subsequently influence 
HIV-1 disease progression via modulation of VLS or CD4+ helper T cell preservation 
(Gaudieri et al., 2005, Jiang et al., 2013, Martin et al., 2002, Pelak et al., 2011). The risk of 
heterosexual HIV-1 transmission also associates with viral load (Quinn et al., 2000, Merino et 
al., 2011) and KIR-HLA combinations such as KIR3DL1(+/-)KIR3DS1(+)HLA-B Bw480I(+) 
and KIR3DL1(+)KIR3DS1(-)HLA-B Bw480I(+) have been associated with a low VLS (Pelak 
et al., 2011, Jiang et al., 2013), while KIR3DL1(+)KIR3DS1(+/-)HLA-B Bw480I(-) and 
KIR3DL1(+)KIR3DS1(-)HLA-B Bw480I(-) genotypes have been associated with a high VLS 
(Jiang et al., 2013). 
 
The cell-surface expression levels of HLA-C molecules have been shown to affect 
HIV-1 VLS via an insertion (Ins)/deletion (Del) polymorphism at position +263 in the 
3’untranslated region (3’UTR) of HLA-C messenger RNA (mRNA) transcripts (Kulkarni et 
al., 2011). The HLA-C +263 Del variant is thought to disrupt the binding site of the Hsa-miR-
148a microRNA that targets HLA-C mRNA transcripts for degradation. 
 
Non-classical HLA class I molecules include HLA-E, -F and -G. NK cells express the 
inhibitory receptor CD94/NKG2A that interacts with HLA-E ligands on target cells (Adams 
and Luoma, 2013). HLA-E binds peptides derived from the HLA-B signal peptide sequence 
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that contain either a methionine (M) or threonine (T) residue at the anchoring position-2 (p2). 
The p2-T variant is associated with resistance to HIV-1 acquisition, but does not influence 
VLS (Yunis et al., 2007, Merino et al., 2013). It is thought that HLA-E is less stable in 
complex with the p2-T peptide variant which leads to lower cell-surface expression levels of 
HLA-E. Consequently NK cells are less inhibited and able detect HIV-1 infected target cells 
more efficiently. 
 
In South Africa HIV-1 prevalence is 12.2% (2012) at a national level, however, 
prevalence rates are disproportionate among the different SA populations. In 2008, the 
prevalence of HIV-1 was estimated at 0.3%, 0.3%, 1.7% and 13.6% in SAI, SAM, SAC and 
SAB populations, respectively (www.mrc.ac.za/pressreleases/2009/sanat.pdf). In 2012, these 
estimates changed to 0.8%, 3.1%, 0.3% and 15.0% in SAI, SAM, SAC and SAB populations, 
respectively (www.hsrc.ac.za/en/research-outputs/view/6871). Although several reasons 
ranging from behavioural to biological differences may underlie the low prevalence of HIV-1 
infection in the SAC, SAM and SAI populations compared to SAB populations, the potential 
contribution of host immunogenetic factors has not been investigated in these populations, 
particularly the SAI and SAM populations. 
 
This study has characterised several immunogenetic factors in healthy individuals of 
SAI (n=50) and SAM (n=50) ethnicity and has included data generated by others for SAC 
(n=94) and SAB (n=159) populations in order to make comparisons between the populations 
with a focus on protective/deleterious genotypes that associate with HIV-1 acquisition and 
VLS. Real-time allele-specific PCR (AS-PCR) assays were used to determine 
CCR5/CCR5Δ32, KIR and HLA-Bw480I/Bw480T/C1/C2 genotypes, while relative 
quantification real-time AS-PCR assays were used to determine copy number variation of 
KIR3DL1/S1 and KIR2DS4f/v. HLA class I A, -B and -C genotyping was done using 
commercial sequence-based typing (SBT) methods and HLA-B signal peptide p2-M/T 
variants were determined from these sequences. HLA-C 3’UTR +263-ins/del variants were 
determined by direct DNA sequencing. 
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5.2. Results 
 
 In order to assess the prevalence of various genotypes associated with HIV-1 
acquisition and VLS in the four populations, the frequency data from Chapter 3 was used to 
perform the respective analyses. Most of the analyses required an examination of 
combinations of particular genes/alleles and thus provide new data in this chapter. Some of 
the frequency data have been used directly as already reported in Chapter 3 and is 
consequently repetitive, however these data have been included where necessary to ensure 
this chapter can be read as a standalone study. 
 
5.2.1. Genotypes associated with HIV-1 acquisition 
 
5.2.1.1 Genotypes associated with resistance to HIV-1 infection 
 
5.2.1.1.1.  CCR5Δ32 homozygosity 
 
 Taken from Chapter 3 and shown in Figure 5.1, no CCR5Δ32 homozygotes were 
identified in the SAI and SAM populations. A low frequency of CCR5Δ32 homozygotes was 
determined for the SAC population (1.1%), while the frequency of CCR5Δ32 homozygotes in 
the SAB population was assumed to be 0%, due to the absence of this gene variant in this 
population (Picton et al., 2010). 
 
5.2.1.1.2. HLA-B p2-T homozygosity 
 
 Taken from Chapter 3 and shown in Figure 5.1, the highest frequency of HLA-B p2-
T/T was observed in the SAI population (78.0%), followed by the SAM population (54.0%) 
and similar frequencies were observed in the SAC and SAB populations (43.6% and 44.7%, 
respectively). A significant difference was observed in the frequency of HLA-B p2-T 
homozygotes in the SAI population compared to the SAM, SAC and SAB populations 
(78.0% vs. 54.0%; p=0.0196, 78.0% vs. 43.6%; p<0.0001 and 78.0% vs. 44.7%; p<0.0001, 
respectively). 
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5.2.1.1.3.  HLA-ABC 
 
 Based on published studies of HLA class I alleles associated with resistance or 
susceptibility to HIV-1 infection (Appendix B) and HLA class I genotypic data available for 
the SAI, SAM, SAC and SAB populations, an individual was considered a carrier of an 
overall HLA-ABC genotype profile associated with “resistance” if after assigning each HLA-
A, -B and -C allele to a protective, deleterious or unknown status, the overall cumulative 
result was an excess of protective alleles (Figure 5.1). Individuals were defined as “neutral” 
if equal numbers of protective and deleterious alleles were present or if all six alleles were of 
unknown status. Based on this analysis, the frequency of resistance HLA-ABC genotypes was 
highest in the SAI population (44.0%), followed by the SAC population (39.4%), while 
similar frequencies were observed in the SAM and SAB populations (32.0% vs. 30.2%, 
respectively). No significant differences were observed between the populations (p>0.05). 
 
5.2.1.1.4. KIR2DL2(+)KIR3DL3(+)HLA-C1(-)HLA-C2(+) 
 
 The frequency of individuals carrying the protective KIR-HLA ligand combination 
2DL2(+)3DL3(+)C1(-)C2(+), defined by the presence of both KIR2DL2 and KIR3DL3 as 
well as an HLA-C2 ligand, was determined by analysis of KIR genotypes and HLA ligand 
genotypes available for the SAI, SAM, SAC and SAB populations (Figure 5.1). The 
frequency of the 2DL2(+)3DL3(+)C1(-)C2(+) genotype was highest in the SAB population 
(13.8%), followed by the SAM population (12.0%), and present at a similar frequency in the 
SAI and SAC populations (8.0% and 7.4%, respectively). No statistically significant 
differences were observed between the populations.  
 
5.2.1.1.5. KIR3DL1(+)3DS1(-)HLA-Bw4(-)HLA-Bw6(+) 
 
 The frequency of individuals carrying the protective KIR-HLA ligand combination 
3DL1(+)3DS1(-)Bw4(-)Bw6(+), defined by the presence of KIR3DL1 and absent KIR3DS1 as 
well as the presence of an HLA-B Bw6 ligand and absence of an HLA-Bw4 ligand, was 
determined by analysis of KIR genotypes and HLA ligand genotypes available for the SAI, 
SAM, SAC and SAB populations (Figure 5.1). The frequency of the 3DL1(+)3DS1(-)Bw4(-
)Bw6(+) genotype was the highest in the SAB population (37.1%), lowest in the SAI 
population (12.0%) and present at similar frequencies in the SAM and SAC populations 
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(22.0% and 22.3%, respectively). A significant difference was observed with this genotype 
when the SAI and SAC populations were compared to the SAB population (12.0 % vs. 
37.1%; p=0.0007 and 22.3% vs. 37.1%; p=0.0173, respectively). 
 
5.2.1.1.6. KIR3DL1(-)KIR3DS1(+)HLA-B Bw480I/T(+) 
 
 The frequency of individuals carrying the protective KIR-HLA ligand combination 
3DL1(-)3DS1(+)HLA-B Bw480I/T(+), defined as the presence of KIR3DS1 and absent 
KIR3DL1 as well as the presence of HLA-B Bw480I and/or HLA-B Bw480T ligands, was 
determined by analysis of KIR genotypes and HLA ligand genotypes available for the SAI, 
SAM, SAC and SAB populations (Figure 5.1). The frequency of 3DL1(-)3DS1(+)HLA-B 
Bw480I/T(+) genotypes was highest in the SAI population (8%), lowest in the SAB population 
(0.6%) and present at a low frequency in SAM populations (2.0%). This genotype was absent 
in the SAC population. A statistically significant difference was observed in the frequency of 
3DL1(-)3DS1(+)HLA-B Bw480I/T(+) genotypes when the SAI population was compared to the 
SAB population (8.0% vs. 0.6%, respectively; p=0.0122). 
 
5.2.1.1.7. KIR3DL1(+)KIR3DS1(+)HLA-B Bw480I/T(+)HLA-Bw6(+) 
 
 The frequency of individuals carrying the protective KIR-HLA ligand combination 
3DL1(+)3DS1(+)HLA-B Bw480I/T(+)Bw6(+), defined as the presence of both KIR3DL1 and 
KIR3DS1 as well as the presence of both an HLA-Bw6 and an HLA-B Bw480I or HLA-B 
Bw480T ligand, was determined by analysis of KIR genotypes and HLA ligand genotypes 
available for the SAI, SAM, SAC and SAB populations (Figure 5.1). The frequency of 
3DL1(+)3DS1(+)HLA-B Bw480I/T(+)Bw6(+) genotypes was highest in the SAI population 
(26.0%), lowest in the SAB population (3.8%) and present at similar frequencies in the SAM 
and SAC populations (16.0% and 18.1%, respectively.). A significant difference in the 
frequency of 3DL1(+)3DS1(+)HLA-B Bw480I/T(+)Bw6(+) genotypes was observed in the 
SAI, SAM and SAC populations compared to the SAB population (26.0% vs. 3.8%; 
p<0.0001, 16.0% vs. 3.8%; p=0.0059 and 18.1% vs. 3.8%; p=0.0002, respectively). 
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5.2.1.1.8. KIR3DL1(+/-)KIR3DS1(+)HLA-A/B Bw4(+) 
 
 The frequency of individuals carrying the protective KIR-HLA ligand combination 
3DL1(+/-)3DS1(+)HLA-A/B Bw4(+), defined as the presence/absence of KIR3DL1 and the 
presence of KIR3DS1 as well as the presence of HLA-A and/or HLA-B Bw4 ligands, was 
determined by analysis of KIR genotypes and HLA ligand genotypes available for the SAI, 
SAM, SAC and SAB populations (Figure 5.1). The frequency of 3DL1(+/-)3DS1(+)HLA-
A/B Bw4(+) genotypes was highest in the SAI population (50.0%), lowest in the SAB 
population (5.7%) and present at similar frequencies in the SAM and SAC populations 
(26.0% and 27.7%, respectively). A statistically significant difference in the frequency of 
3DL1(+/-)3DS1(+)HLA-A/B Bw4(+) genotypes was observed in the SAI population 
compared to the SAM, SAC and SAB populations (50.0% vs. 26.0%; p=0.0228, 50.0% vs. 
27.7%; p=0.0103 and 50.0% vs. 5.7%; p<0.0001, respectively) as well as in the SAM and 
SAC populations compared to the SAB population (26.0% vs. 5.7%; p=0.0002 and 27.7% vs. 
5.7%; p<0.0001, respectively). 
 
5.2.1.2. Genotypes associated with susceptibility to HIV-1 infection 
 
5.2.1.2.1. HLA-B p2-M homozygosity 
 
 Taken from Chapter 3 and shown in Figure 5.1, the lowest frequency of the HLA-B 
p2-M/M genotype was observed in the SAM population (4.0%) and was present at similar 
frequencies in the SAC and SAB populations (8.5% and 8.8%, respectively). This genotype 
was absent in the SAI population. 
 
5.2.1.2.2. HLA-ABC 
 
 Based on published studies of HLA class I alleles associated with resistance or 
susceptibility to HIV-1 infection (Appendix B) and HLA class I genotypic data available for 
the SAI, SAM, SAC and SAB populations, an individual was considered a carrier of a 
“susceptibility” HLA-ABC genotype if after assigning each HLA-A, -B and -C allele to a 
protective, deleterious or unknown status, the overall cumulative result was an excess of 
deleterious alleles (Figure 5.1). Individuals were defined as neutral if equal numbers of 
protective and deleterious alleles were present or if all six alleles were of unknown status. 
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Based on this analysis, the frequency of susceptibility HLA-ABC genotypes was highest in the 
SAB population (57.9%), followed by the SAM population (46.0%) and the SAC population 
(40.4%). The lowest frequency was determined in the SAI population (32.0%).  A significant 
difference was observed in the frequency of susceptibility HLA-ABC genotypes in the SAB 
population compared to the SAI and SAC populations (57.9% vs. 32.0%; p=0.0019 and 
57.9% vs. 40.4%; p=0.0092, respectively). 
 
5.2.1.2.3. KIR2DL3(+)KIR2DL2(-)HLA-C1(+)HLA-C2(+) 
 
 The frequency of individuals carrying the deleterious KIR-HLA ligand combination 
2DL3(+)2DL2(-)C1(+)C2(+), defined as the presence of KIR2DL3 and absent KIR2DL2 as 
well as the presence of both HLA-C1 and HLA-C2 ligands, was determined by analysis of 
KIR genotypes and HLA ligand genotypes available for the SAI, SAM, SAC and SAB 
populations (Figure 5.1). The frequency of the 2DL3(+)2DL2(-)C1(+)C2(+) genotype was 
highest in the SAC population (22.3%), lowest in the SAI population (8.0%) and present at 
similar frequencies in the SAM and SAB populations (16.0% and 12.6%, respectively). A 
significant difference was observed in the frequency of the 2DL3(+)2DL2(-)C1(+)C2(+) 
genotype in the SAC population compared to the SAI population (22.3% vs. 8.0%, 
respectively; p=0.0372). 
 
5.2.1.2.4. KIR3DL1(+)KIR3DS1(-)HLA-A/B Bw4(+) 
 
 The frequency of individuals carrying the deleterious KIR-HLA ligand combination 
3DL1(+)3DS1(-)HLA-A/B Bw4(+), defined as the presence of KIR3DL1, absence of 
KIR3DS1 and the presence of HLA-A and/or HLA-B Bw4 ligands, was determined by analysis 
of KIR genotypes and HLA ligand genotypes available for the SAI, SAM, SAC and SAB 
populations (Figure 5.1). The frequency of the 3DL1(+)3DS1(-)HLA-A/B Bw4(+) genotype 
was highest in the SAB population (67.3%), followed by the SAM population (52.0%) and 
the SAC population (44.7%). The frequency was lowest in the SAI population (40.0%). A 
significant difference in the frequency of the 3DL1(+)3DS1(-)HLA-A/B Bw4(+) genotype 
was observed in the SAB population compared to the SAI and SAC populations (67.3% vs. 
40.0%; p=0.0008 and 67.3% vs. 44.7%; p=0.0006, respectively). 
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Figure 5.1. Bar graph showing frequency (%) of individuals of different populations carrying 
genotypes associated with HIV-1 resistance/susceptibility determined for SAI, South African Indian 
(n=50), SAM, South African Mixed ancestry (n=50), SAC, South African Caucasian (n=94) and SAB, 
South African Black (n=159) populations. HLA, human leukocyte antigen, M, methionine, T, 
threonine. 
 
*Inter-population genotype frequency comparisons showing significance (p<0.05): 
Resistance:   Susceptibility:   
HLA-B p2-T/T SAI vs. SAM p=0.0196 HLA-B p2-M/M SAB vs. SAI p=0.0248 
 SAI vs. SAC p<0.0001 HLA-ABC SAB vs. SAI p=0.0019 
 SAI vs. SAB p<0.0001  SAB vs. SAC p=0.0092 
3DL1+3DS1-Bw4-Bw6+ SAI vs. SAB p=0.0007 2DL3+2DL2-C1+C2+ SAC vs. SAI p=0.0372 
 SAC vs. SAB p=0.0173 3DL1+3DS1-A/B Bw4+ SAB vs. SAI p=0.0008 
3DL1-3DS1+B Bw480I/T+ SAI vs. SAB p=0.0122  SAB vs. SAC p=0.0006 
3DL1+3DS1+B Bw480I/T+Bw6+ SAI vs. SAB p<0.0001    
 SAM vs. SAB p=0.0059    
 SAC vs. SAB p=0.0002    
3DL1+/-3DS1+A/B Bw4+ SAI vs. SAM p=0.0228    
 SAI vs. SAC p=0.0103    
 SAI vs. SAB p<0.0001    
 SAM vs. SAB p=0.0002    
 SAC vs. SAB p<0.0001    
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5.2.1.3. Cumulative analysis of genotypes associated HIV-1 acquisition 
 
The frequencies of each genotype associated with resistance or susceptibility to HIV-
1 infection discussed in Sections 5.2.1.1 and 5.2.1.2 were calculated at a population level. 
Since each of these genotypes can be present in a variable combination at an individual level, 
a cumulative analysis to determine an overall “resistant” or “susceptible” genotype profile 
was performed by scoring the number of genotypes associated with resistance and 
susceptibility present in each individual (Figure 5.2). An individual was considered 
“resistant” if an excess number of resistance genotypes were present or “susceptible” if an 
excess number of susceptibility genotypes were present. An individual was considered 
“neutral” if equal numbers of resistance and susceptibility genotypes were present or if no 
resistance or susceptibility genotypes were present at all. Of note, due to the overlap of some 
of the resistance genotypes involving KIR3DL1/S1 and HLA-Bw4 ligands (Sections 5.2.1.1.5 
to 5.2.1.1.8), an individual was only scored once even if more than one of these genotypes 
was present. 
 
Based on this analysis, the frequency of individuals carrying an overall resistant 
genotype profile was highest in the SAI population (68.0%), lowest in the SAB population 
(31.4%) and present at similar frequencies in the SAM and SAC populations (42.0% and 
42.6%, respectively). A significant difference in the frequency of overall resistant genotype 
profiles was observed in the SAI population compared to the SAM, SAC and SAB 
populations (68.0% vs. 42.0%; p=0.0154, 68.0% vs. 42.6%; p=0.0049 and 68.0% vs. 31.4%; 
p<0.0001, respectively). Similarly, the frequency of individuals carrying an overall 
susceptible genotype profile was highest in the SAB population (42.8%), lowest in the SAI 
population (14.0%) and present at similar frequencies in the SAM and SAC populations 
(34.0% and 31.9%, respectively). A significant difference in the frequency of overall 
susceptible genotype profiles was observed in the SAM, SAC and SAB populations 
compared to the SAI population (34.0% vs. 14.0%; p=0.0338, 31.9% vs. p=0.0267 and 
42.8% vs. 14.0%; p=0.0002, respectively). No significant differences were observed in the 
frequencies of individuals classified as neutral. 
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*Inter-population overall genotype frequency comparisons showing significance (p<0.05): 
Resistant:  Susceptible:  
SAI vs. SAM p=0.0154 SAM vs. SAI p=0.0338 
SAI vs. SAC p=0.0049 SAC vs. SAI p=0.0267 
SAI vs. SAB p<0.0001 SAB vs. SAI p=0.0002 
Neutral: No significant differences  
 
5.2.2. Genotypes associated with HIV-1 VLS 
 
5.2.2.1. Genotypes associated with low HIV-1 VLS 
 
5.2.2.1.1. HLA-ABC 
 
Based on published studies of HLA class I alleles associated with VLS (Appendix C) 
and HLA class I genotypic data available for the SAI, SAM, SAC and SAB populations, an 
individual was considered a carrier of an HLA-ABC genotype profile associated with a “low” 
VLS if after assigning each HLA-A, -B and -C allele to a protective, deleterious or unknown 
status, the overall cumulative result was an excess of protective alleles (Figure 5.3). 
Individuals were defined as “neutral” if equal numbers of protective and deleterious HLA-
ABC alleles were present or if all six HLA class I alleles were of unknown status. Based on 
this analysis, the frequency of HLA-ABC genotypes associated with low VLS was highest in 
the SAI population (66.0%), followed by the SAM population (44.0%) and present at similar 
frequencies in the SAC and SAB populations (39.4% vs. 40.3%, respectively). A significant 
difference in the frequency of HLA-ABC genotypes associated with low VLS was observed in 
the SAI population compared to the SAM, SAC and SAB populations (66.0% vs. 44.0%, 
p=0.0439; 66.0% vs. 39.4%, p=0.0029 and 66.0% vs. 40.3%, p=0.0019, respectively). 
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Figure 5.2. Pie charts showing frequency (%) of individuals carrying overall resistant, susceptible or 
neutral genotype profiles associated with HIV-1 acquisition determined for SAI, South African Indian 
(n=50), SAM, South African Mixed ancestry (n=50), SAC, South African Caucasian (n=94) and SAB, 
South African Black (n=159) populations. 
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5.2.2.1.2. HLA-C +263 Del homozygosity 
 
 Taken from Chapter 3 and shown in Figure 5.3, the highest frequency of HLA-C 
+263 Del/Del genotypes was present in the SAM population (20.0%) and similar frequencies 
were observed in the SAI, SAC and SAB populations (16.0%, 14.9% and 15.7%, 
respectively). No significant differences were observed between the populations. 
 
5.2.2.1.3. CCR5Δ32(+) 
 
Taken from Chapter 3 and shown in Figure 5.3, the highest frequency of CCR5Δ32 
carriers was detected in the SAC population (18.1%) and low frequencies were present in the 
SAI and SAM populations (4.0% and 6.0%, respectively). The frequency of CCR5Δ32 
carriers in the SAB population was assumed to be 0%, due to the absence of this gene variant 
in this population (Picton et al., 2010). A significant difference in the frequency of CCR5Δ32 
carriers was observed in the SAC population compared to the SAI population (18.1% vs. 
4.0%, respectively; p=0.0205). 
 
5.2.2.1.4.  KIR3DL1(+)KIR3DS1(-)HLA-B Bw480I(+) 
 
The frequency of individuals carrying the protective KIR-HLA ligand combination 
3DL1(+)3DS1(-)HLA-B Bw480I(+), defined as the presence of KIR3DL1, the absence of 
KIR3DS1 and the presence of HLA-B Bw480I ligands, was determined by analysis of KIR 
genotypes and HLA ligand genotypes available for the SAI, SAM, SAC and SAB populations 
(Figure 5.3). The frequency of the 3DL1(+)3DS1(-)HLA-B Bw480I(+) genotype was highest 
in the SAB population (47.8%), followed by the SAM population (28.0%) and the SAI 
population (22.0%). The lowest frequency was present in the SAC population (17.0%).  
Significant differences in the frequency of the 3DL1(+)3DS1(-)HLA-B Bw480I(+) genotype 
were observed in the SAB population compared to the SAI, SAM and SAC populations 
(47.8% vs. 22.0%, p=0.0016; 47.8% vs. 28.0%, p=0.0145 and 47.8% vs. 17.0%, p<0.0001, 
respectively). 
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5.2.2.2. Genotypes associated with high HIV-1 VLS 
 
5.2.2.2.1. HLA-ABC 
 
 Based on published studies of HLA class I alleles associated with high or low VLS 
following HIV-1 infection (Appendix C) and HLA class I genotypic data available for the 
SAI, SAM, SAC and SAB populations, an individual was considered a carrier of an HLA-
ABC genotype profile associated with a “high” VLS if after assigning each HLA-A, -B and -C 
allele to a protective, deleterious or unknown status, the overall cumulative result was an 
excess of protective alleles (Figure 5.3). Individuals were defined as neutral if equal numbers 
of protective and deleterious alleles were present or if all six alleles were of unknown status. 
Based on this analysis, the frequency of HLA-ABC genotypes associated with high VLS was 
the highest in the SAC population (33.0%), followed by the SAB population (29.6%) and the 
SAM population (24.0%). The lowest frequency was present in the SAI population (16.0%). 
A significant difference in the frequency of HLA-ABC genotypes associated with high VLS 
was observed in the SAC population compared to the SAI population (33.0% vs. 16.0%, 
respectively; p=0.0316). 
 
5.2.2.2.2. HLA-C 3’UTR +263 Ins homozygosity 
 
 Taken from Chapter 3 and shown in Figure 5.3, the highest frequency of HLA-C 
3’UTR +263 Ins/Ins genotypes was detected in the SAC population (52.1%), followed by the 
SAB population (44.0%) and the SAM population (36.0%). The lowest frequency was 
present in the SAI population (24.0%). Significant differences in the frequency of HLA-C 
3’UTR +263 Ins/Ins genotypes were observed in the SAC and SAB populations in 
comparison to the SAI population (52.1% vs. 24.0%; p=0.0014 and 44.0% vs. 24.0%; 
p=0.0127, respectively). Of note, HLA-C 3’UTR +263 Ins/Del heterozygotes, shown to have 
an intermediate effect on VLS, were present in 60.0%, 44.0%, 33.0% and 40.3% of SAI, 
SAM, SAC and SAB populations, respectively, but were not included in the cumulative 
analysis (Section 5.2.2.3) 
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5.2.2.2.3. KIR3DL1(+)KIR3DS1(+/-)HLA-B Bw480I(-) 
 
 
 The frequency of individuals carrying the deleterious KIR-HLA ligand combination 
3DL1(+)3DS1(+/-)HLA-B Bw480I(-), defined as the presence of KIR3DL1, the 
presence/absence of KIR3DS1 as well as the absence of HLA-B Bw480I ligands, was 
determined by analysis of KIR genotypes and HLA ligand genotypes available for the SAI, 
SAM, SAC and SAB populations (Figure 5.3). The frequency of the 3DL1(+)3DS1(+/-
)HLA-B Bw480I(-) genotype was highest in the SAC population (68.1%) and similar 
frequencies were present in the SAI, SAM and SAB populations (50.0%, 54.0% and 46.5%, 
respectively). Significant differences in the frequency of the 3DL1(+)3DS1(+/-)HLA-B 
Bw480I(-) genotype were observed in the SAC population compared to the SAI and SAB 
populations (68.1% vs. 50.0%; p=0.0471 and 68.1% vs. 46.5%; p=0.0011, respectively). 
 
5.2.2.2.4. KIR3DL1(+)KIR3DS1(-)HLA-B Bw480I(-) 
 
 The frequency of individuals carrying the deleterious KIR-HLA ligand combination 
3DL1(+)3DS1(-)HLA-B Bw480I(-), defined as the presence of KIR3DL1, the absence of 
KIR3DS1 and the absence of HLA-B Bw480I ligands, was determined by analysis of KIR 
genotypes and HLA ligand genotypes available for the SAI, SAM, SAC and SAB populations 
(Figure 5.3). The frequency of the 3DL1(+)3DS1(-)HLA-B Bw480I(-) genotype was highest in 
the SAB population (45.3%), followed by the SAC population (42.6%) and the SAM 
population (36.0%). The lowest frequency was present in the SAI population (22.0%). 
Significant differences in the frequency of the 3DL1(+)3DS1(-)HLA-B Bw480I(-) genotype 
were observed in both the SAC and SAB populations in comparison to the SAI population 
(42.6% vs. 22.0%; p= 0.0173 and 45.3% vs. 22.0%; p= 0.0045, respectively). 
 
5.2.2.2.5. KIR2DS4f(+) 
 
 Taken from Chapter 3 and shown in Figure 5.3, the frequency of KIR2DS4f(+) 
individuals was highest in the SAB population (84.9%), followed by the SAM population 
(66.0%) and the SAC population (36.2%). The lowest frequency was detected in the SAI 
population (28.0%). Significant differences in the frequency of KIR2DS4f(+) individuals 
were observed in both the SAB and SAM populations in comparison to the SAI population 
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(84.9% vs. 28.0%; p=0.0003 and 66.0% vs. 28.0%; p<0.0001, respectively). Significant 
differences were also observed in the SAM population compared to the SAC population 
(66.0% vs. 36.2%, respectively; p=0.0008) as well as in the SAB population in comparison to 
both the SAM and SAC populations (84.9% vs. 66.0%; p=0.0070 and 84.9% vs. 36.2%; 
p<0.0001; respectively). 
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Figure 5.3. Bar graph showing frequency (%) of individuals carrying genotypes associated with high 
or low HIV-1 viral load setpoint (VLS) determined for SAI, South African Indian (n=50), SAM, South 
African Mixed ancestry (n=50), SAC, South African Caucasian (n=94) and SAB, South African Black 
(n=159) populations. HLA, human leukocyte antigen; Del, deletion; Ins, insertion. 
 
*Inter-population genotype frequency comparisons showing significance (p<0.05): 
Low VLS:   High VLS:   
HLA-ABC SAI vs. SAM p=0.0439 HLA-ABC SAC vs. SAI p=0.0316 
 SAI vs. SAC p=0.0029 HLA-C +263 Ins/Ins SAC vs. SAI p=0.0014 
 SAI vs. SAB p=0.0019  SAB vs. SAI p=0.0127 
CCR5Δ32+ SAC vs. SAI p=0.0205 3DL1+3DS1+/-B Bw480I- SAC vs. SAI p=0.0471 
3DL1+/-3DS1+B Bw480I+ SAI vs. SAB p=0.0192  SAC vs. SAB p=0.0011 
 SAM vs. SAB p= 0.0166 3DL1+3DS1-B Bw480I- SAC vs. SAI p= 0.0173 
3DL1+3DS1-B Bw480I+ SAB vs. SAI p=0.0016  SAB vs. SAI p= 0.0045 
 SAB vs. SAM p=0.0145 2DS4f+ SAM vs. SAI p=0.0003 
 SAB vs. SAC p<0.0001  SAB vs. SAI p<0.0001 
    SAM vs. SAC p=0.0008 
    SAB vs. SAM p=0.0070 
    SAB vs. SAC p<0.0001 
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5.2.2.3. Cumulative analysis of genotypes associated with HIV-1 VLS 
 
 The frequencies of each genotype associated with high or low HIV-1 VLS 
discussed in Sections 5.2.2.1 and 5.2.2.2 were calculated at a population level. Since each of 
these genotypes can be present in a variable combination at an individual level, a cumulative 
analysis to determine an overall genotype profile was performed by scoring the number of 
genotypes associated with high and low VLS present in each individual (Figure 5.4). An 
individual was considered “low VLS” if an excess number of genotypes associated with low 
VLS were present, “high VLS” if an excess number of genotypes associated with high VLS 
were present and “neutral” if equal numbers of resistance and susceptibility genotypes were 
present or if no resistance or susceptibility genotypes were present at all. 
 
Based on this analysis, the frequency of individuals carrying an overall low VLS 
genotype profile was highest in the SAI population (48.0%), lowest in the SAB population 
(13.2%) and present at similar frequencies in the SAM and SAC populations (22.0% and 
22.3%, respectively). A significant difference in the frequency of overall resistant genotype 
profiles was observed in the SAI population compared to the SAM, SAC and SAB 
populations (48.0% vs. 22.0%; p=0.0113, 48.0% vs. 22.3%; p=0.0024 and 48.0% vs. 13.2%; 
p<0.0001, respectively). Similarly, the frequency of individuals carrying an overall high VLS 
genotype profile was lowest in the SAI population (30.0%) and present at similar frequencies 
in the SAM, SAC and SAB populations (56.0%, 60.6% and 59.7%, respectively).  Significant 
differences in the frequency of overall high VLS genotype profiles were observed in the 
SAM, SAC and SAB populations compared to the SAI population (56.0% vs. 30.0%; 
p=0.0149, 60.6% vs. 30.0%; p= 0.0008 and 59.7% vs. 30.0%; p= 0.0003, respectively). No 
significant differences were observed in the frequencies of individuals classified as neutral. 
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Figure 5.4. Pie charts showing frequency (%) of individuals carrying overall HIV-1 low VLS, high VLS 
or neutral genotype profiles determined for SAI, South African Indian (n=50), SAM, South African 
Mixed ancestry (n=50), SAC, South African Caucasian (n=94) and SAB, South African Black (n=159) 
populations. 
 
*Inter-population overall genotype frequency comparisons showing significance (p<0.05): 
 
Low VLS: SAI vs. SAM p=0.0113 High VLS: SAM vs. SAI p=0.0149 
 SAI vs. SAC p=0.0024  SAC vs. SAI p= 0.0008 
 SAI vs. SAB p<0.0001  SAB vs. SAI p= 0.0003 
Neutral: No significant difference    
 
5.3. Discussion 
 
A multiplicity of factors, not necessarily mutually exclusive, contribute to the degree 
of spread of HIV-1 within a population and can include sexual behavioural practices, marital 
status, condom usage, circumcision status, antiretroviral drug therapy, host genetics, virus 
genetics and the presence of other sexually transmitted infections. In 2008, HIV-1 prevalence 
estimates were highest in the SAB population (13.6%), followed by the SAC population 
(1.7%) and lowest in the SAM and SAI populations (0.3% and 0.3%, respectively) 
respectively (www.mrc.ac.za/pressreleases/2009/sanat.pdf). In 2012, HIV-1 prevalence 
estimates increased and remained highest for the SAB population (15.0%), also increased the 
SAM population and SAI population (3.1% and 0.8%, respectively), while a decrease in the 
HIV-1 prevalence was recorded in the SAC population (0.3%) (www.hsrc.ac.za/en/research-
outputs/view/6871). It is known that host genes involved in antiviral immunity can impact on 
HIV-1 prevalence since several immunogenetic factors associate with risk of HIV-1 
acquisition. Influences on risk of HIV-1 transmission can also be effected via modulation of 
VLS. By extrapolation from the differences in the prevalence of protective/deleterious 
genetic factors determined for healthy individuals from the four populations, a possible 
influence of host genes in modulation of the observed differential HIV-1 prevalence rates can 
be examined. 
SAI* SAM* SAC* SAB*
Low VLS
High VLS
Neutral
48%
30%
22%
22% 22%
56%
22.3%17%
60.6% 59.7%
27%
13.2%
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A comparative immunogenetic characterisation study has not been done in healthy 
individuals from these populations. In this study, genomic DNA from healthy individuals, 
self-identified as belonging to the SAI, SAM, SAC or SAB populations, was used to first 
characterise the background frequencies of several host genes important in antiviral immunity 
(reported in Chapter 3). A subsequent analysis at a population level, was done regarding the 
prevalence of singular protective/deleterious genetic factors associated HIV-1 acquisition. 
Although some genotypes associated with resistance were significantly more prevalent in 
some populations compared to others, such as HLA-B p2-T/T in the SAI population (78%), 
HLA-ABC profiles in the SAB population (57.9%), 3DL1(+)3DS1(-)Bw6(+)HLA-B 
Bw480I/T(+) and 3DL1(+/-)3DS1(+)Bw6(+)HLA-A/B Bw4(+) genotypes in the SAI 
population (26.0% and 50.0%, respectively) and similarly for genotypes associated with 
susceptibility such as 2DL3(+)2DL2(+)C1(+)C2(+) genotypes in the SAC population 
(22.3%) and 3DL1(+)3DS1(-)HLA-A/B Bw4(+) genotypes in the SAB populations (67.3%), it 
was not possible to draw any conclusions regarding an overall host genetic influence on HIV-
1 acquisition risk for the high and low prevalence populations. 
 
Since individuals carry a combination of protective/deleterious genetic factors, a 
secondary analysis was undertaken an individual level by scoring each participant based on 
the overall number of protective/deleterious genetic factors present. Results from the 
cumulative analysis showed that a predominance of protective genotypes associated with 
resistance was present in 68.0%, 42.0%, 42.6% and 31.4% of SAI, SAM, SAC and SAB 
populations, respectively, while a predominance of deleterious genotypes associated with 
susceptibility was present in 14.0%, 34.0%, 31.9% and 42.8% of SAI, SAM, SAC and SAB 
populations, respectively. A significant difference was found in the frequency of individuals 
carrying predominantly resistant genotypes in the SAI population compared to the SAB 
population (68.0% vs. 31.4%, respectively; p<0.0001). Similarly, a significant difference in 
the frequency of individuals carrying predominantly susceptible genotypes was found in the 
SAB population compared to the SAI population (42.8% vs. 14.0%, respectively; p=0.0002). 
This result suggests that the prevalence of immunogenetic factors associated with resistance 
significantly higher and the frequencies of immunogenetic factors associated with 
susceptibility significantly lower in healthy SAI populations compared to healthy SAB 
populations and by extrapolation the low HIV-1 prevalence in the SAI population (0.8%) 
compared to the high HIV-1 prevalence in the SAB population (15.0%) may influenced, in 
part, by differences in the prevalence of host genetic factors associated with HIV-1 
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acquisition. Although statistical significance was not reached, the analysis also suggested that 
healthy SAM and SAC populations also have a higher prevalence of immunogenetic factors 
associated with resistance compared to the SAB population and a lower prevalence of 
immunogenetic factors associated with susceptibility. 
 
It was also reasoned that the risk of transmission of HIV-1 within a population can be 
influenced by host genes that determine the infectivity of the donor. Studies in serodiscordant 
couples have demonstrated that HIV-1 viral load is the primary mediator of heterosexual 
transmission (Quinn et al., 2000, Merino et al., 2011). This was also confirmed by 
immunogenetic studies of index partners of serodiscordant couples, where specific HLA class 
I alleles such as HLA-B*27, -B*57 and -C*18 that associated with low risk of transmission, 
and HLA-B*35 and -A*36 that associated with high risk of transmission (Gao et al., 2010, 
Tang et al., 2008), were in fact the major determinants of VLS in the donors. 
 
An analysis at the population level was done regarding the prevalence of singular 
protective/deleterious genetic factors associated with VLS. Although some genotypes 
associated with low VLS were significantly different in some populations compared to 
others, such as HLA-ABC genotypes in the SAI population (66.0%), CCR5Δ32 carriage in the 
SAC population (18.1%), 3DL1(+/-)3DS1(+)HLA-B Bw480I(+) genotypes in the SAI 
population (20.0%) and 3DL1(+)3DS1(-)HLA-B Bw480I(+) genotypes in the SAB population 
(47.8%) and similarly for genotypes associated with high VLS such as HLA-ABC genotypes 
in the SAI population (16.0%), HLA-C 3’UTR +263 Ins/Ins in the SAC population (52.1%), 
3DL1(+)3DS1(+/-)HLA-B Bw480I(-) genotypes in the SAC population (68.1%), 
3DL1(+)3DS1(-)HLA-B Bw480I(-) in the SAB population (45.3%) and KIR2DS4f carriage in 
the SAB population (84.9%) it was also not possible to draw any conclusions regarding an 
overall host genetic influence on HIV-1 VLS for the high and low prevalence populations. 
 
A similar cumulative analysis of host genetic factors associated with VLS at the 
individual level was performed and showed that a predominance of protective genotypes 
associated with low VLS resistance was present in 48.0%, 22.0%, 22.3% and 13.2% of SAI, 
SAM, SAC and SAB populations, respectively, while a predominance of deleterious 
genotypes associated with high VLS was present in 30.0%, 56.0%, 60.6% and 59.7% of SAI, 
SAM, SAC and SAB populations, respectively. The results of this analysis suggest that the 
frequencies of immunogenetic factors associated with a low VLS following HIV-1 
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acquisition are significantly higher and the frequencies of immunogenetic factors associated 
with a high VLS following HIV-1 acquisition are significantly lower in healthy SAI 
populations compared to healthy SAB populations. Extrapolation of this finding to a low 
HIV-1 prevalence SAI population (0.8%) and a high HIV-1 prevalence SAB population 
(15.0%) implies that differences in host genetic factors associated with the infectivity of the 
donor may play a role in HIV-1 prevalence. Although statistical significance was not reached, 
the analysis also suggested that healthy SAM and SAC populations also have higher 
frequencies of immunogenetic factors associated with lower VLS. However, the frequencies 
of immunogenetic factors associated with high VLS were similar in the SAM, SAC and SAB 
populations and not statistically significantly different. 
 
Other studies have postulated that a low HIV-1 prevalence in SAI, SAM and SAC 
populations is primarily due to low frequencies of concurrent sexual partnering practices that 
are high in the SAB population (Kenyon et al., 2013, Maughan-Brown, 2013). Taken 
together, the analysis performed in this study suggests that a low prevalence HIV-1 
population, such as the SAI population, is likely influenced by resistance to HIV-1 infection 
at exposure and at a secondary level, the infectivity of donor partners is likely to be reduced 
due to a low VLS. In a high prevalence HIV-1 population, such as the SAB population, 
higher frequencies of susceptible individuals and lower frequencies of resistant individuals 
may be present and at a secondary level; lower frequencies of donor partners with low VLS 
and higher frequencies of donor partners with high VLS promote HIV-1 transmission. These 
same observations may apply to the low HIV-1 prevalence SAM and SAC populations, more 
so in terms of HIV-1 acquisition than transmission, but the statistical analyses lacked 
significance. It is of interest that the HIV-1 prevalence in adults between 15 and 49 in the 
mainland Indian population is 0.3% (http://www.who.int/gho/countries/ind/en/), while the 
HIV-1 prevalence in the same age category in SA was estimated at 1.0%, 4.6%, 0.6%, and 
22.7% in SAI, SAM, SAC and SAB populations, respectively (www.hsrc.ac.za/en/research-
outputs/view/6871). It is possible that similar protective host genetic factors are also 
prevalent in mainland Indian populations. 
 
Importantly, there are limitations in this form of analysis. Firstly, the genetic 
associations reported in studies included from different populations possibly infected with 
different HIV-1 subtypes may not necessarily have the same phenotypic outcome in South 
African populations where subtype C infections predominate. African genetic studies as well 
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as limited studies performed in populations from India were used as well studies from 
Caucasian, African Black and Asian populations that would be relevant to the SAM 
population due to genetic admixture. The cumulative analysis of protective/deleterious 
genotypes associated with HIV-1 acquisition and VLS was done with equal weighting 
assigned to each of the variables, which is not necessarily true at a biological level. The 
influence of other genes that were not investigated in this study cannot be excluded. The 
genes selected for study in this work was based on published work with specific associations 
to HIV-1 acquisition and VLS. The sample size of the SAI and SAM study participants was 
smaller than the number of individuals included from the SAC and SAB populations, which 
may have affected statistical analyses. Due to the large numbers of genetic characterisations 
done per individual it was not feasible to increase the number of individuals genotyped. The 
results of this study have also been generated in healthy individuals and extrapolated to a 
HIV-1 infected population. Future investigations should include an application of the 
methods used in HIV-1 infected individuals, although cohorts in the SAI, SAM and SAC 
populations are more difficult to study due the low HIV-1 prevalence. 
 
In conclusion, new information on the prevalence of individual host genetic factors 
related to HIV-1 acquisition and VLS has been generated for healthy SAI, SAM, SAC and 
SAB populations. The hypothetical analysis of the cumulative effect of individual 
protective/deleterious host genetic factors suggests that differences in the frequencies of these 
genes in the different populations may be influencing the rates of spread of HIV-1 within 
each population as indicated by the differences in HIV-1 prevalence. These findings have 
generated a hypothesis that requires further testing in HIV-1 infected cohorts to confirm the 
speculations based on genotyping of healthy individuals. 
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Chapter 6:                                                                 
The cumulative effect of mutations/insertions in Gag 
contributes to disease progression in HLA-B*58:01 
and HLA-B*58:02-positive South African Black 
individuals with subtype C HIV-1 infection 
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6.1. Introduction 
 
Immunogenetic studies in HIV-1 subtype C infected Black South African individuals 
have established that particular HLA class I alleles, such as HLA-B*57, -B*58:01, -B*81:01, -
A*02:05, -C*04:01 and -B*42:01 are significantly associated with lower viral loads, higher 
CD4 counts and slower disease progression, whereas the opposite is true for deleterious 
alleles such as HLA-B*45:01, -B*58:02, -B*18 and -C*06:02 (Kiepiela et al., 2004). Of note, 
HLA-B*58:01 and -B*58:02 molecules are structurally similar and are differentiated by three 
amino acid changes at positions 94, 95 and 97, which map to the peptide binding cleft. Both 
receptors are grouped within the HLA-B58 Supertype (Sidney et al., 2008) and are predicted 
to bind similar peptide antigens. According to the Los Alamos HIV immunology database, 
the peptide binding motifs are X-(ATSG)-XXXXXX-(WFY) and X-(ST)-XXX-(R)-XX-(F) 
for HLA-B*58:01 and -B*58:02, respectively (http://www.hiv.lanl.gov). In HIV-1 disease, it 
remains unclear why these receptors would associate with opposite clinical outcomes. It 
seems plausible that the amino acid differences in HLA-B*58:02 alter the peptide specificity 
and prevent efficient recognition of crucial epitopes necessary for detection and killing of 
infected cells, which are detectable by HLA-B*58:01. This phenomenon has been observed 
in HLA-B*42:01 carriers who efficiently target p24Gag epitopes and have lower viral loads, in 
contrast to HLA-B*42:02 carriers who have higher viral loads and do not respond to p24Gag 
epitopes (Kloverpris et al., 2012a). Notably, a single amino acid differentiates these two 
proteins. 
 
Previous work has shown that CTL responses directed towards conserved proteins, 
such as Gag, are associated with lower viral loads in comparison to CTL responses to 
epitopes derived from variable proteins such as Env (Kiepiela et al., 2007, Wang et al., 2009, 
Masemola et al., 2004a). Following on from this, studies have demonstrated that Gag-specific 
HLA-B*58:01-restricted CTLs could be identified in individuals controlling HIV-1 
replication, whereas, in non-controlling individuals, HLA-B*58:02-restricted CTLs were 
directed towards Env, and furthermore, selection pressure on viral epitopes was reduced in 
HLA-B*58:02, but not HLA-B*58:01 carriers (Ngumbela et al., 2008). One explanation is the 
theoretical possibility that ineffective HLA-B*58:02-restricted CTL responses relate to 
thymic selection of naïve T cells. In an HLA-B*57 (protective) and -B*07:01 (deleterious) 
context, epitope prediction algorithms have been used to hypothesise that protective HLA 
class I alleles are defined by fewer events of self-peptide binding when compared to non-
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protective alleles and would therefore permit the generation of a greater diversity of naïve T-
cells in the thymus with increased probability of selecting HIV-1 specific T-cells (Kosmrlj et 
al., 2010). This could explain the greater breadth of anti-viral CTL responses and increased 
selective pressure on viral epitopes seen in individuals with protective HLA class I alleles. 
However, this remains to be proven experimentally, but if true, may also apply to the context 
of HLA-B*58:01 and -B*58:02. Another possibility may relate to differences in effector 
function of CTLs restricted by HLA-B*58:01 and -B*58:02 that could impact on the breadth 
and immune selective pressures to HIV-1 epitopes. This was not confirmed in studies 
comparing protective HLA-B*58:01-restricted CTL responses to non-protective HLA-C*07-
restricted CTL responses (Mkhwanazi et al., 2010). In their study the polyfunctionality 
measured by cytokine profiles in these two CTL sets was not significantly different; however, 
HLA-B might not be directly comparable to HLA-C in this context. 
 
It was also observed in the SIV model that an increase in the number of Gag epitopes 
targeted correlated with lower viral load which is also evident from HIV-1 studies 
(Geldmacher et al., 2007). There are three HLA-B*58:01-restricted epitopes in Gag reported 
to be targeted in subtype C HIV-1 infected South African individuals (Kloverpris et al., 
2012b), but no Gag epitopes are known to elicit HLA-B*58:02-restricted CTL responses. 
Putative HLA-B*58:02-restricted epitopes have been reported, but are unconfirmed (Spivak 
et al., 2010, Chopera et al., 2008). It is therefore likely that HLA-B*58:01-mediated immune 
pressure generates early protective CTL responses to incoming p24Gag and these responses 
remain sustained during the chronic stage of disease, whereas HLA-B*58:02 targets epitopes 
derived from late proteins expressed after integration such as Env, but fails to target Gag, 
resulting in poor immunity. 
 
The reason why HLA-B*58:02 fails to target epitopes in Gag may simply be related 
to binding motif, but another possibility involves the accessibility of proteosomally derived 
peptides to the HLA class I molecule in the endoplasmic reticulum. Studies in HLA-B*57 
and -B*58:01 have shown that although the KF11 epitope in p24Gag binds to both molecules, 
there is a failure in presentation of KF11 by HLA-B*58:01 (Kloverpris et al., 2013b), 
although an unconfirmed response to KF11 in a HLA-B*58:01 carrier has been noted in a 
previous study (Chopera et al., 2011). The failure was delineated to an intracellular block in 
access of KF11 to HLA-B*58:01 molecules in the endoplasmic reticulum, since it was noted 
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that in individuals co-expressing HLA-B*58:01 and -B*57 molecules, KF11 was efficiently 
presented by HLA-B*57 but not by HLA-B*58:01. 
 
It has been shown, subsequently, that the benefits attributed to protective HLA class I 
alleles, such as HLA-B*57 and -B*58:01, can be due to fitness costs imposed on replicating 
virus when CTL escape mutations are introduced into conserved proteins (Crawford et al., 
2007). This is further supported by the observation that escape mutations often revert to wild-
type when virus is transmitted to HLA class I mismatched hosts (Leslie et al., 2004). 
Unfortunately, it has also been shown that the benefits of early escape mutations that reduce 
viral replicative capacities can be overcome by compensatory mutations that develop during 
the chronic stage of disease (Brockman et al., 2010, Gijsbers et al., 2013). This has been 
documented in HLA-B*58:01 carriers with subtype C HIV-1 infection in South Africa 
(Chopera et al., 2011). Notably, over time compensatory mutations may become established 
in viruses circulating in the community as shown recently by a decline in the protective 
benefits of HLA-B*57/58:01 alleles in Botswana compared to South Africa due to the longer 
duration of the epidemic in Botswana (Payne et al., 2014). Alternatively, viral replication can 
also be enhanced by mutations that improve the release of virions from infected cells through 
budding. This has been observed to occur via duplication of the PTAP amino-acid motif in 
p6Gag that enhances recruitment of cellular Tsg101 proteins that are required for efficient viral 
budding (VerPlank et al., 2001). There is also an alternative budding pathway that is 
dependent on a  PYRE amino-acid motif in p6Gag that recruits ALG-2-interacting protein X 
(ALIX), normally absent in sub-Saharan subtype C viruses, however, in subtype C HIV-1 
infected Indian individuals, similar 4-amino acid insertions were found to be more common 
in patients failing protease therapy and may represent adaptations of virus to restore fitness 
due to the development of protease resistance mutations (Neogi et al., 2014).  
 
An important finding in individuals carrying protective HLA class I alleles is that 
immune pressure by other HLA class I alleles in the individual’s repertoire, are co-operative 
or additive in the overall control of viral replication (Matthews et al., 2012, Leslie et al., 
2010). Particular haplotypes, such as HLA-C*04:01-B*81:01, -C*12:03-B*39:10, -A*74:01-
B*53:03 associate with improved viral control compared to the singular alleles (Leslie et al., 
2010). Similarly, slow disease progression based on CD4+ T cell count is reported to 
associate with haplotypes HLA-A*74:01-B*15:03, -B*14:02-C*08:02 and -A*74:01-
B*15:03-C*02:02, while accelerated disease progression associates with haplotypes HLA-
124 
 
A*30:02-B*45:01, -A*30:02-C*16:01, -B*53:01-C*04:01, -B*15:10-C*03:04 and -B*58:01-
C*03:02 (Sampathkumar et al., 2014). 
 
Interestingly, an alternative consequence of viral escape mutations in p24Gag comes 
from evidence supporting the impact of Gag mutations on the ability of the intrinsic 
antiretroviral factor, Tripartite motif-containing protein 5 alpha  (TRIM5α), to inactivate 
incoming viral cores (Granier et al., 2013). In addition, evidence of escape mutations in CTL 
epitopes that modulate NK cell recognition of infected target cells via killer-cell 
immunoglobulin-like receptor (KIR) interaction has come to light (Alter et al., 2011). The 
antiviral efficacy of NK cells are often underappreciated since NK cell responses precede 
CTL responses during early stages of acute HIV-1 infection (Alter et al., 2007) and KIRs in 
combination with cognate HLA class I ligands, such as KIR3DL1 and HLA-Bw480I, associate 
with reduced viral load (Jiang et al., 2013, Pelak et al., 2011, Martin et al., 2007). The 
synergistic or epistatic interaction between KIR3DS1 and HLA-Bw480I also associates with 
low viral load (Pelak et al., 2011, Martin et al., 2002). KIR3DS1 and -3DL1 are similar in 
structure in the extracellular domains, however, functional studies have not shown direct 
interaction of KIR3DS1 with HLA-Bw480I ligands (Carr et al., 2007, Gillespie et al., 2007, 
O'Connor et al., 2007). An alternative explanation may stem from a report that subsets of 
CTLs can also express KIR3DL1 and KIR3DS1, and KIR3DS1-positive CTLs are more 
effective in targeting HIV-infected target cells  (Zipperlen et al., 2014). Unfortunately, HIV-1 
attempts to evade NK cell detection by positive selection of mutations in HLA class I-
restricted epitopes that affects KIR recognition. Mutations mapping to several viral proteins 
such as Gag, Vpr, Tat, Vpu, Env and Nef that mediate escape from NK cell recognition have 
been shown to influence NK cell activation governed by KIRs such as KIR2DS1, -2DS2, -
2DS3, 2DS5, -2DL2, -2DL3 and -3DS1 (Alter et al., 2011). Since KIRs can either transduce 
activating or inhibitory signals, a plausible explanation for this finding is that mutations in 
HLA class I-restricted viral epitopes either strengthen inhibitory signals or dampen activation 
signals, thereby reducing NK cell activation potential. Other investigators have shown that 
sequence variation in the YL9 epitope in p24Gag, restricted by HLA-C*03:04, can influence 
binding to KIR2DL2 inhibitory receptors (van Teijlingen et al., 2014) and similarly, HLA-
B*57 and KIR3DL1 binding studies have shown the same effect of amino acid substitutions 
in the p24Gag TW10 epitope (Brackenridge et al., 2011). 
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In the current study, an extensive analysis of mutations in inferred Gag protein 
sequences from progressors with subtype C HIV-1 infection and carrying either HLA-
B*58:01 (n=5) or -B*58:02 (n=13) was performed. The identification of immune escape 
mutations that contribute to a lack of control of HIV-1 replication, resulting in a CD4+ T cell 
decline to <350 cells/ml, may give insight into the mechanisms of failure of protective HLA-
B*58:01 in sustaining effective virological control and a lack HLA-B*58:02-mediated 
control of viral replication. Plasma samples stored at baseline and 6 and 12 months after 
baseline sampling were used to extract viral RNA. The partial gag gene (nt 958-nt 2288, 
HXB2 numbering), spanning partial p17Gag ORF (codon 53) to the Gag stop codon, was 
sequenced. Mutations in deduced protein sequences were identified to investigate the short 
term evolution of Gag during late stage chronic HIV-1 infection. Gag sequences were 
examined with a specific focus on CTL escape mutations and compensatory mutations, as 
well as changes that may impact on NK cell surveillance or TRIM-5α antiretroviral activity. 
 
6.2. Results 
 
6.2.1. Study participant information 
 
6.2.1.1. Analysis of CD4+ T cell count, viral load and CD4+ T cell decline 
 
 Measurements for CD4+ T cell count, viral load (VL) and rate of CD4+ T cell decline 
for the study participants as well as the availability of gag sequences are listed in Table 6.1. 
CD4+ T cell counts and VL measurements at baseline, 6 months and 12 months were 
stratified according to HLA-B*58:01 and -B*58:02 carriage and compared (Figure 6.1 and 
Figure 6.2). No significant differences were found (p>0.05). The rate of CD4+ T cell decline 
was calculated using the earliest and last available CD4+ T cell counts divided by the number 
of months. Results were stratified according to HLA-B*58:01 and -B*58:02 carriage were 
compared (Figure 6.3). Again, no significant differences were found (p=0.554). Since there 
were no significant differences in the CD4+ T cell count or VL at baseline, 6 months or 12 
months as well as in the rates of CD4+ T cell decline for HLA-B*58:01 and -B*58:02 carriers, 
these two groups could be considered equivalent in terms of the stage of HIV-1 disease 
progression. Since HLA-B*58:01 is a protective allele usually associated with lower VLs, 
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higher CD4+ T cell counts and slower decline in CD4+ T cell count, it was interesting that 
HLA-B*58:01 carriers appeared clinically similar to the HLA-B*58:02 carriers. However, the 
duration of infection is not known and this could mean that immune control has been lost in 
HLA-B*58:01 carriers over a longer period of time. The possibility of viral mutation 
mediating escape from immune surveillance was therefore investigated in these two groups. 
 
Table 6.1. Study participant information. 
 Baseline 6 months 12 months  
Participant 
ID 
CD4+ T cell 
count 
Log10 
VL 
Gag 
sequences 
CD4+ T cell 
count 
Log10 
VL 
Gag 
sequences 
CD4+ T cell 
count 
Log10 
VL 
Gag 
sequences 
CD4+ T cell 
decline* 
1 208 4.17 Yes 165 3.99 Yes - - - -7.167 
2 254 3.77 Yes 286 4.38 Yes 222 4.01 Yes -2.667 
3 268 4.48 Yes - - Yes 243 4.83 Yes -2.083 
4 252 3.85 Yes 156 3.42 Yes - - - -16.0 
5 241 3.70 Yes 203 4.07 - 200 4.02 Yes -3.417 
6 259 2.73 Yes 47 5.68 Yes - - - -35.33 
7 226 3.84 Yes 154 4.30 Yes - - - -12.0 
8 154 4.46 Yes 134 4.33 Yes - - - -3.333 
9 243 4.04 Yes 162 4.01 Yes - - - -13.5 
10 - - Yes 6 5.11 Yes 3 5.29 Yes -0.5 
11 239 4.69 Yes 133 3.90 Yes - - - -17.67 
12 324 3.94 - 178 1.69 Yes 253 2.14 Yes -5.917 
13 246 4.23 Yes 216 3.85 Yes 91 3.66 Yes -12.92 
14 245 4.93 Yes 273 5.40 Yes 157 5.08 Yes -7.333 
15 207 3.09 Yes 191 3.39 Yes 200 3.73 Yes -0.583 
16 273 2.94 Yes 310 2.86 - 258 2.92 Yes -1.25 
17 307 2.41 - 247 3.10 Yes 246 3.51 Yes -5.083 
18 351 2.31 Yes 299 2.99 Yes - - - -8.667 
CD4+ T cell count measurements in cells/µl; VL, viral load measurements in copies/ml; “-“, data not available; HLA-
B*58:01-positive participants are shaded in grey; *CD4+ T cell decline measured in cells/µl/month and calculated using the 
earliest and last available measurements for CD4+ T cell count. 
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Figure 6.1. Comparison of CD4+ T cell counts at (a) baseline, (b) 6 months and (c) 12 months for 
participants with either HLA-B*58:01 or HLA-B*58:02. 
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6.2.1.2. Phylogenetic analysis of gag sequences 
 
 To confirm that gag sequences generated for each study participant were correctly 
assigned, a phylogenetic analysis was performed using alignments of sequences as input for 
phylogenetic tree construction using MEGA v5 software. A bootstrapped (n=1000) 
neighbour-joining tree was constructed using the Kimura 2-paramater model and showed that 
gag sequences generated for each study participant correctly clustered together (Figure 6.4). 
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Figure 6.2. Comparison of Log10 viral load at (a) baseline, (b) 6 months and (c) 12 months for study 
participants with either HLA-B*58:01 or HLA-B*58:02. 
Figure 6.3. Comparison of CD4+ T cell decline for study participants with either HLA-B*58:01 or HLA-
B*58:02. Rate of CD4+ T cell decline was calculated as the difference between the earliest and last 
measurement for CD4+ T cell count divided by the number of months. 
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Figure 6.4. Neighbour-joining phylogenetic tree constructed using gag sequences generated for each 
of the study participants  (sequences from individual participants are shown in shaded boxes). 
Subtype C HIV-1 reference sequences and SIV Chimpanzee outlier sequences were included. 
Numbers at the nodes indicate bootstrap scores (%). 
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6.2.2. Presence of protective/deleterious HLA class I alleles 
 
 An analysis of the distribution of known protective or deleterious HLA class I alleles 
associated with disease progression was performed based on high resolution HLA class I -A, -
B and -C genotyping data generated by Roche 454 FLX deep sequencing methods (Table 
6.2). A detailed analysis of singular HLA class I alleles at each locus is presented below, 
however in summary, the number of protective HLA class I alleles was 20 in the total of 30 
alleles present (66.7%) in the 5 HLA-B*58:01 carriers compared to 28 protective HLA class I 
alleles in a total of 76 alleles present (36.8%) in the 13 HLA-B*58:02 carriers (two alleles 
were not counted due to unknown associations). Comparison of the two frequencies was 
significant (p=0.0149; OR=3.257[1.329-7.984]). Based on the additive effect of protective 
HLA class I alleles (Matthews et al., 2012, Leslie et al., 2010), it is unexpected that the HLA-
B*58:01 carriers would be at the same stage of disease progression as HLA-B*58:02 carriers. 
The duration of infection is not known and the protective benefits of the additional alleles 
may have been lost, hence an analysis of viral mutations mediating escape from other HLA 
class I-restricted epitopes was undertaken. 
6.2.2.1. Alleles at the HLA-A locus 
 
 HLA-A genotypes determined for each study participant, HLA Supertypes and allele 
frequencies reported for the SAB population are listed in Table 6.2. Twelve different HLA-A 
alleles were identified in the study population. HLA-A*02:01, found in 4 individuals, is 
reported to be a deleterious allele in South African and Japanese populations (Leslie et al., 
2010, Naruto et al., 2012), while African studies report that HLA-A*02:05, also present in 4 
individuals, is a protective allele (Novitsky et al., 2003, Leslie et al., 2010, Kiepiela et al., 
2004, Saathoff et al., 2010). Of note, HLA-A*02:05 is in high linkage disequilibrium with 
HLA-B*58:01 (D’=0.73, p<0.001) (Paximadis et al., 2012) and therefore HLA-B*58:01 
carriers may often inherit an additional protective allele. Within the study participants, HLA-
A*02:05 was present in three HLA-B*58:01 carriers and one HLA-B*58:02 carrier. Two 
individuals carried HLA-A*68:02 reported as deleterious in a South African study (Kiepiela 
et al., 2004), however, a study from Botswana found the opposite association (Novitsky et al., 
2003). HLA-A*68:02 is in low linkage disequilibrium (D’=0.33, p<0.001) with HLA-B*15:10 
(Paximadis et al., 2012) which has been reported to be a deleterious allele in African 
populations (Kiepiela et al., 2004, Leslie et al., 2010, Matthews et al., 2012). HLA-A*03:01, 
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present in 3 individuals, was found to be protective in Chinese populations (Zhang et al., 
2013), but deleterious in African populations (Matthews et al., 2012, Carlson et al., 2012). 
HLA-A*66:01, present in 3 individuals and -A*68:01, present in 4 individuals, are both 
reported to be deleterious alleles in African populations (Leslie et al., 2010, Matthews et al., 
2012, Kiepiela et al., 2004, Carlson et al., 2012). HLA-A*03:01:01 is in moderate linkage 
disequilibrium with HLA-B*58:02 (D’=0.46, p<0.001), while HLA-A*68:01:01 is in high 
linkage disequilibrium with HLA-B*58:02 (D’=0.67, p<0.001) (Paximadis et al., 2012) and 
therefore HLA-B*58:02 carriers can often inherit a second deleterious allele. HLA-A*80:01 
present in one individual and -A*36:01, also present in one individual, have not been reported 
in any HIV-1 association studies. HLA-A*30:02, found in 5 individuals, (Carlson et al., 2012) 
and -A*29:02, also found in five individuals, (Tang et al., 2010) are protective in African 
populations. HLA-A*30:01 was present in one study participant and is also a protective allele 
associated in African populations (Carlson et al., 2012). HLA-A*23:01, present in two study 
participants, is a protective allele in South African populations (Kiepiela et al., 2004). 
 
Table 6.2. HLA-A alleles present in HLA-B*58:01 and -B*58:02-positive progressors their association 
with HIV-1 disease progression, HLA Supertype, HLA ligand designation and allele frequencies 
known for the SAB population. 
 HLA-A 
ID Allele 1 P/D 
HLA 
Supertype 
HLA 
ligand 
Allele 
frequency 
SAB (%) 
Allele 2 P/D 
HLA 
Supertype 
HLA 
ligand 
Allele 
frequency 
SAB (%) 
1 A*02:01:01 D A02 non-Bw4 8.29 A*66:01:01 D A03 non-Bw4 0.75 
2 A*02:05:01 P A02 non-Bw4 6.78 A*30:02:01 P A01 non-Bw4 9.55 
3 A*23:01:01 P A24 Bw480I 8.04 A*68:01:01 D A03 non-Bw4 3.27 
4 A*03:01:01 D A03 non-Bw4 6.53 A*68:01:01 D A03 non-Bw4 3.27 
5 A*02:05:01 P A02 non-Bw4 6.78 A*30:02:01 P A01 non-Bw4 9.55 
7 A*68:01:01 D A03 non-Bw4 3.27 A*68:02:01 D A02 non-Bw4 8.54 
8 A*02:05:01 P A02 non-Bw4 6.78 A*29:02:01 P A01 A24 non-Bw4 6.28 
9 A*03:01:01 D A03 non-Bw4 6.53 A*30:02:01 P A01 non-Bw4 9.55 
6 A*23:01:01 P A24 Bw480I 8.04 A*29:02:01 P A01 A24 non-Bw4 6.28 
10 A*03:01:01 D A03 non-Bw4 6.53 A*36:01 ? A01 non-Bw4 1.01 
11 A*29:02:01 P A01 A24 non-Bw4 6.28 A*66:01:01 D A03 non-Bw4 0.75 
12 A*02:01:01 D A02 non-Bw4 8.29 A*66:01:01 D A03 non-Bw4 0.75 
13 A*29:02:01 P A01 A24 non-Bw4 6.28 A*30:02:01 P A01 non-Bw4 9.55 
14 A*29:02:01 P A01 A24 non-Bw4 6.28 A*80:01 ? A01 non-Bw4 0.50 
15 A*30:01:01 P A01 A03 non-Bw4 10.05 A*30:02:01 P A01 non-Bw4 9.55 
16 A*02:01:01 D A02 non-Bw4 8.29 A*68:02:01 D A02 non-Bw4 8.54 
17 A*02:05:01 P A02 non-Bw4 6.78 A*23:01:01 P A24 Bw480I 8.04 
18 A*02:01:01 D A02 non-Bw4 8.29 A*68:01:01 D A03 non-Bw4 3.27 
HLA, human leukocyte antigen, P, protective, D, deleterious, “?”, undetermined; HLA-B*58:01-positive participants shaded 
in grey. 
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6.2.2.2. Alleles at the HLA-B locus 
 
 HLA-B genotypes determined for each study participant, HLA Supertypes and allele 
frequencies reported for the SAB population are listed in Table 6.3. Ten different HLA-B 
alleles were identified in the study population. HLA-B*58:01 (n=5) and -B*58:02 (n=13), the 
subject of the current study, are both common alleles in the SAB population (Paximadis et al., 
2012). Numerous studies in diverse populations, including Caucasian, African and Japanese 
individuals have associated HLA-B*58:01 with low VL (Brockman et al., 2010, Carlson et 
al., 2012, Gao et al., 2010, Geldmacher et al., 2007, Kiepiela et al., 2004, Leslie et al., 2010, 
Matthews et al., 2012, Mlisana et al., 2014, Naruto et al., 2012, Saathoff et al., 2010), while 
HLA-B*58:02, an allele mostly found in African populations, associates with high VL 
(Carlson et al., 2012, Kiepiela et al., 2004, Leslie et al., 2010, Matthews et al., 2012, Mlisana 
et al., 2014, Saathoff et al., 2010). Other HLA-B alleles present in the study population 
included HLA-B*08:01 (n=1) which is considered a deleterious allele in African populations 
(Leslie et al., 2010, Matthews et al., 2012, Kiepiela et al., 2004, Carlson et al., 2012). HLA-
B*15:03 (n=2) (Geldmacher et al., 2007, Leslie et al., 2010, Kiepiela et al., 2004, Saathoff et 
al., 2010, Frahm et al., 2006, Matthews et al., 2012) and -B*15:10 (n=3) (Kiepiela et al., 
2004, Leslie et al., 2010, Matthews et al., 2012) are also considered deleterious alleles, 
although two studies showed the opposite association for these alleles (Mlisana et al., 2014, 
Novitsky et al., 2003). HLA-B*39:10, present in one individual, is a deleterious allele 
(Matthews et al., 2012, Tang et al., 2002), although one study reported the opposite finding 
(Leslie et al., 2010). HLA-B*42:01, found in 2 individuals, is considered protective (Carlson 
et al., 2012, Kiepiela et al., 2004, Leslie et al., 2010, Matthews et al., 2012, Saathoff et al., 
2010), while HLA-B*53:01, also present in 2 individuals, was reported to be deleterious in 
African-American populations (Lazaryan et al., 2011). HLA-B*44:03, present in 4 
individuals, is protective in African (Carlson et al., 2012, Kiepiela et al., 2004, Leslie et al., 
2010, Matthews et al., 2012) and Asian (Naruto et al., 2012, Zhang et al., 2013) populations, 
while -B*45:01, found in 2 individuals, is deleterious in African populations (Carlson et al., 
2012, Geldmacher et al., 2007, Kiepiela et al., 2004, Lazaryan et al., 2011, Leslie et al., 2010, 
Matthews et al., 2012, Saathoff et al., 2010, Tang et al., 2010). 
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Table 6.3. HLA-B alleles present in HLA-B*58:01 and -B*58:02-positive progressors, their association 
with HIV-1 disease progression, HLA Supertype, HLA ligand designation and allele frequencies 
known for the SAB population. 
HLA-B 
ID Allele 1 P/D 
HLA 
Supertype 
HLA 
ligand 
Allele 
frequency 
SAB (%) 
Allele 2 P/D 
HLA 
Supertype 
HLA 
ligand 
Allele 
frequency 
SAB (%) 
1 B*15:03:01 D B27 Bw6 8.40 B*58:02 D B58 Bw480I 9.41 
2 B*45:01:01 D B44 Bw6 6.36 B*58:02 D B58 Bw480I 9.41 
3 B*44:03:02 P B44 Bw480T 3.31 B*58:02 D B58 Bw480I 9.41 
4 B*45:01:01 D B44 Bw6 6.36 B*58:02 D B58 Bw480I 9.41 
5 B*08:01:01 D B08 Bw6 6.36 B*58:01:01 P B58 Bw480I 8.14 
7 B*15:10:01 D B27 Bw6 7.89 B*58:02 D B58 Bw480I 9.41 
8 B*15:03:01 D B27 Bw6 8.40 B*58:01:01 P B58 Bw480I 8.14 
9 B*39:10 P B07 Bw6 2.54 B*58:02 D B58 Bw480I 9.41 
6 B*44:03:02 P B44 Bw480T 3.31 B*58:02 D B58 Bw480I 9.41 
10 B*53:01:01 D B07 Bw480I 4.33 B*58:02 D B58 Bw480I 9.41 
11 B*58:01:01 P B58 Bw480I 8.14 B*58:01:01 P B58 Bw480I 8.14 
12 B*53:01:01 D B07 Bw480I 4.33 B*58:02 D B58 Bw480I 9.41 
13 B*44:03:02 P B44 Bw480T 3.31 B*58:02 D B58 Bw480I 9.41 
14 B*44:03:02 P B44 Bw480T 3.31 B*58:02 D B58 Bw480I 9.41 
15 B*42:01:01 P B07 Bw6 8.91 B*58:02 D B58 Bw480I 9.41 
16 B*15:10:01 D B27 Bw6 7.89 B*58:01:01 P B58 Bw480I 8.14 
17 B*15:10:01 D B27 Bw6 7.89 B*58:01:01 P B58 Bw480I 8.14 
18 B*42:01:01 P B07 Bw6 8.91 B*58:02 D B58 Bw480I 9.41 
HLA, human leukocyte antigen, P, protective, D, deleterious, HLA-B*58:01-positive participants shaded in grey. 
 
6.2.2.3. Alleles at the HLA-C locus 
 
HLA-C genotypes determined for each study participant and allele frequencies 
reported for the SAB population are listed in Table 6.4. Ten different HLA-C alleles were 
identified in the study population. HLA-C*07:01, identified in 7 individuals, was found to be 
protective in African individuals (Kiepiela et al., 2004, Leslie et al., 2010), but not in 
African-Americans (International et al., 2010). HLA-C*06:02, present in 13 individuals, is 
deleterious allele in African populations (Kiepiela et al., 2004, Leslie et al., 2010, Matthews 
et al., 2012) and Japanese populations (Naruto et al., 2012). HLA-C*04:01, found in 3 
individuals, is considered a protective allele in African populations (Matthews et al., 2012, 
Tang et al., 2002, Kiepiela et al., 2004, Leslie et al., 2010) and Japanese populations (Naruto 
et al., 2012). HLA-C*02:10, present in 2 individuals, have been found to be deleterious in a 
study from South Africa/Botswana (Matthews et al., 2012). HLA-C*03:02, found in 2 
individuals, is protective in African populations (Matthews et al., 2012, Leslie et al., 2010). 
HLA-C*03:04, found in one study participant, is considered deleterious in African and 
Japanese populations (Kiepiela et al., 2004, Naruto et al., 2012). HLA-C*08:04, also present 
in one individual, was reported as a protective allele in a recent study in long-term surviving 
adolescents infected at birth in Zimbabwe (Shepherd et al., 2015). HLA-C*16:01, found in 3 
individuals, is reported to be deleterious in African populations (Kiepiela et al., 2004, 
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Matthews et al., 2012). HLA-C*12:03, found in one individual, is considered protective allele 
in African populations (Carlson et al., 2012, Leslie et al., 2010, Matthews et al., 2012). HLA-
C*17:01, found in two individuals, is also considered a protective allele in African 
populations (Carlson et al., 2012, Matthews et al., 2012, Tang et al., 2002). 
 
Table 6.4. HLA-C alleles present in HLA-B*58:01 and -B*58:02-positive progressors, their association 
with HIV-1 disease progression, HLA Supertype, HLA ligand designation and allele frequencies 
known for the SAB population. 
 HLA-C 
ID Allele 1 P/D 
HLA 
ligand 
Allele 
frequency SAB 
(%) 
Allele 2 P/D 
HLA 
ligand 
Allele 
frequency SAB 
(%) 
1 C*04:01:01 P C2 11.9 C*04:01:01 P C2 11.9 
2 C*06:02:01 D C2 14.94 C*16:01:01 D C1 6.58 
3 C*06:02:01 D C2 14.94 C*07:01:01 P C1 7.59 
4 C*06:02:01 D C2 14.94 C*16:01:01 D C1 6.58 
5 C*07:01:01 P C1 7.59 C*07:01:01 P C1 7.59 
7 C*03:04:02 D C1 5.06 C*06:02:01 D C2 14.94 
8 C*02:10 D C2 7.1* C*07:01:01 P C1 7.59 
9 C*06:02:01 D C2 14.94 C*12:03:01 P C1 1.52 
6 C*06:02:01 D C2 14.94 C*07:01:01 P C1 7.59 
10 C*04:01:01 P C2 11.9 C*06:02:01 D C2 14.94 
11 C*02:10 D C2 7.1* C*03:02:01 P C1 1.52 
12 C*04:01:01 P C2 11.9 C*06:02:01 D C2 14.94 
13 C*06:02:01 D C2 14.94 C*07:01:01 P C1 7.59 
14 C*06:02:01 D C2 14.94 C*07:01:01 P C1 7.59 
15 C*06:02:01 D C2 14.94 C*17:01:01 P C2 11.4 
16 C*03:02:01 P C1 1.52 C*08:04 P C1 2.53 
17 C*07:01:01 P C1 7.59 C*16:01:01 D C1 6.58 
18 C*06:02:01 D C2 14.94 C*17:01:01 P C2 11.4 
HLA, human leukocyte antigen, P, protective, D, deleterious, HLA-B*58:01-positive participants shaded in grey. 
 
6.2.3. KIR genotypes 
 
 The presence/absence of the 16 known KIR genes was determined by real-time PCR 
assay (Hong et al., 2011) and KIR genotypes were assigned according to the system of 
nomenclature used by the online Allele Frequency Net Database (AFND) 
(http://www.allelefrequencies.net) (Table 6.5). In HLA-B*58:01 carriers, two individuals 
were genotyped as Bx6, while the remaining 3 were AA1, Bx4 and Bx91. In HLA-B*58:02 
carriers, the AA1 genotype was found in 3 individual, Bx4 and Bx5 genotypes were each 
found in two individuals, while the remaining individuals were classified as Bx6, Bx20, Bx71, 
Bx92, Bx112 and Bx393. Although the difference was not significant, the average number of 
activating KIRs (i.e. KIR2DS1-5 and KIR3DS1) was higher in HLA-B*58:01 carriers 
compared to HLA-B*58:02 carriers (4.0 vs. 2.76, respectively), while the average number of 
inhibitory KIRs detected in HLA-B*58:01 carriers compared to HLA-B*58:02 carriers was 
similar (7.2 vs. 7.1, respectively). 
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Table 6.5. KIR genes and KIR genotypes determined for the HLA-B*58:01 and -B*58:02-positive 
progressors. 
ID1 
KIR gene2 
KIR 
genotype1 
Inhibitory 
KIRs 
Activating 
KIRs 
KIR 
pseudogenes 
2D
L1
 
2D
L2
 
2D
L3
 
2D
L
4 
2D
L5
 
3D
L1
 
3D
L
2 
3D
L
3 
2D
S1
 
2D
S2
 
2D
S3
 
2D
S4
 
2D
S5
 
3D
S1
 
2D
P1
 
3D
P1
 
1                 Bx6 
2                 AA1 
3                 Bx5 
4                 AA1 
5                 Bx6 
6                 Bx71 
7                 AA1 
8                 Bx4 
9                 Bx92 
10                 Bx5 
11                 AA1 
12                 Bx4 
13                 Bx112 
14                 Bx4 
15                 Bx393 
16                 Bx91 
17                 Bx6 
18                 Bx20 
KIR, killer-cell immunoglobulin-like receptor. KIRs in bold are framework genes; 1ID numbers and KIR genotypes of HLA-
B*58:01-positive participants are shaded in grey; 2The presence of a KIR gene is indicated by a blue shaded box under the 
respective KIR gene labelled column. 
 
6.2.4. Mutational analysis of HIV-1 Gag 
 
6.2.4.1.  Mutations in p17Gag 
   
6.2.4.1.1.  CTL epitopes 
 
 We were unable to analyse mutations in the RY10 (20RLRPGGKKHY29) epitope 
restricted by HLA-B*42:01 (Chopera et al., 2011), since the coding region for the first 52 
amino acids of p17Gag were not sequenced. However, partial p17Gag sequences were available 
to analyse mutations in the highly antigenic region that includes the RY11 
(76RSLYNTVATLY86), LY9 (78LYNTVATLY86), SL9 (77SLYNTVATL85), GY9 
(70GSEELRSLY79), EV9 (73ELRSLYNTV83) and TI9 (84TLYCVHQRI92) epitopes restricted 
by HLA-A*30, -A*29/-B*44, -A*02, -A*01, -B*08 and -A*11, respectively (Tenzer et al., 
2009).  
 
 In subtype C HIV-1 studies it has been reported that the RY11 epitope (Figure 6.5) is 
restricted by HLA-A*30:02 (Masemola et al., 2004b, Kiepiela et al., 2004, Chopera et al., 
2008, Kiepiela et al., 2007) and Frahm et al. reported that RY11 is possibly also restricted by 
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HLA-B*58:01 (Frahm et al., 2005). Due to insertions/deletions that obscured sequence 
analysis, the baseline p17Gag sequence was not available for ID8. Many mutations were 
presented in this region and may be indicative of immune selection pressure due to the 
presence of relevant HLA class I alleles or other HLA class I alleles belonging to the same 
Supertype (Sidney et al., 2008). Alleles of the same Supertype that may target this region 
were present in the study participants and included HLA-A*02:01, -A*02:05 and -A*68:02 
(A02 Supertype); HLA-A*30:02, -A*30:01, -A*29:02, -A*36:01 and -A*80:01 (A01 
Supertype) and HLA-B*44:03 and -B*45:01 (B44 Supertype) (Table 6.2). HLA-B*08:01, 
that targets the EV9 epitope, was present in 1/18 study participants, but no participants were 
positive for HLA-A*01 or -A*11, that targets the GY9 and TI9 epitopes, respectively. 
 
 The Y79F mutation p17Gag was the most common change observed in 10/18 (56%) of 
the study participants. This change is expected to alter the P2 anchor residue of the RY11 
epitope restricted by HLA-A*30, however this is a TCR escape mutation with respect to the 
SL9 epitope restricted by HLA-A*02. R76K was a common mutation in HLA-B*58:02 
carriers, 5/13 (38%). Only one HLA-B*58:01 carrier had R76K present at baseline, but this 
reverted by the 6 month time-point. L75I was also seen in 6 individuals. Two individuals, 
ID5 and ID9, did not show any other mutations besides L75I, while L75I was found in 
combination with R76K in three individuals (ID16, ID13 and ID15), although reversion to 
wild type occurred in ID16. R76K is a flanking mutation in the SL9 epitope and is not 
associated with failure of peptides to bind to HLA-A*02 receptors (Brander et al., 1999), 
however, minor variations in proteosomal cleavage patterns, more so if downstream 
mutations were also present, have been reported suggesting that this change may be selected 
as a minor processing escape mutation (Tenzer et al., 2009). An association between L75I 
and HLA-A*02:02 in subtype A HIV-1 infection has been reported, also suggesting a 
processing escape mutation (Peters et al., 2008). 
 
The R76K and Y79F mutations were present in one HLA-B*58:01 carrier (ID16) at 
baseline, but reverted to wild-type at the 12 month time-point, with the concomitant 
appearance of T81A and T84I mutations. R76K and T84V escape mutations have been 
observed in an HLA-A*30:02 carrier (Chopera et al., 2011). T81A is unusual, but was found 
in subtype A HIV-1 infections associated with HLA-A*02:01. T84V is a more common 
escape mutation that is observed in HLA-A*02 carriers (Tenzer et al., 2009). ID16 is both 
HLA-A*02:01 and -A*68:02 positive and both of these alleles are members of the A02 
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Supertype (Geldmacher et al., 2007). Changes in position 81 and 84 were also noted in an 
HLA-A*02:01 positive subtype C infected individuals (Liang et al., 2011). Five HLA-
B*58:02 carriers (ID12, ID10, ID13, ID7 and ID15) also had R76K and Y79F mutations in 
combination with HLA-A*02:01 (ID12), -A*36:01 (ID10), -A*29:02/-A*30:02/-B*44:03 
(ID13), -A*68:02 (ID7) and -A*30:01/-A*30:02 (ID15), the most likely HLAs applying 
immune selective pressure. ID8 is a HLA-A*02:05 and -A*29:02 carrier, but did not show 
any mutations in this region. ID17 is a HLA-A*02:05 carrier and only demonstrated a V82I 
escape mutation (Tenzer et al., 2009). Y79F alone was found in ID11 (HLA-A*29:02), ID2 
(HLA-A*02:05/-A30:02) and ID14 (HLA-A*29:02/-A*80:01/-B*44:03). Surprisingly, Y79F 
reverted to wild-type at the 12 month time-point in ID14. ID1 is HLA-A*02:01 positive and 
showed Y79F only at baseline and both Y79F and V82L at the 6 month time-point. ID18 
unexpectedly did not show any mutations in this region, but is HLA-A*02:01 positive. ID3 
did not show any changes in this region but is a HLA-B*44:03 carrier. Similarly, ID6 did not 
show any changes and is HLA-A*29:02 and -B*44:03 positive. LY9 is presented by HLA-
B*44:03 and -A*29:02 (Masemola et al., 2004b, Chopera et al., 2008). Unexpectedly, ID4 
had no changes in this epitope and is HLA-B*45:01-positive (B44 Supertype), while ID9 also 
had no changes and is a HLA-A*30:02 carrier. It has been postulated that reversion of escape 
mutations to wild-type in the presence of the restricting HLA molecule may be associated 
with a lack of immune pressure due to immune dysfunction associated with late stage AIDS 
(Iversen et al., 2006, Tenzer et al., 2009). An unusual L75I mutation was present often in 
combination with R76K in 6 individuals (ID5, 16, 11, 13, 9 and 15). In ID16, reversion to 
wild-type was seen at the 12 month time-point. In ID11, L75F was observed at baseline and 
L75I at 6 month time-point. L75I was present in two individuals (ID5 and ID9) who did not 
have any other mutations in the epitope target region. ID5 is HLA-B*58:01-positive and L75I 
lies within the EV9 epitope which may represent an escape mutation in this case. 
 
Of interest was the noticeable lack of R76K in HLA-B*58:01 carriers compared to 
HLA-B*58:02 carriers. R76K occurred in combination with Y79F in only one HLA-B*58:01 
carrier at baseline, but this reverted within a 6 month period. A closer examination of the 
position of these changes raised the possibility that the Y79F mutation potentially creates a 
new epitope that may be restricted by both HLA-B*58:01 and -B*58:02 molecules. A 
conserved threonine residue at position 72 could serve as the anchor residue with the 
phenylalanine change at position 79 serving as anchor residue at the carboxy terminus. This 
is based on the peptide binding motifs predicted for HLA-B*58:01 and -B*58:02, i.e. X-
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(ATSG)-XXXXXX-(WFY) and X-(ST)-XXX-(R)-XX-(F), respectively 
(http://www.hiv.lanl.gov). HLA-B*58:02 has an additional requirement of arginine in a 
central position, which may explain the R76K change that predominated in HLA-B*58:02 
carriers. L75I may additionally contribute to escape by interfering with TCR recognition or 
this may indeed be an epitope processing mutation, since 2 individuals had no other changes 
except L75I, and a third individual with Y79F, showed evolution from L75F to L75I between 
baseline and 6 months. This possibility of a new epitope being generated by the L75F change 
may explain avoidance of this change in HLA-B*58:01 carriers and secondary R76K changes 
in HLA-B*58:02 carriers, but should be determined by functional assays. Interestingly, a 
R76K change in an HLA-A*30:02/-B*58:01 carrier, has been observed, but there was an 
absence of R79F over the 13 month study period, suggesting that this change may not have 
evolved due to the presence of HLA-B*58:01. The phenomenon of mutations that escape 
from one HLA class I molecule but inadvertently create detectable epitopes restricted by 
another HLA class I molecule have been reported before as in two instances in the HIV-1 Nef 
protein, aptly termed “tug-of-war” mutations (Brumme et al., 2007). Mutations in reverse 
transcriptase due to drug resistance development have also been shown to influence CTL 
detection of modified epitopes (Mahnke and Clifford, 2006). 
 
6.2.4.1.2.  Insertions 
 
Amino-acid insertions in p17Gag (Figure 6.5) were noted in 3 individuals (ID2, ID6 
and ID10) at amino acid position 117 near the p17Gag/p24Gag cleavage site. A 3 amino acid 
insertion (EQN) was present at all time-points in ID2. An insertion of 4 amino acids (KTQQ) 
was present at all time-points in ID6 and a similar 8 amino acid insertion (ASQQKTQQ) was 
detected at baseline in ID10, but was lost at the 6 and 12 months time-points. Other 
investigators have observed that similar mutations were related to restoration of viral 
replicative fitness due to the development of protease resistance mutations (Tamiya et al., 
2004). The loss of the insertion in ID10 is possibly due to transmission of a protease resistant 
virus to a drug naïve recipient leading to reversion. 
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Figure 6.5. Protein sequence alignment of the partial p17Gag open reading frame with a subtype C 
consensus reference showing the RY11 epitope and a region containing insertions. The arrow 
indicates the p17Gag/p24Gag cleavage site. Gaps introduced into the sequence are indicated by “~”; 
Identical amino acids to the consensus are indicated by “.” HLA-B*58:01-positive individuals’ 
sequences are shown in red box. 
6.2.4.2. Mutations in p24Gag 
6.2.4.2.1.  CTL epitopes 
 
 Analysis of the ISW9 (147ISPRTLNAW155) epitope in p24Gag (Figure 6.6) known to 
be targeted by HLA-B*57 and -B*58:01 (Chopera et al., 2008) showed the presence of 
A146P in three HLA-B*58:01 carriers (ID5, ID16 and ID11) and one HLA-B*58:02 carrier 
(ID18).  An unusual A146S mutation was present at baseline in one HLA-B*58:01 carrier 
(ID8), but reverted by the 6 month time-point. Two HLA-B*58:02 carriers also had unusual 
changes, i.e. A146V which was present at baseline but reverted by the 6 month time-point in 
ID7 and A146H that was established in ID9. The I147L mutation was present in only one 
HLA-B*58:01 carrier (ID8) and two HLA-B*58:02 carriers (ID6 and ID18). ISW9 is not a 
common epitope targeted by HLA-B*58:01 carriers, hence the mutations observed in 4/5 
60        70        80        90      100       110       120       130       140       150               
..|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|..
CONC2004     TSEGCKQIIKQLQPALQTGTEELRSLYNTVATLYCVHEKIEVRDTKEALDKIEEEQNKSQQKTQQ~~~~~~~~AKAAD~GKVSQNYPIVQNLQGQMVHQA
ID5 baseline .A..........H.........I.................................K.C......~~~~~~~~.E..G~..I.................P
ID5 12m      .A..........H...K.....I.................................K.C......~~~~~~~~.E..G~..I.................P
ID8 baseline ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~I.................S
ID8 6m       ........M............................AGV.....................NMP.~~~~~~~~..E.A~.~T..................
ID11 baseline .T.......Q............F...F..........KG............L.......K.....~~~~~~~~.Q..G~.Q..................P
ID11 6m      .A.......Q............I...F..........KG............L.......K.....~~~~~~~~.Q..G~.Q..................P
ID16 baseline ........M.............IK..F...........R...........Q..K....IK.Q...~~~~~~~~.E...K....................P
ID16 12m     ........L.......P...........A..I......RV..........Q..K....IK.Q...~~~~~~~~.EE..K....................P
ID17 6m      .........R..H................I.......AG.................K.V......~~~~~~~~..D..~.....................
ID17 12m     .........R..H................I.......AG.................K.V......~~~~~~~~..E..~.....................
ID1 baseline .........R.....I..........F...............K.............K........~~~~~~~~.E...K.....................
ID1 6m       .......L.R.....I..........F..L.......S....K.......R.....K.C...L..~~~~~~~~.E...K..I..................
ID2 baseline ........M.................F.......................R..A....I.A.MEK~~~~~EQNKSQ..~.....................
ID2 6m       ........M.................F.......................R..A....I.A.MEK~~~~~EQNKSQ..~.....................
ID2 12m      ........M.................F.......................R..A....I.A.MEK~~~~~EQNKSQ..~.....................
ID3 baseline ..D.............K....................QG...................C...A..~~~~~~~~.E...K.....................
ID3 6m       ..D..R......P...K....................QG...................C...A..~~~~~~~~.E...K.....................
ID3 12m     ..D..R..........K....................QG...................C...A..~~~~~~~~.E...K.....................
ID4 baseline ........MG......K................................................~~~~~~~~..T.G~E....................
ID4 6m       ........MG......K................................................~~~~~~~~....G~E....................
ID6 baseline .P.......Q.....IK....................R..K.Q...............N......~~~~KTQQE.KD.~E...H................
ID6 6m       .........Q.....IK....................R..K.Q...............N......~~~~KTQQE.KD.~E...H................
ID7 baseline .T...R...G....P........K..F...VV.....A.............L....K.G......~~~~~~~~..E~.~..I.................V
ID7 6m       .....R...S....S........K..F...VV.....A.............L....K.G......~~~~~~~~V.E~.~..I..................
ID9 baseline ........MA..H.........I..............A.............V.............~~~~~~~~.G..G~..I.................H
ID9 6m       ........MA..H.........I..............A.............V.............~~~~~~~~.G..G~..I.................H
ID10 baseline .A...R.................K..F..........Q....................C......ASQQKTQQ.E..G~.....................
ID10 6m      .A...R.................K..F..........Q....................C......~~~~~~~~.E..G~.....................
ID10 12m     .A...R..M..............K..F..........Q....................C......~~~~~~~~.E..G~.....................
ID12 6m      ........M..............K..F.............K........................~~~~~~~~.G...~............M........
ID12 12m     ........M..............K..F.............K.................G......~~~~~~~~.G...~............M........
ID13 baseline ........MA............IK..F..........KR.D........................~~~~~~~~.T...~.....................
ID13 6m      ........MA............IK..F..........KR.D........................~~~~~~~~.T...~.....................
ID13 12m     ........MA............IK..F..........KR.D........................~~~~~~~~.T...~.....................
ID14 baseline .A.......Q......K.........F..........KE...................C...M..~~~~~~~~E....~E.....F.....A........
ID14 6m      .A.......Q................F..........KE.D..........V..........M..~~~~~~~~E....~E...........A........
ID14 12m     .A.......Q......K....................KE...................C...M..~~~~~~~~E....~E.....F.....A........
ID15 baseline .A......LA............IK..F..........AR.D.....................A..~~~~~~~~....E~E....................
ID15 6m      .A.......A.........K..IK..F..........AR.D.....................A..~~~~~~~~E...E~.....................
ID15 12m     .A......LA............IK..F..........AR.D.....................A..~~~~~~~~....E~.....................
ID18 baseline ........L...H.........................N...Q...............G......~~~~~~~~TQV..~E...................P
ID18 6m      ........L...H.........................N...Q...............G......~~~~~~~~TQV..~E...................P
RY11                                              Insertion p17Gag/p24Gag
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HLA-B*58:01 carriers may be an aspect of virological failure at late stages of chronic HIV-1 
infection (Kloverpris et al., 2012b). The presence of mutations such as I146P in ISW9 in 
HLA-B*58:02 carriers not known to respond to this epitope, may be genetic footprints 
undergoing reversion due to transmission from HLA-B*57/58:01 donors (Chopera et al., 
2008). 
 
Mutations in the KF11 (162KAFSPEVIPMF172) epitope (Figure 6.6) were not present 
in HLA-B*58:01 carriers, as expected, due to an intrinsic failure in presentation of this 
epitope (Kloverpris et al., 2013b, Kloverpris et al., 2012b), although in one report, an HLA-
B*58:01-positive individual, who was HLA-B*57-negative, showed a response to this epitope 
(Chopera et al., 2011). Two HLA-B*58:02 carriers (ID2 and ID6) carried V36I mutations 
within KF11, suggestive of possible weak CTL responses to this epitope that may mediate 
escape from TCR recognition. A weak CTL response to two peptides containing the KF11 
epitope were reported in a subtype B HIV-1 infected individual who was HLA-B*58:02-
positive (Spivak et al., 2010). 
 
A p24Gag epitope AT12 (179ATPQDLNTMLNT190) (Figure 6.6) predicted to be 
restricted by HLA-B*58:02 (Chopera et al., 2008), was examined and found unchanged in 
10/13 HLA-B*58:02 carriers. Three individuals, however, had polymorphisms at position 182 
(Q182G in ID9; Q182S in ID14 and Q182T in ID15) possibly reflecting TCR contact escape 
mutations, but this epitope may be rarely targeted. Another p24Gag epitope DW10 
(203DTINEEAAEW212) (Figure 6.6), newly described as a HLA-B*58:01-restricted epitope 
was examined, but did not appear to be under selection pressure in our cohort. One HLA-
B*58:01 carrier (ID11) showed an E207D mutation at baseline but this reverted at the 6 
month time-point. An E211D mutation was observed at baseline in an HLA-B*58:02 carrier 
(ID12), but reverted at 12 months, while a second HLA-B*58:02 carrier (ID10) had two 
established changes, D203E and A209I. 
 
As anticipated, the well characterised T242N escape mutation in the TW10 
(240TSTLQEQIAW249) epitope (Figure 6.7) of p24Gag (Chopera et al., 2011, Leslie et al., 
2004) was already established in all HLA-B*58:01 carriers at baseline and also present at 
subsequent time-points. In HLA-B*58:02 carriers, one T242N (ID18) and an unusual T242S 
(ID10) mutation was also found. A T242S mutation in an HLA-B*58:01-positive individual 
has been reported (Leslie et al., 2004) and in HLA-B*58:02-positive individuals these 
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changes most likely represent footprints from HIV-1 transmission from a HLA-B*57 or -
B*58:01-positive donor (Chopera et al., 2008). A transition from T242N to T242S before 
final reversion to 242T has been recorded in one HLA-B*58:01-negative individual, 
suggesting that T242S is an intermediate change during the reversion process (Chopera et al., 
2008). In our study, surprisingly, one HLA-B*58:02 positive individual (ID10), developed the 
242S mutation at 6 months and maintained the change at 12 months, suggesting an alternative 
benefit of T242S in this individual. An E245D change was noted in one HLA-B*58:02 
individual, ID2, which was reported in the HLA-B*58:01-negative group and I247V, present 
in ID12, was observed in the HLA-B*57-positive group (Leslie et al., 2004). In subtype B 
(Miura et al., 2009) and subtype C (Leslie et al., 2004) HIV-1 studies, a guanine at position 
248 is considered wild-type. However, in the cohort under current study, an alanine was the 
most common amino acid at position 248 (11/18). Sequence polymorphisms involving G 
(n=3), T (n=2) and Q (n=2) at position 248 of TW10 were noted, possibly influencing TCR 
escape recognition. 
 
 In two HLA-B*58:01 (ID16 and ID17) carriers who were also HLA-B*15:10-positive, 
T303I and T303A changes were observed in YL9 epitope (296YVDRFFKTL304) in p24Gag 
(Figure 6.8). CTL responses to YL9 in B*15 carriers has been reported previously 
(Masemola et al., 2004b). In HLA-B*58:02 carriers, T303I was also seen in two individuals 
(ID12 and ID4) and T303C was present in one individual (ID10), however, none of these 
individuals were HLA-B*15-positive or -C*03-positive. CTL responses to YL9 in HLA-C*03 
carriers and T303AIC escape mutations that decreased viral fitness have been documented 
(Honeyborne et al., 2010). Notably, ID16 was also HLA-C*03:02-positive and the T303I 
change may therefore be escape from two HLA restricted CTL responses.  
 
In HLA-B*58:01 carriers, analysis of the QW9 epitope (308QATQDVKNW316) in p24Gag 
(Figure 6.8), showed two established T310S mutations (ID16 and ID11) and one individual 
(ID5) acquired the change between baseline and 12 months. Positive selection of T310S and 
S309A mutations have been seen in HLA-B*58:01 carriers (Carlson et al., 2012). All HLA-
B*58:01 carriers in our study also carried the S309A mutation. The T310S change was only 
seen at baseline in one HLA-B*58:02 carrier (ID10), but reverted to wild-type by 6 months. 
The T303S mutation in ID10 at baseline was accompanied by an A309G mutation. The 
positive selection of A309X and N315G mutations in QW9 has been observed in HLA-
B*53:01-positive individuals (Carlson et al., 2012). Reversion of both T303S and A309G to 
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wild-type at the 6 month time-point and the appearance of N315V and D312E in ID10 (HLA-
B*53:01-positive) suggests immune selection pressure on this epitope. D312E was also 
present in ID12 who was also an HLA-B*53:01 carrier. The E312D change sometimes found 
in HLA-B*57 carriers, was present in all except one HLA-B*58:01 carrier (ID16), where this 
change was present at baseline but reverted to 312E by 12 months. Other studies, however 
did not find E312D to be a significant change in HLA-B*58:01 carriers (Miura et al., 2009). 
In HLA-B*58:02 carriers, 312E was more common (8/13) and two individuals (ID10 and 
ID13) acquired D312E mutations after baseline and before the 6 month time-point. 
 
6.2.4.2.2. Compensatory mutations 
 
Since the T242N mutation in TW10 is known to confer a fitness cost to the virus (Crawford 
et al., 2007, Leslie et al., 2004), compensatory mutations such as H219X, I223X and M228X 
in p24Gag that restore viral replicative capacities, can subsequently develop (Gijsbers et al., 
2013). The H219Q mutation maps to the CypA binding site (Figure 6.7) and has been found 
to enhance viral fitness (Gatanaga et al., 2006). This change was found in one HLA-B*58:01 
carrier (ID8) and three HLA-B*58:02 carriers (ID12, ID3 and ID9). I223V was found in all 
HLA-B*58:01 carriers, one of which was acquired between the 6 and 12 month time-point 
(ID17). I223V was also found in nine HLA-B*58:02 carriers (ID1, ID18, ID10, ID2, ID3, 
ID6, ID7, ID9 and ID14), two of which acquired the change between baseline and 6 month 
time-points (ID1 and ID10). The two HLA-B*58:02 carriers with the T242N and T242S 
changes also carried the I223V compensatory mutations. In HLA-B*58:01 carriers, M228I 
and M228L were present in two individuals (ID16 and ID11). M228I was also present in two 
HLA-B*58:02 carriers (ID12 and -3) as well as one M228L mutation (ID7). As expected, the 
M250I mutation, that causes a fitness cost to subtype C viruses and does not occur together 
with T242N (Chopera et al., 2012), was not present in any of the individuals with T242N, but 
was present in an HLA-B*58:02 carrier who did not have T232N. Notably, partial 
compensatory mutations S252G and D260E described in other studies were also present in 
this individual (Chopera et al., 2012). 
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Figure 6.6. Protein sequence alignment of the partial p24Gag open reading frame with a subtype C 
consensus reference showing the RY11, KF11, AT12 and DW10 epitopes. The arrow indicates the 
p17Gag/p24Gag cleavage site. Gaps introduced into the sequence are indicated by “~”; Identical amino 
acids to the consensus indicated by “.”; HLA-B*58:01-positive individuals’ sequences are shown in red 
box. 
 
 
 
 
 
 
 
 
 
 
 
 
130      140       150       160       170       180       190       200       210       220                  
.|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
CONC2004     SQNYPIVQNLQGQMVHQAISPRTLNAWVKVIEEKAFSPEVIPMFTALSEGATPQDLNTMLNTVGGHQAAMQMLKDTINEEAAEWDRLHPVHAGPIAPGQM
ID5 baseline .................P....................................................................V.......V.....
ID5 12m      .................P....................................................................V.......V.....
ID8 baseline ............ ....SL.......................................................................Q...V.....
ID8 6m       ..................L.......................................................................Q...V.....
ID11 baseline .................P............................................................D...............V....L
ID11 6m      .................P............................................ .........................S.....V....L
ID16 baseline .................P............................................................................V....I
ID16 12m     ............... .P............................................................................V....I
ID17 6m      ..............................V.....................................................................
ID17 12m ..............................V...............................................................V.....
ID1 baseline ......................................................................................V.............
ID1 6m       ......................................................................................V.......V.....
ID2 baseline .......................................I......................................................V.....
ID2 6m       .......................................I.................................................I....V.....
ID2 12m      .......................................I.................................................I....V.....
ID3 baseline ......................................................................................T...Q...V....I
ID3 6m       ..................................................................H...................T...Q...V....I
ID3 12m      ......................................................................................T...Q...V....I
ID4 baseline ....................................................................................................
ID4 6m       ....................................................................................................
ID6 baseline .H................L....................I......................................................V.....
ID6 6m       .H................L.............A......I......................................................V.....
ID7 baseline .................V............V.......................................................T.......V....L
ID7 6m       ..............................V.......................................................T.......V....L
ID9 baseline .................H................G..................G....................................Q...V.....
ID9 6m       .................H................G..................G....................................Q...V.....
ID10 baseline ....................................................................................................
ID10 6m      .......................................................................I..E.....I.............V.....
ID10 12m     .......................................................................I..E.....I.............V.....
ID12 6m      .........M....................V...................................................D.......Q........I
ID12 12m     .........M....................V...........................................................Q........I
ID13 baseline ....................................................................................................
ID13 6m      ....................................................................................................
ID13 12m     ....................................................................................................
ID14 baseline ...F.....A....................V......................S........................................V.....
ID14 6m      .........A....................V......................S........................................V.....
ID14 12m     ...F.....A....................V......................S........................................V.....
ID15 baseline .....................................................T..............................................
ID15 6m      .....................................................T..............................................
ID15 12m     .....................................................T..............................................
ID18 baseline .................PL...........................................................................V..N..
ID18 6m      .................PL...........................................................................V..N..
ISW9 KF11 AT12 DW10p17Gag/p24Gag
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Figure 6.7. Protein sequence alignment of the partial p24Gag open reading frame with a subtype C 
consensus reference showing the CypA binding site and the TW10 epitope. Gaps introduced into the 
sequence are indicated by “~”; Identical amino acids to the consensus indicated by “.” ; HLA-B*58:01-
positive individuals’ sequences are shown in red box. 
 
 
 
 
 
 
 
 
 
 
 
 
210       220       230       240       250       260       270       280       290     300           
..|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|..
CONC2004     INEEAAEWDRLHPVHAGPIAPGQMREPRGSDIAGTTSTLQEQIAWMTSNPPIPVGDIYKRWIILGLNKIVRMYSPVSILDIKQGPKEPFRDYVDRFFKTL
ID5 baseline ..........V.......V..................N.............V...E.........................R..................
ID5 12m      ..........V.......V..................N.............V...E.........................R..................
ID8 baseline ..............Q...V..................N.....G...........E............................................
ID8 6m       ..............Q...V..................N.....G.......F...E............................................
ID11 baseline ..D...............V....L.............N.............V.............................R..................
ID11 6m      ............S.....V....L.............N.............V.............................R..................
ID16 baseline ..................V....I.............N.....T...N..................................................I.
ID16 12m     ..................V....I.............N.....T...N..................................................I.
ID17 6m      ..................................S..N.........A...............M..................................A.
ID17 12m     ..................V...............S..N.........A...............M..................................A.
ID1 baseline ..........V.........................................................................................
ID1 6m       ..........V.......V.................................................................................
ID2 baseline ..................V.....................D......A.................................R..................
ID2 6m       .............I....V.....................D......A.................................R..................
ID2 12m      .............I....V.....................D......A.................................R..................
ID3 baseline ..........T...Q...V....I...................Q.......M.............................R..................
ID3 6m       ..........T...Q...V....I...................Q.......M.............................R..................
ID3 12m      ..........T...Q...V....I...................Q.......M...E.........................R..................
ID4 baseline ..................................................................................................I.
ID4 6m       ..................................................................................................I.
ID6 baseline ..................V..............................................................R..................
ID6 6m       ..................V..............................................................R..................
ID7 baseline ..........T.......V....L.......................N...V...E.........................R..................
ID7 6m       ..........T.......V....L.......................N...V...E.........................R..................
ID9 baseline ..............Q...V......D............T.......................V.....................................
ID9 6m       ..............Q...V......D............T.......................V.....................................
ID10 baseline .........................G.........................V.............................R................C.
ID10 6m      ....I.............V......D...........S.....G.......V.............................R................C.
ID10 12m     ....I.............V......D...........S.....G.......V.............................R................C.
ID12 6m      ......D.......Q........I..................VQ...G.......E..........................................I.
ID12 12m     ..............Q........I..................VQ...G.......E..........................................I.
ID13 baseline .............................................I.G..A....E............................................
ID13 6m      .........................D...................I.G..A....E.....................................E......
ID13 12m     .........................D...................I.G..A....E............................................
ID14 baseline ..................V........................T........................................................
ID14 6m ..................V........................T........................................................
ID14 12m     ..................V........................T........................................................
ID15 baseline ...............................................N...V................................................
ID15 6m      ...............................................N...V................................................
ID15 12m     ...............................................N...V................................................
ID18 baseline ..................V..N...............N.....G........................................................
ID18 6m      ..................V..N...............N.....G........................................................
CypA TW10
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Figure 6.8. Protein sequence alignment of the partial p24Gag open reading frame with a subtype C 
consensus reference showing the YL9 and QW9 epitopes. The arrow indicates the p24Gag/p2Gag 
cleavage site. Gaps introduced into the sequence are indicated by “~”; Identical amino acids to the 
consensus indicated by “.”; HLA-B*58:01-positive individuals’ sequences are shown in red box. 
 
6.2.4.2.3. KIR binding 
 
Mutations in the TW10 epitope (Figure 6.7) have also been shown to influence the 
strength of binding of KIR3DL1 to HLA-B*57 ligands (Brackenridge et al., 2011). In their 
report, an alanine at position 248, that we found as the consensus, was shown to marginally 
increase the binding affinity of KIR3DL1. Two individuals, ID16 and -14 had a threonine at 
position 248, which was reported to show the highest increase in binding affinity for 
KIR3DL1. A glutamine at position 248, however, which was present in two individuals, ID12 
and -3, decreases the strength of binding of KIR3DL1. Mutations that increase the binding 
affinity of inhibitory receptors such as KIR3DL1 with HLA class I ligands, may be positively 
selected in order to prevent activation of antiviral NK cells. This may also apply to HLA-
B*58:01 and -B*58:02 since these receptors are also Bw4 ligands for KIR3DL1 and may 
270      280       290       300       310       320       330       340       350       360                  
|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....
CONC2004     LNKIVRMYSPVSILDIKQGPKEPFRDYVDRFFKTLRAEQATQDVKNWMTDTLLVQNANPDCKTILRALGPGATLEEMMTACQGVGGPSHKARVLAEAMSQ
ID5 baseline ................R...................................................................................
ID5 12m      ................R.......................S....................R...K..................................
ID8 baseline ....................................................................................................
ID8 6m       ....................................................................................................
ID11 baseline ................R.......................S...........................................................
ID11 6m      ................R.......................S...........................................................
ID16 baseline .................................I......S.........................G..Q.................G............
ID16 12m     .................................I......S.E.......................G..Q.................G............
ID17 6m      .................................A...............E................G.................................
ID17 12m     .................................A...............E................G..Q..............................
ID1 baseline .......................................S..E............................................G............
ID1 6m       .......................................S..E............................................G............
ID2 baseline ................R.....................................................................LG............
ID2 6m       ................R......................................................................G............
ID2 12m      ................R......................................................................G............
ID3 baseline ................R.........................E..H...E..................................................
ID3 6m       ................R.........................E..H...ES.................................................
ID3 12m      ................R.........................E......ES.................................................
ID4 baseline .................................I........E.......................G..Q..S..............G............
ID4 6m       .................................I........E.......................G..Q..S..............G............
ID6 baseline ................R.........................E............................................G............
ID6 6m       ................R.........................E............................................G............
ID7 baseline ................R.............................................L..KG.....S...........................
ID7 6m       ................R.............................................L...G.....S...........................
ID9 baseline ..............................................................N.........S...........................
ID9 6m       ..............................................................N.........S...........................
ID10 baseline ................R................C.....GS............I..............................................
ID10 6m      ................R................C........E..V...............R...K..................................
ID10 12m     ................R................C........E..V...............R...K..................................
ID12 6m      .................................I........E.......................G..A.................G............
ID12 12m     .................................I........E.......................G..A.................G............
ID13 baseline .......................................................................................G............
ID13 6m      ............................E.............E............................................G............
ID13 12m     ..........................................E............................................G............
ID14 baseline ..........................................E......E................G.....S...................M.......
ID14 6m      ..........................................E.......................G.................................
ID14 12m     ..........................................E......E................G.................................
ID15 baseline ....................................................................................................
ID15 6m      ....................................................................................................
ID15 12m     ....................................................................................................
ID18 baseline ........................................................................S..............G............
ID18 6m      ........................................................................S..............G............
YL9 QW9 p24Gag/ p2Gag
145 
 
explain the increased frequency of alanine at this position at end stage chronic HIV-1 
infection. 
 
 Similarly, changes at position 303 of the YL9 epitope such as T303A and T303I have 
also been associated with increased binding of KIR2DL2 to HLA-C*03 molecules, while 
T303C reduced the binding affinity (van Teijlingen et al., 2014). ID16 had the T303I change 
and was also KIR2DL2-positive, suggesting potential escape from NK cell responses. ID17 
with T303A was also KIR2DL2-positive, but did not have HLA-C*03; however both HLA-C 
molecules were C1 ligands. ID10 and ID12, with T303I and T303C, carried C2 ligands only 
and are not expected to bind KIR2DL2, even though they carried this KIR. ID4 had T303I, 
but was negative for KIR2DL2. Therefore, the presence of mutations at position 303 in the 
HLA-B*58:02 carriers cannot be explained by known CTL epitope responses or escape from 
NK cell surveillance. These may likely be footprints of escape mutations generated in the 
donor partner. 
 
6.2.4.2.4.  TRIM5α sensitivity 
 
Another possibility worth discussion is the effect of mutations in p24Gag on the ability 
of TRIM5α to restrict viral cores (Granier et al., 2013). Within the TW10 epitope (Figure 
6.7), the T242N mutation alone or in combination with amino acid substitutions at position 
248, was shown to increase the sensitivity to TRIM5α. Notably, T242N in the presence of 
248G showed the highest sensitivity, while T242N in the presence of 248A was reduced. This 
may explain the presence of T242N and 248A in 3/5 HLA-B*58:01 carriers. The presence of 
248Q and 248T was not evaluated by the investigators, which were polymorphisms present in 
some of the p24Gag sequences. Most of the HLA-B*58:02 carriers (7/13), however, carried a 
248A mutation, which implies greater sensitivity to TRIM5α, and presumably a greater 
benefit to the virus, such as decreased NK cell detection, as mentioned earlier, was provided 
by this change. Interestingly, one HLA-B*58:02 carrier (ID10) had 242T and 248A at 
baseline, which mutated to 242S and 248G at 6 months and this change was maintained at 12 
months. Unfortunately, a 242S change was not evaluated, but it could be speculated that the 
two changes in combination may have reduced sensitivity to TRIM5α. 
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6.2.4.3.  Insertions in p6Gag 
 
 Analysis of p6Gag protein sequences showed the presence of PTAP insertions in 4/5 
HLA-B*58:01 carriers and in 5/13 HLA-B*58:02 carriers (Figure 6.9). The PTAP duplication 
is reported to be more common in subtype C viruses, but is also present in other HIV-1 
subtypes (Flys et al., 2005). A putative CTL epitope restricted by HLA-B*58:01 
(453EPTAPPAESFRF464) that contains the PTAP motif has been predicted previously 
(Chopera et al., 2011) and it is therefore plausible that insertions in this region in HLA-
B*58:01 carriers may disrupt presentation of the epitope as a means of CTL escape. On the 
other hand PTAP duplications are known to enhance viral budding through recruitment of 
Tsg101 (VerPlank et al., 2001). It has been demonstrated that deletion of the first PTAP motif 
leads to a 50% reduction in Tsg101 binding compared to a 25% reduction when the second 
PTAP motif is deleted. In our study, we noticed that the first PTAP motif appeared to be 
deleted in ID5, however sequences from this individual at baseline and 12 month time-point, 
had an unusual 4 amino insertion (PYRE) just upstream of the Vpr binding site. In subtype C 
HIV-1 infected Indian individuals, similar 4-amino acid insertions were found to be more 
common in patients failing protease therapy and are thought to be restoration of fitness 
changes due to the development of protease resistance mutations (Neogi et al., 2014). The 
functional significance of this insertion is that it restores the ALIX-binding motif that serves 
as an alternative budding pathway, normally absent in sub-Saharan subtype C viruses. In 
terms of viral budding efficiency, in ID5, the original PTAP duplication may have become 
redundant due to the PYRE insertion. Loss of the first PTAP motif was most likely of no 
consequence to the virus, since the deletion of the second PTAP motif has been shown to 
associate with a lesser reduction in Tsg101 recruitment than deletion of the first PTAP motif. 
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Figure 6.9. Protein sequence alignment of the p6Gag open reading frame with a subtype C consensus 
reference showing the site of the PTAP duplication and the PYRE insertion. The arrows indicate the 
NC/p1 and p1/p6Gag cleavage sites. Gaps introduced into the sequence are indicated by “~”; Identical 
amino acids to the consensus indicated by “.”; HLA-B*58:01-positive individuals’ sequences are 
shown in red box. 
 
6.2.4.4. Insertions and p6Pol 
 
 In addition, insertions in the p6Gag region also the impact on the primary sequence of 
the p6Pol transframe protein generated by the -1 frameshifting during Gag-Pol polyprotein 
synthesis (Figure 6.10). The possible significance of p6Pol mutations is that this domain was 
found to be necessary for regulation of protease autocatalysis required for virion maturation 
(Paulus et al., 2004) as well as incorporation of Nef into virions (Costa et al., 2004). It 
seemed plausible to speculate that enhanced incorporation of Nef into virions may lead to 
increased downregulation of HLA class I molecules on the surface of newly infected cells. 
430       440       450       460       470       480       490       500       510        
...|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....
CONC2004     RQANFLGKIWPSHK~GRPGNFLQNRPEPTAP~~~~~~~~~~~~~~PAESFRFEETTPAPKQEPKDRE~~~~PLTSLKSLFGSDPLSQ*
ID5 baseline ............Q.~..........TD~~~~~~~~~~~RIEPTAP.....G.G..............PYRE..I.......N.....
ID5 12m      ............Q.~..........TD~~~~~~~~~~~~~~PTAP..Q..GIG.........Q....PYRE..I.......NY....
ID8 baseline ..............~.............I..~~~~~QSRLEPTAP.....G.G.........QNN..~~~~..I.............
ID8 6m    ..............~.............I..~~~~~QSRIEPTAP.....G.G.........QNN..~~~~..I.............
ID11 baseline ..............~........S.......PA~~~~~~~EPTAP..................R...~~~~A...............
ID11 6m      ..............~........S.......PV~~~~~~~EPTAP..................R...~~~~A...............
ID16 baseline ..............~........S.......PAENFRSRPEPTAP...........~~~~...R...~~~A.....R....N.....
ID16 12m     ..............~........S.......PAENFRSRLEPTAP...........~~~~...R..K~~~A.....R....N.....
ID17 6m      .......R......~........S.......PL~~~QSRPEPTAP..........~~~.N..S....~~~~A....R..........
ID17 12m     .......R......~........S.......PL~~~QSRPEPTAP..........~~~....S....~~~~A....R..........
ID1 baseline ............I.~........S.......~~~~~~~~~~~~~~.....K...EN.........K.P~~~............L...
ID1 6m       ..............~........S.......PA~~~~~~~EPSAP.........EN.....GL..K.P~~~............L...
ID2 baseline ..............~........S.......~~~~~~~~~~~~~~......................~~~~................
ID2 6m       ..............~........S.......~~~~~~~~~~~~~~......................~~~~................
ID2 12m      ..............~........S.......~~~~~~~~~~~~~~......................~~~~................
ID3 baseline ..............~.............S..~~~~~~~~~~~~~~.....K......T.R..Q....~~~~................
ID3 6m       ..............~.............S..~~~~~~~~~~~~~~............T.R..Q....~~~~................
ID3 12m      ..............~.............S..~~~~~~~~~~~~~~............T.R..Q....~~~~................
ID4 baseline ............Q.~........S.......PA~~~~~~~~PTAP.V......G.........Q...~~~~..I.............
ID4 6m       ............Q.~........S.......PA~~~~~~~~PTAP..................Q...~~~~..I.............
ID6 baseline ..............~................~~~~~~~~LEPTAP......C..........S....~~~~..I..........W..
ID6 6m       ..............~................~~~~~~~~LEPTAP......C..........S....~~~~..I..........W..
ID7 baseline ..............~................P~~~~~~~~EPTAP.....K.......SR.~~N...~~~~..I.............
ID7 6m       ..............~................P~~~~~~~~EPTAP......S.....V.R.~~....~~~~..I.............
ID9 baseline ..............~........S.......PA~~~~~~~EPTAP.................R....~~~~..........N.L...
ID9 6m       ..............~........S.......PA~~~~~~~EPTAP.................R....~~~~..........N.L...
ID10 baseline ..............~......I.S....S..~~~~~~~~~~~~~~.....S.G.P.......S....~~~~................
ID10 6m      ..............~......I.S....S..~~~~~~~~~~~~~~.....S.G.........S....~~~~................
ID10 12m     ..............~......I.S....S..~~~~~~~~~~~~~~.....S.G.........S....~~~~................
ID12 6m      ............Q.~................~~~~~~~~~~~~~~............T.EE.S....~~~~................
ID12 12m     ............Q.~................~~~~~~~~~~~~~~............T.........~~~~................
ID13 baseline .......R......~................~~~~~~~~LEPTAP.......G...L..........~~~~..I.............
ID13 6m      .......R......~................~~~~~~~~LEPTAP.......G...L..........~~~~..I.............
ID13 12m     .......R......~................~~~~~~~~LEPTAP.......G...L..........~~~~..I.............
ID14 baseline ..............G......P.S.L.....~~~~~~~~~~~~~~............T....Q....~~~~................
ID14 6m      ..............G......P.S.L.....~~~~~~~~~~~~~~............T....Q....~~~~................
ID14 12m     ..............G......P.S.L.....~~~~~~~~~~~~~~............T....Q....~~~~................
ID15 baseline ..............~........S.......~~~~~~~~~~~~~~............T.R..Q....~~~~..I.............
ID15 6m      ..............~......P.S.L.....~~~~~~~~~~~~~~.................Q....~~~~..I.............
ID15 12m     ..............~......P.S.L.....~~~~~~~~~~~~~~.................Q....~~~~..I.............
ID18 baseline ..............~........S.S.....PVESFR~~PEPTAP.............S...G..K.~~~~..I.......R.....
ID18 6m      ..............~........S.S.....PVESFR~~PEPTAP.............S...G..K.~~~~..I.......R.....
PTAP duplication PYRE insertionNC/p1 p1/p6Gag
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However, other investigators have analysed p6Pol mutants containing an ISSEQTRANSPT 
insertion in p6Pol as a consequence of PTAP duplications in p6Gag, and no differences in Nef 
incorporation compared to the wild-type strain were noted (Leiherer et al., 2009). This report, 
however, did demonstrate other consequences of the p6Pol insertion, which included increased 
infectivity and enhanced replication in PBMC’s. This implies that the insertions in p6Gag, 
similar to insertions observed in the current study, that enhance virus budding may also 
impact on viral infectivity and replication kinetics mediated by p6Pol. 
 
Figure 6.10. Protein sequence alignment of the p6Pol open reading frame with a subtype C consensus 
reference showing the site of duplication. The arrows indicate the p6Pol/PR cleavage site. Gaps 
introduced into the sequence are indicated by “~”; Identical amino acids to the consensus indicated by 
“.”; HLA-B*58:01-positive individuals’ sequences are shown in red box. 
 
 
 
0         10        20        30        40        50        60        70        80                   
|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
CONC2004     ERQANXFRENLAFPQG~EAREFPSEQTRANSP~~~~~~~~~~~~~~TSRELQVRGDNPRSEAGAER~~~~QG~TLNFPQITLWQRPLVS
ID5 baseline ..............E.~.........N.~~~~~~~~~~~QNRANSP....FR......S......GQGTL..~...............T
ID5 12m      ..............E.~........~~~~~~~~~~~~~~QNRPNSP..PKFRD.R...S.Q.....PGTL..~...........L...P
ID8 baseline ................~..G............T~~~~~EQTRANSP.....R.......P...T.Q~~~~..~................
ID8 6m       ................~..G............T~~~~~EQNRANSP.....R.......P...T.Q~~~~..~................
ID11 baseline ................~...............TS~~~~~~~RANSS...........SC.......~~~~..S~............ACL
ID11 6m      ................~...............TS~~~~~~~RANSP.........N..C.......~~~~..S~...............
ID16 baseline ................~..GK.....A.....TSRELQEQTRTNSP..........~~~~H.....~~~~..S...L............
ID16 12m     ................~..GK.....A.....TSRELQEQTRANSS.........N~~~~H.....~~~~.ES...L............
ID17 6m      ................~......P........TS~~~SEQTRANSPA.....I...~~~T.S.I..~~~~..S~...............
ID17 12m     ................~......P........TS~~~SEQTRANSP......I...~~~....V..~~~~..S~...............
ID1 baseline .............H..~..G......A.....~~~~~~~~~~~~~~.........GE.........~~~~..T................
ID1 6m       ................~..G......A.....TS~~~~~~~RAISP.........GE.........~~~~..T................
ID2 baseline ................~........P......~~~~~~~~~~~~~~..........D.S.......~~~~..~................
ID2 6m       ................~........P......~~~~~~~~~~~~~~..........D.S.......~~~~..~................
ID2 12m      ................~........P......~~~~~~~~~~~~~~..........D.S.......~~~~..~................
ID3 baseline ................~....L....A..IG.~~~~~~~~~~~~~~............H..T....~~~~..~................
ID3 6m       ................~....L....A..IG.~~~~~~~~~~~~~~............H..T....~~~~..~................
ID3 12m      ................~....L....A..IG.~~~~~~~~~~~~~~............H..T....~~~~..~................
ID4 baseline .........D....E.~...............TS~~~~~~~~TNSP..........D.......AG~~~~.R~.............V..
ID4 6m       .........D....E.~...............TS~~~~~~~~TNSP..........D.......AG~~~~..~.............V..
ID6 baseline ................~..G............~~~~~~~~TRANSP...........S.....V.G~~~~..~................
ID6 6m       ................~..G............~~~~~~~~TRANSP...........S.....V.G~~~~..~................
ID7 baseline ................~...............~~~~~~~~TRANSP.............L..~~..~~~~..~................
ID7 6m       ................~...............~~~~~~~~TRANSP.............P..~~.G~~~~..~................
ID9 baseline ................~......P........TS~~~~~~~RANSP....................~~~~..~...............A
ID9 6m       ................~......P........TS~~~~~~~RANSP....................~~~~..~...............T
ID10 baseline ................~K...LH...A..V..~~~~~~~~~~~~~~......L..A..C....V..~~~~..~................
ID10 6m      ................~K...LH...A..V..~~~~~~~~~~~~~~......L.....C....V..~~~~..~..............I.
ID10 12m     ................~K...LH......V..~~~~~~~~~~~~~~......L.....C....V..~~~~..~..............I.
ID12 6m    ..............E.~......PK.A.....~~~~~~~~~~~~~~............H.RR.V..~~~~..~................
ID12 12m     ..............E.~......PK.A.....~~~~~~~~~~~~~~............H.......~~~~..~................
ID13 baseline ................~...............~~~~~~~~TRANSP....................~~~~..~................
ID13 6m      ................~...............~~~~~~~~TRANSP....................~~~~..~................
ID13 12m     ................~...............~~~~~~~~TRANSP....................~~~~..~................
ID14 baseline ................G...............~~~~~~~~~~~~~~.........N..H....T..~~~~..~................
ID14 6m      ................G...............~~~~~~~~~~~~~~.........N..H....T..~~~~..~................
ID14 12m     ................G...............~~~~~~~~~~~~~~.........N..H....T..~~~~..~................
ID15 baseline ................~....L....A.T...~~~~~~~~~~~~~~........R...H.......~~~~..~................
ID15 6m      ................~...Q.....A.....~~~~~~~~~~~~~~....................~~~~..~................
ID15 12m     ................~..GQL....A.....~~~~~~~~~~~~~~....................~~~~..~................
ID18 baseline ................~.........I.....TSREL~~QTRTNSS..G......N..CF...G..~~~~..~A...............
ID18 6m ................~.........I.....TSREL~~QTRTNSS..G......N..CF...G..~~~~..~A...............
duplication-1 frameshift p6Pol/PR
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6.2.5. Summary of mutations in Gag 
 
A summary of the mutations and insertions detected in Gag in the HLA-B*58:01 and -
B*58:02 progressors is depicted in Table 6.5. Red squares indicate a change. Similar changes 
between the HLA-B*58:01 and -B*58:02 carriers are evident in the p17Gag RY11 epitope, 
compensatory mutations in p24Gag, insertions in p6Gag, NK escape mutations and TRIM5α 
sensitivity. Differences are evident between the HLA-B*58:01 and -B*58:02 progressors in 
the ISW9, TW10, YL9 and QW9 p24Gag epitopes. It is known that HLA-B*58:02 carriers do 
not target p24Gag, while the changes in p24Gag epitopes in HLA-B*58:01 carriers are escape 
mutations in epitopes restricted by HLA-B*58:01. The summary of results suggest that 
similar escape mutations can develop in both HLA-B*58:01 and -B*58:02 carriers in targets 
that are independent of HLA-B*58:01 and -B*58:02-mediated CTL responses and these 
changes contribute to virological failure in both groups. However in HLA-B*58:01 carriers, 
p24Gag is a major target for HLA-B*58:01-restricted CTLs, hence escape mutations develop 
in these epitopes and also contribute to virological failure. A lack of HLA-B*58:02-restricted 
epitopes in p24Gag explains why no escape mutations were detected in HLA-B*58:02 carriers 
and the virus therefore does not compromise fitness. 
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Table 6.6. Summary of mutations in Gag detected in HLA-B*58:01 and -B*58:02-positive progressors. 
CTL, Cytotoxic T cell; NK, Natural killer; KIR, killer-cell Immunoglobulin-like receptor; TRIM5α, tripartite motif-5α; HLA-B*58:01 carriers are shaded in grey. 
 
 
 
 
 
CTL escape 
mutations 
Fitness compensatory 
mutations 
Insertions NK Cell escape 
mutations 
TRIM5α 
sensitivity 
 p17Gag p24Gag p24Gag p17Gag p6Gag p24Gag p24Gag 
ID RY11 ISW9 TW10 YL9 QW9   KIR3DL1 KIR2DL2  
 L75 R76 Y79 T81 V82 T84 A146 I147 T242 T303 T310 H219 I223 M228 G248  T303 G248 
5 I      P  N  S  V    PYRE A  A 
8       S L N   Q V   PTAP     
11 I/F  F    P  N    V L  PTAP  A  A 
16 I K F A  I P  N I S  V I  PTAP  T I  
17     I    N A S  V   PTAP  A A A 
1   F  I        V   PSAP  A  A 
2   F          V  EQN   A  A 
3            Q V I       
4          I      PTAP  A I A 
6        L     V  KTQQ PTAP  A  A 
7  K F   V V      V L  PTAP  A  A 
9 I      H     Q V   PTAP  A  A 
10  K F      S C   V      I  
12  K F       I  Q  I       
13 I K F             PTAP  A  A 
14   F          V     T   
15 I K F               A  A 
18       P L N    V   PTAP     
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6.3 Discussion. 
 
 In the current study, drug-naive HIV-1-positive South African Black individuals, 
followed up at 6 monthly intervals, who required treatment based on CD4+ T cell counts 
declining to <350 cells/µl, were sub-selected for further investigation based on HLA class I 
genotype and the availability of two follow up plasma samples. Plasma samples stored prior 
to treatment were used for genetic characterisation of HIV-1 gag sequences. HLA-B*58:01 
and -B*58:02-positive participants were specifically selected for further study due to 
published reports that HLA-B*58:01 associates with early Gag responses and low viraemia, 
while HLA-B*58:02 associates with CTL responses to Env and rapid disease progression 
(Kiepiela et al., 2007, Ngumbela et al., 2008). However, HLA-B*58:01 carriage does not 
guarantee slow disease progression since it has been shown that CTL escape mutations that 
incur fitness costs to the virus can be overcome by compensatory mutations that restore viral 
replicative capacities (Chopera et al., 2011). In contrast uncontrolled viral replication 
associates with HLA-B*58:02, which is not known to mediate antiviral CTL responses to Gag 
and preferentially targets variable proteins such as Env. Importantly, other investigators have 
reported multiple immune mechanisms inhibiting HIV-1 replication including the additive 
effect of the other HLA class I alleles present in the individual’s repertoire (Leslie et al., 
2010, Sampathkumar et al., 2014), NK cell-mediated targeting of infected cells (Alter et al., 
2011) and the sensitivity of viral cores to the intrinsic antiretroviral factor, TRIM5α (Granier 
et al., 2013). It is the concerted effort of singular counter-measures mediated by adaptive and 
innate immune pressures on replicating virus, and the subsequent circumvention of these 
individual mechanisms, that determines the rate of disease progression. Via constant 
mutagenesis of viral proteins, HIV-1 reduces sensitivity to TRIM5α, evades NK cell 
detection and overcomes the debilitating effect of CTL escape mutations, particularly in Gag, 
that reduces viral fitness (Honeyborne et al., 2010, Crawford et al., 2007) by selecting 
compensatory mutations that restore viral replicative capacities. In addition, insertions in Gag 
can enhance viral budding, infectivity and replication kinetics (VerPlank et al., 2001), which 
in concert with immune evasion, further increases virus production. 
 
 An investigation of genetic alterations in HIV-1 gag sequences derived from viral 
RNA extracted from plasma virus in stored samples taken at baseline, 6 months or 12 months 
prior to initiation of antiretroviral therapy in HLA-B*58:01 and -B*58:02-positive 
progressors, was carried out. In agreement with previous reports, all HLA-B*58:01 carriers 
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demonstrated known CTL escape mutations in Gag epitopes, particularly the TW10 epitope, 
where the T242N mutation was present at baseline and subsequent time-points. This was not 
unexpected, since the study participants were in the late chronic stage of HIV-1 infection and 
T242N mutations have been reported to emerge as early as 2 weeks following acute infection, 
but usually within the first 3-4 months (Chopera et al., 2011). Mutations in other HLA-
B*58:01-restricted epitopes, such as ISW9 and QL9 were also detected, suggesting that even 
though T242N prevents recognition of the TW10 epitope, the continuation of HLA-B*58:01 
targeting of Gag, necessitates escape mutations in subdominant epitopes. Mutations in other 
HLA-B*58:01 epitopes were not observed in other similar studies (Chopera et al., 2011), 
however, the participants in the current study have most likely been infected for much longer 
than the follow up period of their study, allowing for more time for escape mutations to 
emerge. 
 
 In HLA-B*58:02 carriers, despite the similar binding motifs predicted, no consistent 
mutations were observed when known HLA-B*58:01-restricted epitopes were examined, in 
agreement with reports that there are no HLA-B*58:02-restricted epitopes present in Gag 
(Ngumbela et al., 2008). One HLA-B*58:02 carrier had escape mutations in ISW9 and 
TW10, but this was most likely genetic footprints of escape in a HLA-B*58:01 donor prior to 
transmission to this participant. As expected, no mutations were observed in the KF11 
epitope, consistent with a previous report that even though this epitope binds to HLA-
B*58:01, there is an intracellular block of access of the peptide to HLA-B*58:01 molecules 
prior to localisation to the cell membrane (Kloverpris et al., 2013b). 
 
 The additive effect of CTL pressure on Gag by other HLA class I molecules was well 
illustrated by analysis of the highly immunogenic p17Gag region between residues 70 and 92, 
containing several CTL epitopes (RY11, LY9, SL9, GY9, EV9 and TI9).  This region is 
targeted by numerous HLA class I molecules including HLA-A*30, -A*29/-B*44, -A*02, -
A*01, -B*08 and -A*11.  HLA-A*30, -A*29/-B*44, -A*02 alleles were all present in the 
study participants. R76K and Y79F were commonly detected mutations that mediate anchor 
residue changes, TCR contact changes or peptide processing interference. It was noted that 
R76K was only present in one HLA-B*58:01-positive individual, but reverted at 6 months, 
whereas 5 HLA-B*58:02 carriers had this change. The possibility exists that the Y79F 
mutation could have been induced by other HLA class I-mediated pressures, but was less 
tolerated in HLA-B*58:01 carriers, because the change potentially creates a new HLA-
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B*58:01-restricted epitope. These viral variants would therefore be quickly eliminated. Y79F 
may also create a new HLA-B*58:02-restricted epitope, however based on binding motif 
predictions, an arginine is required at position 76. The frequent occurrence of an R76K 
mutation in combination with Y79F in HLA-B*58:02 carriers provides speculation that the 
natural arginine at position 76 does generate a new HLA-B*58:02 epitope, that is 
subsequently overcome by a R76K change. Hence the two changes, Y79F and R76K, would 
provide escape from both additive HLA class I pressure as well as newly induced HLA-
B*58:02 responses as a consequence of Y79F. However, functional studies are required to 
confirm that HLA-B*58:01 and -B*58:02-restricted CTLs respond to this potential epitope. 
 
 A contributory factor to non-progression in HLA-B*58:01 carriers is the observation 
that this allele is often in linkage disequilibrium with other protective HLA class I alleles. In 
the current study, a significantly higher allele frequency of protective HLA class I alleles was 
observed in HLA-B*58:01 carriers compared to HLA-B*58:02 carriers (66.7% vs. 36.8%; 
p=0.0149; OR=3.257[1.329-7.984]). Leslie et al. reported improved HIV-1 control for the 
HLA-C*12:03-B*39:10 haplotype, which are both protective alleles (Leslie et al., 2010). This 
haplotype was found in one HLA-B*58:02 progressor, but may have been insufficient in 
controlling HIV-1 due to the development of escape mutations. An association of HLA-
A*30:02-B*45:01, -A*30:02-C*16:01, -B*53:01-C*04:01, -B*15:10-C*03:04 and -B*58:01-
C*03:02 haplotypes with accelerated disease progression has been reported (Sampathkumar 
et al., 2014). Both HLA-A*30:02-B*45:01 and -A*30:02-C*16:01 haplotypes were present in 
one HLA-B*58:02 carrier and although HLA-A*30:02 is a protective allele, both HLA-
B*45:01 and HLA-C*16:01 are deleterious alleles. Two HLA-B*58:02 carriers had the HLA-
B*53:01-C*04:01 haplotype while in HLA-B*58:01 carriers, one HLA-B*15:10-C*03:04 and 
two -B*58:01-C*03:02 haplotypes were detected. Taken together the additive protective 
effect of HLA class I genotype may be compromised in both HLA-B*58:01 and -B*58:02 
carriers, but more so in HLA-B*58:02 carriers due to linkage disequilibrium with other 
deleterious alleles.  
 
 Immune surveillance by NK cells augments the antiviral CTL responses in HIV-1 
infection. NK cell detection of HIV-1 infected cells is dependent on interaction of inhibitory 
or activating KIRs with HLA class I ligands. Interference with KIR3DL1 and KIR2DL2 
interaction by mutations at the 7th and 8th position of HIV-1 peptides bound to the HLA 
ligand molecules have been reported (Brackenridge et al., 2011, van Teijlingen et al., 2014). 
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The mechanism of escape from NK cell detection can be mediated by mutations in the 
peptide that either promote increased strength of binding to inhibitory receptors or reduced 
strength of binding to activating receptors and this has been noted for other KIRs (Alter et al., 
2011). Mutations in the 8th position of the TW10 epitope were detected in four HLA-B*58:01 
carriers, namely G248A and G248T, which have been shown to increase the binding affinity 
of KIR3DL1 to HLA-B*57 molecules (Brackenridge et al., 2011). HLA-B*58:01 and -
B*58:02 molecules are ligands of KIR3DL1 due to the presence of the Bw480I epitope. 
G248T and G248Q changes were noted in one and two respective HLA-B*58:02 carriers. 
These mutations possibly promote escape from KIR3DL1-mediated NK cell detection of 
virus-infected cells. Similarly, T303IAC mutations were present in the YL9 epitope which 
also interferes with KIR2DL2-mediated NK cell detection of HLA-C*03 ligands on infected 
cells (van Teijlingen et al., 2014). KIR2DL2 interacts with many HLA-C2 ligands, but the 
YL9 epitope is only restricted by HLA-B*15 and -C*03 (Masemola et al., 2004b, 
Honeyborne et al., 2010). One individual with a T303I mutation was HLA-C*03-positive 
suggesting escape from NK cell surveillance in this individual. T303IAC mutations are also 
reported to reduce viral fitness (Honeyborne et al., 2010), hence it was unexpected that these 
mutations were present in Gag from three individuals who did not carry HLA-B*15 or -C*03 
alleles. Either compensatory mutations were also present or interactions with other KIRs may 
be in effect. Both HLA-B*58:01 and -B*58:02 carriers had similar numbers of inhibitory 
KIRs, however the number of activating KIRs tended to be higher in HLA-B*58:01 carriers 
compared to HLA-B*58:02 carriers. NK cell responses to HIV-1 peptides have been shown to 
be associated with a more activating KIR repertoire in the presence of at least one HLA-C1 
allotype (Tiemessen et al., 2011). Notably, all 5 HLA-B*58:01 carriers were HLA-C1-positive 
compared to 8/13 (61.5%) in the HLA-B*58:02 group. This observation has implications of 
potential enhancement of NK cell mediated immune pressure on HIV-1 in HLA-B*58:01 
carriers, although this may not be true in all HLA-B*58:01 carriers, since KIR and HLA genes 
are not necessarily inherited together. There is, however, the possibility that immune escape 
from NK cell surveillance may have contributed to disease progression in the HLA-B*58:01 
carriers in the current study. 
 
 Interference with the activity of intrinsic antiretroviral factor TRIM5α was also 
detected. Three HLA-B*58:01 carriers demonstrated G248A mutations in combination with 
T242N together in the TW10 epitope. Recent work showing that the T242N mutation in 
combination with wild-type 248G renders the p24Gag capsid more sensitive to TRIM5α has 
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come to light (Granier et al., 2013). The G248A change reduces sensitivity to TRIM5α and 
may be an alternative escape mechanism that HIV-1 employs to escape from immune 
pressure at an early stage of the viral replication cycle. 
 
 In addition to the additive effects of other HLA class I alleles, NK cell activity and 
TRIM5α sensitivity that drive the selection of escape mutations, we also observed a 
propensity for the virus to select for changes in Gag that enhance viral production. It is 
known that compensatory mutations develop during the chronic stage of disease that can 
restore viral replicative capacity mediated by the T242N mutation in TW10 (Brockman et al., 
2010). Alternatively, compensatory mutations may be pre-existing at transmission as 
observed in a previous study (Chopera et al., 2011). This phenomenon of the accumulation of 
compensatory mutations in circulating virus over time at a population level has been 
observed in Botswana where the protective benefit of HLA-B*57 and -B*58:01 has been lost 
(Payne et al., 2014). In HLA-B*58:01-positive participants, the compensatory mutations, 
I223V, H219Q and M228I/L were present in 5/5, 1/5 and 2/5 individuals, respectively. 
Notably, I223V, H219Q and M228I/L was also found in 9/13, 3/13 and 3/13, respective HLA-
B*58:02 carriers. This finding suggests that these mutations were either pre-existing at 
transmission or that viral fitness compensatory mutations do not necessarily develop solely in 
response to low fitness escape mutations such as T242N in p24Gag TW10, but may represent a 
natural tendency for HIV-1 to increase replicative capacities in general. In further support of 
this, PTAP duplications in p6Gag are known to develop in subtype C viruses in order to 
enhance virus budding efficiency through the Tsg101-mediated pathway. PTAP duplications 
were more common in HLA-B*58:01 carriers, suggesting a greater necessity for an increase 
in virus production due to the higher fitness cost incurred by escape mutations, such as 
T242N. A priority to enhance viral budding efficiency, was further exemplified by the 
observation of a rare PYRE insertion in p6Gag that restores the ALIX-mediated budding 
pathway, not common in sub-Saharan subtype C viruses. This same sample appeared to have 
lost the first of the PTAP duplications in preference for the PYRE change. PTAP duplications 
were also observed HLA-B*58:02 carriers, but at a lower frequency. It is not known whether 
the PTAP duplications pre-existed or if they developed after infection. The duplication of the 
PTAP motif during the chronic stage was shown to occur in one HLA-B*58:02 carrier 
between baseline and 6 months. This implies that PTAP duplications are not necessarily 
inherited at transmission, but may evolve following immune pressure that possibly reduces 
viral fitness. In addition, changes introduced into p6Gag by PTAP duplications are reflected by 
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changes in the p6Pol transframe protein due to overlapping reading frames. The corresponding 
changes in p6Gag-Pol have been shown to enhance viral infectivity and replication kinetics, 
particularly in PBMCs, and this may serve as an additional mechanism to further increase 
virus production (Leiherer et al., 2009). 
 
 This study however has a number of limitations. Besides the small sample sizes 
used in this study, other limitations include the absence of analysis of mutations in other viral 
proteins, such as Nef, that contribute to CTL-mediated immune control. We focused on Gag 
because it has been established that early Gag targeting associates with better immune control 
(Kiepiela et al., 2007) and it has also emerged that early control of HIV-1 infection can be 
mediated by CTLs and TRIM5α that target p24Gag capsid proteins derived from incoming 
cores of infecting virions (Kloverpris et al., 2013a, Granier et al., 2013). We also did not 
analyse Gag mutations in HLA-B*58:01 and -B*58:02 carriers with non-progression of HIV-
1 disease, since we did not have access to samples from such individuals and due to lower 
viral loads, this may pose difficulties in amplifying gag sequences from plasma RNA. Lastly, 
there are many other host genetic factors besides HLA class I and KIR genotypes that can 
influence HIV-1 disease progression that we have not examined.  
 
 In conclusion, as others have shown, disease progression in HLA-B*58:01 carriers 
associates with the presence of CTL escape mutations in HLA-B*58:01-restricted Gag 
epitopes that may transiently confer a fitness cost to replicating virus, but are subsequently 
overcome by the development of compensatory mutations. Alternatively, compensatory 
mutations may already be present in transmitting virus. In contrast, HLA-B*58:02 carriers do 
not target Gag via HLA-B*58:02-restricted CTLs and therefore do not have the advantage of 
early immune control of HIV-1 replication. However, some additional observations can be 
added to this picture in terms of the contribution of escape mutations that impact on other 
antiviral pressures, including the additive effect of other HLA class I molecules, NK cell 
targeting and sensitivity to TRIM5α. Furthermore, increased virus production can also be 
mediated by selection of viral fitness compensatory mutations as well as insertions that 
enhance viral budding, infectivity and replication kinetics. It was observed that escape 
mutations from CTLs/NK cells and enhancements of viral production were more common in 
HLA-B*58:01-positive progressors than in HLA-B*58:02-positive progressors. Since HLA-
B*58:01 is more frequently in linkage with other protective HLA class I alleles, it is 
speculated that the increased CTL-mediated immune pressure on replicating virus resulted in 
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more frequent selection of escape mutations that incur viral fitness costs, necessitating 
genetic alterations in Gag to overcome these defects. However, in both HLA-B*58:01 and -
B*58:02 carriers, disease progression was likely a consequence of the combined influence of 
accumulating escape mutations from multiple immune targets as well as enhancing mutations 
that increase virus production. 
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Chapter 7:                                                    
Concluding remarks 
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 South Africa is a unique geographical region well suited for the study of the influence 
of immunogenetic variation on HIV-1 disease, since four distinct populations are present 
(SAI, SAM, SAC and SAB) and a single viral subtype predominates (subtype C HIV-1). For 
reasons unknown, HIV-1 prevalence is disproportionate between the populations. Low 
prevalence populations include the SAI, SAM and SAC populations (0.8%, 3.1% and 0.3%, 
respectively), while the SAB population has a high prevalence (15.0%). Naturally many host 
genetic differences are expected to be present between the populations, but if one set of host 
genes could be selected that differs even between individuals of the same population and is 
also integral in host defense against pathogens, it would be the HLA class I -A, -B and -C set 
of genes. These genes demonstrate the highest degrees of genetic heterogeneity in the human 
genome as evidenced by the number of allelic variants characterised (HLA-A alleles, n=2,995; 
HLA-B alleles, n=3,760 and HLA-C alleles, n=2,553), yet humans only carry two HLA-A, B 
and -C alleles. The encoded proteins are expressed on the surface of nucleated cells and bind 
small peptide antigens derived from proteins processed in the cytoplasm. HLA class I 
molecules serve as ligands for three different receptors expressed by cells of the immune 
system. Interaction with the T cell receptor and CD8 molecule modulates CTL activity, 
interaction with KIRs modulates NK cell activity and interaction with leukocyte 
immunoglobulin-like receptors (LILRs) modulates the activation of antigen presenting cells 
(macrophages and dendritic cells). Allelic variants of HLA class I molecules have different 
peptide antigen specificities which modulates CTL activity and different binding affinities for 
KIRs and LILRs, likewise modulates NK cell and antigen presenting cell activities. These 
differences can translate into variation in disease susceptibility or severity. An additional role 
for HLA class I molecules in precipitating immune hypersensitivity reactions to antiretroviral 
drugs in susceptible individuals has been shown. 
 
 Whereas many genotypic characterisation studies have been done in the SAC and 
SAB populations, the SAI and SAM populations are relatively understudied and there is 
therefore a lack of HLA class I genotypic information for these populations. New data was 
generated for the SAI and SAM populations containing the frequencies of important 
immunogenetic factors such as HLA class I genotypes as well as other host genetic factors 
reported to influence HIV-1 acquisition or viral load, including the CCR5Δ32 variant, KIR 
genotypes, HLA-Bw480I/Bw480T/C1/C2 ligands, HLA-C 3’UTR +263 insertion/deletion 
variants and the p2-M/T variant of the HLA-B signal peptide. Data available for the SAC and 
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SAB populations were included for comparative purposes. Generating the data for these 
populations also presented the opportunity for novel assays to be designed such as the real-
time PCR assay for the determination of CCR5Δ32 genotypes and for existing real-time PCR 
assays to be modified and improved such as the KIR genotyping assay and HLA-
Bw480I/Bw480T/C1/C2 ligand assay. 
 
  There is a rich diversity in the HLA class I alleles detected in the SAI, SAM, SAC and 
SAB populations. At the HLA-A, -B and -C loci, 42, 61 and 38 different alleles were detected. 
The presence of specific HLA class I alleles such as HLA-B*57:01 that associates with 
immune hypersensitivity reaction to abacavir and HLA-B*35:05, -C*04 and -C*08 that are 
associated with immune hypersensitivity reaction to nevirapine could be determined from the 
data collected. HLA-B*57:01 was prevalent with allele frequencies of  8.0%, 12.0% and 8.2% 
in SAM, SAI and SAC individuals, respectively and absent in the SAB population, while 
HLA-B*35:05 was present in 6.0% and 1.0% in SAM and SAC populations, respectively and 
absent in SAC and SAB populations. HLA-C*04 was present at frequencies of 22.0%, 24.0%, 
18.6% and 23.7% in SAM, SAI, SAC and SAB populations, respectively, while HLA-C*08 
was present at frequencies of 10.0%, 8.0%, 6.9% and 10.2% in SAM, SAI, SAC and SAB 
populations, respectively. The number of HIV-1 infected South Africans potentially at risk of 
developing ABC IHR and NVP IHR, was estimated at 14,235 and 2,212,700 people, 
respectively, from the known allele frequencies and available demographic data for the South 
African population. Since treatment of HIV-1 infected individuals is underway on a large 
scale in South Africa and both ABC and NVP are in current use, the substantial number of 
individuals that may be at risk warranted the development of a novel real-time AS-PCR assay 
for the detection of the alleles associated with immune hypersensitivity reaction. 
 Susceptibility and resistance to HIV-1 infection has been associated with particular 
HLA class I alleles and specific HLA class I alleles have also been shown to associate with 
HIV-1 viral load. However, even though singular alleles can be classified as favourable or 
deleterious, humans carry 6 HLA class I alleles and therefore the impact on immunity must be 
additive. To address this, a scoring system was used to determine whether the HLA class I 
allelic variants present in an individual were cumulatively protective, deleterious or neutral. 
This was done for HLA class I alleles reported to be associated with either susceptibility or 
resistance to HIV-1 infection and also for alleles reported to be associated with a high or a 
low viral load. The analysis showed no significant differences between the populations for 
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overall HLA genotypes considered resistant (44.0%, 32.0%, 39.4% and 30.2% in SAI, SAM, 
SAC and SAB populations, respectively), however, the frequency of overall HLA genotypes 
considered susceptible was significantly higher in the SAB population compared to the other 
populations (32.0%, 46.0%, 40.4% and 57.9% in SAI, SAM, SAC and SAB populations, 
respectively). For genotypes associated with viral load, the analysis determined that overall 
HLA genotypes associated with a low viral load was significantly higher in the SAI 
population compared to the other populations (66.0%, 44.0%, 39.4% and 40.3% in SAI, 
SAM, SAC and SAB populations, respectively, while overall HLA genotypes associated with 
a high viral load were significantly lower in the SAI population compared to the other 
populations (16.0%, 24.0%, 33.0% and 29.6% in SAI, SAM, SAC and SAB populations, 
respectively). This result on its own suggested that based on HLA class I genotype, the SAB 
population is the most susceptible to HIV-1 infection, and that the SAI population has the 
lowest likelihood of transmitting HIV-1 due to genotypes associated with low viral loads. 
However, the effects of other host genetic factors in modulating HIV-1 susceptibility or viral 
load were not considered. 
 Additional genes or gene combinations reported to be associated with HIV-1 
acquisition/viral load were included in a broader cumulative analysis incorporating HLA class 
I genotype, KIR genotype, CCR5Δ32 variants, HLA-Bw480I/Bw480T/C1/C2 ligands, HLA-C 
3’UTR +263 insertion/deletion variants and the p2-M/T variant of the HLA-B signal peptide. 
Results from this regarding HIV-1 acquisition suggested that the SAB population may be 
significantly more susceptible to HIV-1 infection in comparison to the SAI population (SAB 
vs. SAI, 42.8% vs. 14.0%, p=0.0002), while the SAI population may be significantly more 
resistant to HIV-1 infection in comparison to the SAB population (SAI vs. SAB, 68.0% vs. 
31.4%, p<0.0001). Similarly, results regarding HIV-1 VLS suggested that in the SAB 
population, significantly more individuals with overall genotypes associated with high HIV-1 
VLS may be present compared to the SAI population (SAB vs. SAI, 59.7% vs. 30.0%, 
p=0.0003) and significantly more individuals with genotypes associated with low HIV-1 VLS 
may be present in the SAI population in comparison to the SAB population (SAI vs. SAB, 
48.0% vs. 13.2%, p<0.0001). Based on extrapolation from data analysed in healthy 
individuals, it was concluded that host genetic differences regarding HIV-1 
resistance/susceptibility and high/low VLS may contribute to the differential HIV-1 
prevalence rates seen in the four South African populations. This hypothesis naturally 
requires further testing in HIV-1 infected populations for verification.  
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 The contribution of host genotype to the immune response directed towards HIV-1, 
once infected, is only representative of a component of the complex and dynamic relationship 
between the host and the virus and the influence of environmental factors. The role of HLA 
class I molecules in mediating viral evolution was studied in HIV-1 infected individuals, in 
the context of two alleles, HLA-B*58:01 and -B*58:02, found in all of the populations, but 
most common in the SAB population. HLA-B*58:01 is present at allele frequencies of 5.0%, 
2.0%, 2.1% and 8.8% in SAI, SAM, SAC and SAB populations, respectively, while HLA-
B*58:02 is present at allele frequencies of 1.0%, 5.0%, 0.5% and 9.4% in SAI, SAM, SAC 
and SAB populations, respectively. Many studies show that HLA-B*58:01 is a protective 
allele associated with low viral load and higher CD4+ T cell count, while HLA-B*58:02 
associates with fast disease progression. However, unlike the presence of HLA class I alleles 
that are positively predictive of adverse drug reactions, carriage of HLA-B*58:01 or -B*58:02 
does not necessarily serve as an absolute predictor of slow or fast disease progression. HLA-
B*58:01 can be present in individuals who do not present with low viral load and higher 
CD4+ T cell counts. It appears that all untreated HIV-1-positive individuals ultimately reach 
the stage of disease when treatment is required, but it is the time period that is variable. Since 
viral mutagenesis causes the host immune response to become compromised, it is the host 
genetic makeup, particularly HLA class I genotype, which dictates the length of time the virus 
takes to accumulate the genetic alterations necessary to overwhelm the host. 
 
 To establish whether patterns of immune escape might be different between HLA-
B*58:01 and -B*58:02-positive individuals at the stage of disease when treatment is required, 
mutations in the Gag protein were investigated in HLA-B*58:01 (n=5) and -B*58:02 (n=13) 
carriers from an untreated HIV-1 infected SAB cohort. Gag sequences were generated from 
viral RNA extracted from plasma samples at baseline, 6 months and 12 months that were 
available prior to initiation of treatment. The study presented an opportunity for the novel 
design of the PCR primers needed for reverse transcription of viral RNA, DNA PCR and 
sequencing of the gag gene. An analysis of deduced Gag protein sequences was done to 
identify amino acid changes. Epitopes known to be targeted by HLA-B*58:01-restricted 
CTLs were examined and mutations were identified in the ISW9, TW10, YL9 and QW9 
epitopes in p24Gag. No HLA-B*58:02-restricted CTL epitopes were evident. CTL escape 
mutations often reduce viral replicative capacity and known compensatory mutations, 
H219Q, I223 and M228I/L in p24Gag were detected in both HLA-B*58:01 and -B*58:02 
carriers. As other investigators have shown previously, disease progression in HLA-B*58:01 
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carriers associates with the presence of CTL escape mutations in HLA-B*58:01-restricted 
Gag epitopes and these changes are accompanied by compensatory mutations that restore 
viral fitness, while in contrast, HLA-B*58:02 carriers do not target Gag. Escape mutations in 
other HLA class I-restricted epitopes were present in p17Gag in both HLA-B*58:01 and -
B*58:02 carriers illustrating the additive effect of immune pressure by other HLA class I 
molecules, but these responses were subsequently lost. Mutations in the p24Gag TW10 epitope 
that affects KIR3DL1 binding and mutations in the YL9 epitope that affects KIR2DL2 were 
present in both HLA-B*58:01 and -B*58:02 carriers and may represent escape mutations 
from NK cells. In general, escape mutations from CTLs/NK cells were more frequent in 
HLA-B*58:01 progressors than in HLA-B*58:02 progressors. This is possibly due to the more 
frequent linkage of HLA-B*58:01 with other protective HLA class I alleles. Due to increased 
CTL-mediated immune pressure, more frequent selection of CTL escape mutations that 
impose fitness costs may occur, necessitating genetic alterations in Gag to overcome these 
defects. Although the duration of infection was not known, in both HLA-B*58:01 and -
B*58:02 carriers, disease progression was likely a consequence of accumulating mutations 
mediating escape from multiple immune targets. 
 
 In conclusion, the information presented in this thesis gives a broader insight into the 
immune mechanisms influencing HIV-1 acquisition and VLS determination and 
demonstrates how protective/deleterious immunogenetic factors can vary between 
populations. Extrapolation from studies in healthy populations suggested that host genetic 
differences between populations may affect HIV-1 prevalence. The importance of HLA class 
I alleles associated with immune hypersensitivity was highlighted. Lastly, the protective 
effect of HLA class I alleles associated with slow disease progression were shown to be lost 
due to viral escape mutations and allelic variation may simply influence the time it takes to 
progress. The data presented here could be useful for the development of novel epitope-based 
vaccines that take advantage of both innate and adaptive immune defense mechanisms, 
however host genetic differences between the populations in South Africa must be 
considered.   
  
  
164 
 
Appendices 
 
Appendix A 
 
 
165 
 
Appendix B 
List of studies associating HLA class I alleles with HIV-1 acquisition. 
HLA-A Study Country 
01 Peterson et al., 2013 Kenya 
01:01 Liu et al., 2012; Koehler et al., 2010; Mori et al., 2014 China; Tanzania; Thailand 
02 Shankarkumar et al., 2009; Singh et al., 2008 India; India 
02:01 Singh et al., 2008; Koehler et al., 2010 India; Tanzania 
02:02 Koehler et al., 2010; Macdonald et al., 2000 Tanzania; Kenya 
02:05 Koehler et al., 2010; Macdonald et al., 2000 Tanzania; Kenya 
02:11 Shankarkumar et al., 2012 India 
02:14 Macdonald et al., 2000 Kenya 
03 Zhang et al., 2013 China 
03:01 Koehler et al., 2001; Liu et al., 2012 Tanzania; China 
11 Beyrer et al., 1999; Selvaraj et al., 2006; Sriwanthana et al., 2001 Thailand; India; Thailand 
11:01 Raghavan et al., 2009; Sriwanthana et al., 2001 Thailand; Thailand; India; Thailand 
23:01 Peterson et al., 2013; Macdonald et al., 2000; Koehler et al., 2010; Olvera 
et al., 2015 
Kenya; Kenya; Tanzania; Peru 
24 Singh et al., 2008 India 
24:02 Macdonald et al., 2000 Kenya 
24:07 Umapathy et al., 2007 India 
29:02 Koehler et al., 2010 Tanzania 
30:01 Koehler et al., 2010 Tanzania 
30:02 Koehler et al., 2010 Tanzania 
31 Figueiredo et al., 2008 Brazil 
32 Habegger et al., 2013 Argentina 
32:04 Umapathy et al., 2007 India 
34:02 Koehler et al., 2010 Tanzania 
36 Tang et al., 2008 Zambia 
36:01 Koehler et al., 2010; Tang et al., 2008 Tanzania; Zambia 
66:01 Koehler et al., 2010 Tanzania 
68:01 Shankarkumar et al., 2003; Umapathy et al., 2007 India; India 
68:02 Macdonald et al., 2000; Song et al., 2011; Koehler et al., 2010 Kenya; Zambia; Tanzania 
74:01 Koehler et al., 2010 Tanzania 
HLA-B Study Country 
07 Xu et al., 2004 China 
07:02 Peterson et al., 2013; Koehler et al., 2010 Kenya; Tanzania 
07:05 Peterson et al., 2013 Kenya 
08:01 Shankarkumar et al., 2012; Koehler et al., 2010; Shankarkumar et al., 
2009 
India; Tanzania; India 
08:04 Shankarkumar et al., 2009 India 
13 Zhang et al., 2013 China 
13:01 Shankarkumar et al., 2003 India 
14 Song et al., 2011 Zambia 
15 Umapathy et al., 2007 India 
15:01 Liu et al., 2012; Huang et al., 2009; Umapathy et al., 2007 China; China; India 
15:03 Koehler et al., 2007 Tanzania 
15:10 Koehler et al., 2007 Tanzania 
18 Beyrer et al., 1999; Chaudhari et al., 2013 Thailand; India 
18:01 Chaudhari et al., 2013; Macdonald et al., 2000; Shankarkumar et al., 
2003; Koehler et al., 2010 
India; Kenya; India; Tanzania 
27 Gao et al., 2010 USA/Europe 
35 Chaudhari et al., 2013; Gao et al., 2010; Keynan et al., 2015; Singh et al., 
2008; Umapathy et al., 2007; Xu et al., 2004 
India; USA/Europe; Canada; India; 
India; China 
35:01 Koehler et al., 2010; Peterson et al., 2013 China; Tanzania; Kenya 
35:02 Peterson et al., 2013 China; Kenya 
35:03 Peterson et al., 2013 China; Kenya 
35:20 Shankarkumar et al., 2003; Umapathy et al., 2007 India; India 
35:43 Olvera et al., 2015 Peru 
37 Huang et al., 2009 China 
39 Chaudhari et al., 2013 India 
40 Chaudhari et al., 2013; Selvaraj et al., 2006 India; India 
40:01 Chaudhari et al., 2013; Shankarkumar et al., 2003;  India; India 
40:02 Olvera et al., 2015 Zimbabwe 
40:06 Chaudhari et al., 2013; Raghavan et al., 2009 India; India 
41 Figueiredo et al., 2008 Brazil 
42:01 Peterson et al., 2013; Song et al., 2011; Koehler et al., 2010 Kenya; Zambia; Tanzania 
44 Habegger et al., 2013; Song et al., 2011; Xu et al., 2004 Argentina; China 
44:02 Chaudhari et al., 2013 India 
45:01 Koehler et al., 2010 Tanzania 
50:01 Chaudhari et al., 2013 India 
46 Huang et al., 2009; Xu et al., 2004 China; China 
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49:01 Koehler et al., 2010 Tanzania 
51 Peterson et al., 2013; Keynan et al., 2015; Singh et al., 2008; Song et al., 
2011; Umapathy et al., 2007 
Kenya; Canada; India; Zambia; India 
51:01 Liu et al., 2012; Shankarkumar et al., 2012; Umapathy et al., 2007;  
Shankarkumar et al., 2009 
China; India; India; India 
51:02 Shankarkumar et al., 2009 India 
51:04 Shankarkumar et al., 2009 India 
52 Huang et al., 2009 China 
52:01 Liu et al., 2012; Shankarkumar et al., 2009 China; India 
53 Gao et al., 2010 USA/Europe 
53:01 Koehler et al., 2010; Peterson et al., 2013 Tanzania; Kenya 
54:01 Shankarkumar et al., 2009 India 
55 Xu et al., 2004 China 
55:01 Habegger et al., 2013; Shankarkumar et al., 2012; Shankarkumar et al., 
2009 
Argentina; India; India 
55:02 Shankarkumar et al., 2009 India 
56:01 Peterson et al., 2013; Shankarkumar et al., 2012; Shankarkumar et al., 
2009; Umapathy et al., 2007 
Kenya; India; India; India 
56:03 Shankarkumar et al., 2009 India 
56:04 Shankarkumar et al., 2009 India 
57 Gao et al., 2010; Tang et al., 2008 USA/Europe; Zambia 
57:01 Umapathy et al., 2007; Shankarkumar et al., 2012; Shankarkumar et al., 
2009 
India; India; India 
57:02 Shankarkumar et al., 2009 India 
57:03 Koehler et al., 2010; Olvera et al., 2015 Tanzania; Peru 
57:04 Shankarkumar et al., 2009 India 
58:01 Koehler et al., 2010; Shankarkumar et al., 2009 Tanzania; India 
58:02 Tang et al., 2010; Koehler et al., 2010; Shankarkumar et al., 2009 Zambia; Tanzania; India 
67 Huang et al., 2009 China 
78 Xu et al., 2004 China 
81:01 Koehler et al., 2010 Tanzania 
HLA-C Study Country 
02:10 Peterson et al., 2013; Koehler et al., 2010 Kenya; Tanzania 
03 Zhang et al., 2013 China 
03:04 Koehler et al., 2010 Tanzania 
04:01 Koehler et al., 2010 Tanzania 
05:01 Umapathy et al., 2007 India 
06 Zhang et al., 2013 China 
06:02 Peterson et al., 2013; Koehler et al., 2010 Kenya; Tanzania 
07:01 Peterson et al., 2013; Koehler et al., 2010 Kenya; Tanzania 
07:02 Koehler et al., 2010; Peterson et al., 2013 Tanzania; Kenya 
07:04 Koehler et al., 2010 Tanzania 
08:01 Umapathy et al., 2007 India 
08:02 Koehler et al., 2010 Tanzania 
12:02 Umapathy et al., 2007 India 
15 Umapathy et al., 2007 India 
15:02 Liu et al., 2012 China 
15:07 Shankarkumar et al., 2003; Umapathy et al., 2007 India; India 
16:01 Koehler et al., 2010 Tanzania 
17:01 Koehler et al., 2010 Tanzania 
18 Tang et al., 2008 Zambia 
18:01 Tang et al., 2010; Koehler et al., 2010 Zambia; Tanzania 
18:02 Tang et al., 2010 Zambia 
Black ink = resistant; red ink = susceptible; yellow highlight = study shows opposite association; HLA, human leukocyte antigen. 
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Appendix C 
List of studies associating HLA class I alleles with viral load setpoint in HIV-1 infection. 
HLA-A Study Country 
01 Kiepiela et al., 2004; Leslie et al., 2010; Naruto et al., 
2012; Zhang et al., 2013 
RSA; RSA; Japan; China 
01:01 Kiepiela et al., 2004; Leslie et al., 2010; Naruto et al., 
2012; Mori et al., 2014 
RSA; RSA; Japan; Thailand 
02:01 Leslie et al., 2010; Naruto et al., 2012; Kiepiela et al., 
2004; Mori et al., 2014; Novitsky et al., 2003; Olvera et 
al., 2015; Zhang et al., 2013 
RSA; Japan; RSA; Thailand; Botswana; Peru; China 
02:02 Novitsky et al., 2003 Botswana 
02:03 Novitsky et al., 2003; Mori et al., 2014 Botswana; Thailand 
02:04 Novitsky et al., 2003 Botswana 
02:05 Novitsky et al., 2003; Leslie et al., 2010; Kiepiela et al., 
2004; Saathof et al., 2010 
Botswana; RSA; RSA; Tanzania 
02:06 Novitsky et al., 2003; Naruto et al., 2012; Mori et al., 
2014 
Botswana; Japan; Thailand 
02:07 Novitsky et al., 2003; Mori et al., 2014; Naruto et al., 
2012 
Botswana; Thailand; Japan 
02:22 Olvera et al., 2015 Peru 
03 Matthews et al., 2012; Zhang et al., 2013 RSA/Botswana; China 
03:01 Carlson et al., 2012; Kiepiela et al., 2004 RSA/Botswana/Malawi/Zimbabwe; RSA 
11 Zhang et al., 2013 China 
11:01 Mori et al., 2014; Naruto et al., 2012; Olvera et al., 2015 Thailand; Japan; Peru 
11:02 Mori et al., 2014 Thailand 
23 Zhang et al., 2013 China 
23:01 Kiepiela et al., 2004; Novitsky et al., 2003; Mackelprang 
et al., 2015 
RSA; Botswana; 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
24 Zhang et al., 2013 China 
24:02 Kiepiela et al., 2004; Naruto et al., 2012; Mori et al., 
2014; Novitsky et al., 2003 
RSA; Japan; Thailand; Botswana 
24:03 Novitsky et al., 2003 Botswana 
24:04 Novitsky et al., 2003 Botswana 
24:07 Mori et al., 2014 Thailand 
24:10 Mori et al., 2014 Thailand 
25 Int. HIV controllers study et al., 2010; Catano et al., 
2008 
USA/Europe; USA 
26 Zhang et al., 2013 China 
26:01 Leslie et al., 2010; Naruto et al., 2012; Mori et al., 2014 RSA; Japan; Thailand 
26:02 Naruto et al., 2012 Japan 
26:03 Naruto et al., 2012 Japan 
29 Kiepiela et al., 2004; Tang et al., 2010; Zhang et al., 
2013 
RSA; Zambia; China 
30 Zhang et al., 2013 China 
30:01 Carlson et al., 2012; Kiepiela et al., 2004; Mori et al., 
2014; Novitsky et al., 2003; Mackelprang et al., 2015 
RSA/Botswana/Malawi/Zimbabwe; RSA; Thailand; 
Botswana; 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
30:02 Carlson et al., 2012; Kiepiela et al., 2004; Novitsky et 
al., 2003 
RSA/Botswana/Malawi/Zimbabwe; RSA; Botswana 
30:03 Novitsky et al., 2003 Botswana 
30:04 Leslie et al., 2010 RSA 
31 Zhang et al., 2013 China 
31:01 Carlson et al., 2012; Naruto et al., 2012; Mori et al., 
2014 
RSA/Botswana/Malawi/Zimbabwe; Japan; Thailand 
32 Zhang et al., 2013 China 
32:01 Lazaryan et al., 2011; Mori et al., 2014 USA(African-American); Thailand 
33 Zhang et al., 2013 China 
33:03 Leslie et al., 2010; Matthews et al., 2012; Carlson et al., 
2012; Naruto et al., 2012; Mori et al., 2014; Olvera et al., 
2015; Mackelprang et al., 2015 
RSA, RSA/Botswana; 
RSA/Botswana/Malawi/Zimbabwe; 
Japan; Thailand; Peru; 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
34:01 Mori et al., 2014; Catano et al., 2008 Thailand; USA 
34:02 Carlson et al., 2012; Leslie et al., 2010; Kiepiela et al., 
2004 
RSA/Botswana/Malawi/Zimbabwe; 
RSA; RSA 
36 Tang et al., 2008; Tang et al., 2010; Zhang et al., 2013 Zambia; Zambia; China 
36:01 Carlson et al., 2012; Tang et al., 2002 RSA/Botswana/Malawi/Zimbabwe; Zambia 
43:01 Kiepiela et al., 2004; Catano et al., 2008 RSA; USA(Caucasian) 
66 Kiepiela et al., 2004; Matthews et al.; 2012; Zhang et al., 
2013 
RSA; RSA/Botswana; China 
66:01 Leslie et al., 2010; Carlson et al., 2012; Catano et al., 
2008 
RSA, RSA/Botswana/Malawi/Zimbabwe; USA(Caucasian) 
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66:03 Carlson et al., 2012 RSA/Botswana/Malawi/Zimbabwe 
68 Tang et al., 2002; Zhang et al., 2013 Zambia; China 
68:01 Leslie et al., 2010; Matthews et al., 2012; Kiepiela et al., 
2004; Carlson et al., 2012; Mori et al., 2014 
RSA; RSA/Botswana; RSA; 
RSA/Botswana/Malawi/Zimbabwe; Thailand 
68:02 Novitsky et al., 2003; Kiepiela et al., 2004 Botswana; RSA 
69 Zhang et al., 2013 China 
69:01 Novitsky et al., 2003 Botswana 
74 Mathews et al., 2012; Tang et al., 2010 RSA/Botswana; Zambia 
74:01 Carlson et al., 2012; Kiepiela et al., 2004; Lazaryan et 
al., 2011; Mori et al., 2014 
RSA/Botswana/Malawi/Zimbabwe; RSA; USA(African-
American); Thailand 
80 Mathews et al., 2012 RSA/Botswana 
HLA-B Study Country 
07 Emu et al., 2008 USA 
07:02 Geldmacher et al., 2007; Leslie et al., 2010; Kiepiela et 
al., 2004; Naruto et al., 2012; Mclaren et al., 2012 
Tanzania; RSA, 
RSA; Japan; USA(African-American) 
07:05 Leslie et al., 2010; Mclaren et al., 2012; Mori et al., 2014 RSA; USA(African-American); Thailand 
08 Matthews et al., 2012 RSA/Botswana 
08:01 Leslie et al., 2010; Kiepiela et al., 2004; Carlson et al., 
2012; Mclaren et al., 2012; Mori et al., 2014; Olvera et 
al., 2015 
RSA; RSA; 
RSA/Botswana/Malawi/Zimbabwe; USA(African-American); 
Thailand; Peru 
13 Emu et al., 2008; Honeyborne et al., 2007; Mathews et 
al., 2012; Tang et al., 2002; Tang et al., 2010; Zhang et 
al., 2013 
USA; RSA; RSA/Botswana; Zambia; Zambia; China 
13:01 Brockman et al., 2010; Leslie et al., 2010; Naruto et al., 
2012; Mori et al., 2014 
USA/Australia/Germany; RSA; Japan; Thailand 
13:02 Mclaren et al., 2012; Mori et al., 2014 USA(African-American); Thailand 
14 Kiepiela et al., 2004; Lazaryan et al., 2011; Mathews et 
al., 2012 
RSA; USA(African-American); RSA/Botswana 
14:01 Lazaryan et al., 2011; Mathews et al., 2012; Novitsky et 
al., 2003; Mclaren et al., 2012; Mackelprang et al., 2015 
USA(African-American); RSA/Botswana; Botswana; 
USA(African-American); 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
14:02 Lazaryan et al., 2011; Mathews2012; Novitsky2003; 
Mclaren et al., 2012; Mori et al., 2014 
USA(African-American); RSA/Botswana; Botswana; 
USA(African-American); Thailand 
15:01 Mathews et al., 2012; Naruto et al., 2012; Mori et al., 
2014; Mclaren et al., 2012; Olvera et al., 2015 
RSA/Botswana; Japan; Thailand; USA(African-American); 
Peru 
15:02 Mori et al., 2014 Thailand 
15:03 Novitsky et al., 2003; Geldmacher et al., 2007; Leslie et 
al., 2010; Kiepiela et al., 2004; Saathof et al., 2010; 
Frahm et al., 2006; Mathews et al., 2012; Mclaren et al., 
2012 
Botswana; Tanzania; RSA; 
RSA; Tanzania; USA/RSA; 
RSA/Botswana; USA(African-American) 
15:04 Mori et al., 2014 Thailand 
15:07 Mori et al., 2014 Thailand 
15:09 Novitsky et al., 2003 Botswana 
15:10 Novitsky et al., 2003; Leslie et al., 2010; Kiepiela et al., 
2004; Mathews et al., 2012; Mclaren et al., 2012 
Botswana; RSA; RSA; 
RSA/Botswana; USA(African-American) 
15:11 Naruto et al., 2012 Japan 
15:12 Mori et al., 2014 Thailand 
15:16 Frahm et al., 2005; Carlson et al., 2012; Lazaryan et al., 
2006; Mclaren et al., 2012; Novitsky et al., 2003; Olvera 
et al., 2015 
USA/RSA; RSA/Botswana/Malawi/Zimbabwe 
Zambia/Rwanda; USA(African-American); Botswana; Peru 
15:17 Frahm et al., 2005; Carlson et al., 2012; Lazaryan et al., 
2006; Novitsky et al., 2003 
USA/RSA; RSA/Botswana/Malawi/Zimbabwe 
Zambia/Rwanda; Botswana 
15:18 Naruto et al., 2012; Novitsky et al., 2003 Japan; Botswana 
15:21 Mori et al., 2014 Thailand 
15:25 Mori et al., 2014 Thailand 
15:27 Mori et al., 2014 Thailand 
15:35 Mori et al., 2014 Thailand 
16 Mathews et al., 2012 RSA/Botswana 
18 Kiepiela et al., 2004; Li et al., 2014; Matthews et al., 
2012; Novitsky et al., 2003 
RSA; Kenya/Rwanda/Uganda/Zambia; RSA/Botswana; 
Botswana 
18:01 Carlson et al., 2012; Geldmacher et al., 2007; Leslie et 
al., 2010; Saathof et al., 2010; Mclaren et al., 2012; Mori 
et al., 2014; Olvera et al., 2015 
RSA/Botswana/Malawi/Zimbabwe; Tanzania; RSA; 
Tanzania; USA(African-American); Thailand; Peru 
18:02 Mori et al., 2014 Thailand 
24:02 Mori et al., 2014 Thailand 
24:07 Gao et al., 2010 USA/Europe 
24:10 Mori et al., 2014 Thailand 
26:01 Mori et al., 2014 Thailand 
27 Gao et al., 2010 USA/Europe 
27:01 Novitsky et al., 2003 Botswana 
27:02 Novitsky et al., 2003 Botswana 
27:03 Novitsky et al., 2003; Mackelprang et al., 2015 Botswana; 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
27:04 Novitsky et al., 2003; Mori et al., 2014 Botswana; Thailand 
27:05 Novitsky et al., 2003; Gao et al., 2010; Int. HIV Botswana; USA/Europe; USA/European; USA(African-
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controllers study et al., 2010; Mclaren et al., 2012 American) 
27:06 Novitsky et al., 2003; Mori et al., 2014 Botswana; Thailand 
27:07 Novitsky et al., 2003 Botswana 
27:08 Novitsky et al., 2003 Botswana 
33 Mathews et al., 2012 RSA/Botswana 
34:01 Mori et al., 2014 Thailand 
35 Gao et al., 2010; Int. HIV controllers study et al., 2010 USA/Europe; USA/Europe 
35:01 Carlson et al., 2012; Lazaryan et al., 2011; Naruto et al., 
2012; Mclaren et al., 2012; Mori et al., 2014; Olvera et 
al., 2015 
RSA/Botswana/Malawi/Zimbabwe; 
USA(African-American); Japan; USA(African-American); 
Thailand; Peru 
35:02 Carlson et al., 2012; Lazaryan et al., 2011 RSA/Botswana/Malawi/Zimbabwe; 
USA(African-American) 
35:03 Carlson et al., 2012; Lazaryan et al., 2011; Mori et al., 
2014 
RSA/Botswana/Malawi/Zimbabwe; Thailand 
USA(African-American) 
35:05 Carlson et al., 2012; Lazaryan et al., 2011; Mori et al., 
2014; Olvera et al., 2015 
RSA/Botswana/Malawi/Zimbabwe; 
USA(African-American); Thailand; Peru 
35:09 Olvera et al., 2015 Peru 
37:01 Novitsky et al., 2003; Mclaren et al., 2012; Naruto et al., 
2012 
Botswana; USA(African-American); Japan 
38:01 Novitsky et al., 2003 Botswana 
38:02 Novitsky et al., 2003; Mori et al., 2014 Botswana; Thailand 
39 Mathews et al., 2012; Tang et al., 2002 RSA/Botswana; Zambia 
39:01 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
39:02 Novitsky et al., 2003 Botswana 
39:03 Novitsky et al., 2003; Olvera et al., 2015 Botswana; Peru 
39:04 Novitsky et al., 2003 Botswana 
39:06 Tang et al., 2002 Zambia 
39:10 Mathews et al., 2012; Tang et al., 2002; Leslie et al., 
2010; Carlson et al., 2012; Mclaren et al., 2012 
RSA/Botswana; Zambia; RSA; 
RSA/Botswana/Malawi/Zimbabwe; USA(African-American) 
39:13 Olvera et al., 2015 Peru 
39:14 Olvera et al., 2015 Peru 
40:01 Mori et al., 2014; Naruto et al., 2012; Mclaren et al., 
2012; Novitsky et al., 2003 
Thailand; Japan; USA(African-American); Botswana 
40:02 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
40:04 Olvera et al., 2015 Peru 
40:06 Mori et al., 2014; Naruto et al., 2012; Novitsky et al., 
2003 
Thailand; Japan; Botswana 
41 Tang et al., 2002 Zambia 
41:01 Leslie et al., 2010; Novitsky et al., 2003 RSA; Botswana 
41:02 Mclaren et al., 2012 USA(African-American) 
42 Matthews et al., 2012 RSA/Botswana 
42:01 Leslie et al., 2010; Matthews et al., 2012; Kiepiela et al., 
2004; Carlson et al., 2012; Saathof et al., 2010; Mclaren 
et al., 2012 
RSA; RSA/Botswana; RSA; 
RSA/Botswana/Malawi/Zimbabwe; 
Tanzania; USA(African-American) 
42:02 Mclaren et al., 2012 USA(African-American) 
44 Matthews et al., 2012 RSA/Botswana 
44:02 Zhang et al., 2013; Mclaren et al., 2012; Novitsky et al., 
2003 
China; USA(African-American); Botswana 
44:03 Leslie et al., 2010; Kiepiela et al., 2004; Carlson et al., 
2012; Zhang et al., 2013; Naruto et al., 2012; Mclaren et 
al., 2012; Mori et al., 2014; Novitsky et al., 2003 
RSA; RSA; 
RSA/Botswana/Malawi/Zimbabwe; China; Japan; 
USA(African-American); Thailand; Botswana 
44:05 Zhang et al., 2013 China 
44:29 Zhang et al., 2013 China 
45 Lazaryan et al., 2011; Li et al., 2014; Matthews et al., 
2012; Tang et al., 2002; Tang et al., 2010 
USA(African-American); Kenya/Rwanda/Uganda/Zambia; 
RSA/Botswana; Zambia; Zambia 
45:01 Leslie et al., 2010; Kiepiela et al., 2004; Carlson et al., 
2012; Saathof et al., 2010; Geldmacher et al., 2007; 
Mclaren et al., 2012 
RSA; RSA; RSA/Botswana/Malawi/Zimbabwe; 
Tanzania; Tanzania; USA(African-American) 
46:01 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
48:01 Novitsky et al., 2003; Mori et al., 2014; Naruto et al., 
2012 
Botswana; Thailand; Japan 
48:02 Novitsky et al., 2003 Botswana 
49:01 Leslie et al., 2010; Mclaren et al., 2012; Novitsky et al., 
2003 
RSA; USA(African-American); Botswana 
50:01 Mclaren et al., 2012; Novitsky et al., 2003 USA(African-American); Botswana 
50:02 Carlson et al., 2012 RSA/Botswana/Malawi/Zimbabwe 
51 Leslie et al., 2010 Japan; RSA; RSA/Botswana/Malawi/Zimbabwe 
51:01 Naruto et al., 2012; Carlson et al., 2012; Mclaren et al., 
2012; Mori et al., 2014 
Japan; RSA/Botswana/Malawi/Zimbabwe; USA(African-
American); Thailand 
51:02 Mori et al., 2014 Thailand 
52 Int. HIV controllers study et al., 2010; Naruto et al., 
2012 
USA/Europe; Japan 
52:01 Mclaren et al., 2012; Naruto et al., 2012; Mori et al., 
2014 
USA(African-American); Japan; Thailand 
53 Lazaryan et al., 2011; Li et al., 2014 USA(African-American); Kenya/Rwanda/Uganda/Zambia 
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53:01 Carlson., 2012; Mclaren et al., 2012; Mackelprang et al., 
2015 
RSA/Botswana/Malawi/Zimbabwe; USA(African-American); 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
54 Dorak et al., 2003 USA(Caucasian), Holland 
54:01 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
55 Dorak et al., 2003 USA(Caucasian), Holland 
55:02 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
56 Dorak et al., 2003 USA(Caucasian), Holland 
56:01 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
56:02 Mori et al., 2014 Thailand 
57 Silva et al., 2010; Emu et al., 2008; Gao et al., 2010; Int. 
HIV controllers study et al., 2010; Kiepiela et al., 2004; 
Li et al., 2014; Mathews et al., 2012; Tang et al., 2002; 
Tang et al., 2008; Tang et al., 2010 
Brazil; USA; USA/Europe; USA(African-American); RSA; 
Kenya/Rwanda/Uganda/Zambia; RSA/Botswana; Zambia; 
Zambia; Zambia 
57:01 Brockman et al., 2010; Leslie et al., 2010; Carlson et al., 
2012; Lazaryan et al., 2011; Matthews et al., 2012; Gao 
et al., 2010; Int. HIV controllers study et al., 2010; 
Mclaren et al., 2012; Mori et al., 2014; Novitsky et al., 
2003 
USA/Australia/Germany; RSA; 
RSA/Botswana/Malawi/Zimbabwe; 
RSA, USA(African-American); RSA/Botswana; 
USA/Europe; USA/European; USA(African-American); 
Thailand; Botswana 
57:02 Brockman et al., 2010; Tang et al., 2010; Leslie et al., 
2010; Carlson et al., 2012; Lazaryan et al., 2011; 
Matthews et al., 2012; Gao et al., 2010; Mclaren et al., 
2012; Novitsky et al., 2003 
USA/Australia/Germany; Zambia; RSA; 
RSA/Botswana/Malawi/Zimbabwe; USA(African-American); 
RSA/Botswana; USA/Europe; USA(African-American); 
Botswana 
57:03 Carlson et al., 2012; Int. HIV controllers study et al., 
2010; Lazaryan et al., 2006; Lazaryan et al., 2011; 
Limou et al., 2013; Mclaren et al., 2012; Olvera et al., 
2015; Saathof et al., 2010 
RSA/Botswana/Malawi/Zimbabwe; USA(African-American); 
Zambia/Rwanda; USA(African-American); USA(African-
American); USA(African-American); Peru; Tanzania 
58 Emu et al., 2012; Novitsky et al., 2003 USA; Botswana 
58:01 Brockman et al., 2010; Carlson et al., 2012; Geldmacher 
et al., 2007; Leslie et al., 2010; Kiepiela et al., 2004; 
Saathof et al., 2010; Matthews et al., 2012; Gao et al., 
2010; Naruto et al., 2012; Mclaren et al., 2012; Mori et 
al., 2014 
USA/Australia/Germany; RSA/Botswana/Malawi/Zimbabwe; 
Tanzania; RSA; RSA; Tanzania; RSA/Botswana; 
USA/Europe; Japan; USA(African-American); Thailand 
58:02 Carlson et al., 2012; Leslie et al., 2010; Kiepiela et al., 
2004; Saathof et al., 2010; Matthews et al., 2012; Tang 
et al., 2010; Lazaryan et al., 2006; Mclaren et al., 2012 
RSA/Botswana/Malawi/Zimbabwe; RSA; RSA; Tanzania; 
RSA/Botswana; Zambia; Zambia/Rwanda; USA(African-
American) 
59:01 Naruto et al., 2012 Japan 
67 Zhang et al., 2013 China 
67:01 Naruto et al., 2012 Japan 
73:01 Novitsky et al., 2003 Botswana 
78:01 Mclaren et al., 2012 USA(African-American) 
81 Emu et al., 2008; Matthews et al., 2012; Tang et al., 
2008; Tang et al., 2010 
USA; RSA/Botswana; Zambia; Zambia 
81:01 Carlson et al., 2012; Geldmacher et al., 2007; Tang et 
al., 2010; Leslie et al., 2010; Kiepiela et al., 2004; 
Saathof et al., 2010; Mclaren et al., 2012 
RSA/Botswana/Malawi/Zimbabwe; Tanzania; Zambia; RSA; 
RSA; Tanzania; USA(African-American) 
HLA-C Study Country 
01 Zhang et al., 2013 China 
01:02 Naruto et al., 2012; Mori et al., 2014 Japan; Thailand 
01:03 Naruto et al., 2012 Japan 
02 Matthews et al., 2012 RSA/Botswana 
02:02 Kiepiela et al., 2004; Mackelprang et al., 2015 RSA; 
Botswana/RSA/Zambia/Kenya/Rwanda/Tanzania/Uganda 
03 Zhang et al., 2013 China 
03:02 Leslie et al., 2010; Matthews et al., 2012; Mori et al., 
2014; Naruto et al., 2012 
RSA; RSA/Botswana; Thailand; Japan 
03:03 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
03:04 Kiepiela et al., 2004; Naruto et al., 2012; Mori et al., 
2014 
RSA; Japan; Thailand 
04 Matthews et al., 2012 RSA/Botswana 
04:01 Tang et al., 2002; Leslie et al., 2010; Kiepiela et al., 
2004; Naruto et al., 2012; Mori et al., 2014; Olvera et al., 
2015 
Zambia; RSA, RSA; Japan; Thailand; Peru 
04:03 Tang et al., 2002; Mori et al., 2014 Zambia; Thailand 
04:06 Mori et al., 2014 Zambia; Thailand 
05:01 Leslie et al., 2010 RSA 
06 Matthews et al., 2012; Zhang et al., 2013 RSA/Botswana; China 
06:02 Leslie et al., 2010; Kiepiela et al., 2004; Naruto et al., 
2012; Mori et al., 2014 
RSA; RSA; Japan; Thailand 
07 Int. HIV controllers study et al., 2010 USA/Europe 
07:01 Leslie et al., 2010; Kiepiela et al., 2004; Mori et al., 
2014 
RSA; RSA; Thailand 
07:02 Leslie et al., 2010; Kiepiela et al., 2004; Naruto et al., 
2012; Mori et al., 2014; Olvera et al., 2015 
RSA; RSA; Japan; Thailand; Peru 
07:04 Leslie et al., 2010; Naruto et al., 2012; Mori et al., 2014 RSA; Japan; Thailand 
08 Lazaryan et al., 2011; Matthews et al., 2012 USA(African-American); RSA/Botswana 
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08:01 Tang et al., 2002; Naruto et al., 2012; Leslie et al., 2010; 
Kiepiela et al., 2004; Mori et al., 2014; Olvera et al., 
2015 
Japan; RSA; RSA; Thailand; Peru 
08:02 Tang et al., 2002; Leslie et al., 2010 Zambia; RSA 
08:03 Tang et al., 2002; Naruto et al., 2012 Zambia; Japan 
12 Matthews et al., 2012; Tang et al., 2002 RSA/Botswana; Zambia 
12:02 Naruto et al., 2012; Mori et al., 2014 Japan; Thailand 
12:03 Carlson et al., 2012; Leslie et al., 2010; Mori et al., 2014 RSA/Botswana/Malawi/Zimbabwe; 
RSA; Thailand 
14:02 Carlson et al., 2012; Naruto et al., 2012; Mori et al., 
2014 
RSA/Botswana/Malawi/Zimbabwe; Japan; Thailand 
14:03 Naruto et al., 2012 Japan 
15:02 Mori et al., 2014; Naruto et al., 2012 Thailand; Japan 
16 Tang et al., 2002 Zambia 
16:01 Matthews et al., 2012; Kiepiela et al., 2004 RSA/Botswana; RSA 
16:02 Matthews et al., 2012 RSA/Botswana 
17 Matthews et al., 2012 RSA/Botswana 
17:01 Tang et al., 2002; Kiepiela et al., 2004; Carlson et al., 
2012 
Zambia; RSA; RSA/Botswana/Malawi/Zimbabwe 
18 Silva et al., 2010; Lazaryan et al., 2011; Matthews et al., 
2012; Tang et al., 2002; Tang et al., 2008; Tang et al., 
2010 
Brazil; USA(African-American); RSA/Botswana; Zambia; 
Zambia; Zambia 
18:01 Kiepiela et al., 2004 RSA 
18:02 Kiepiela et al., 2004 RSA 
Black ink = low viral load setpoint; red print = high viral load setpoint; yellow highlight = study shows opposite association; HLA, human 
leukocyte antigen. 
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